<SEC-DOCUMENT>0001047469-18-001732.txt : 20180316
<SEC-HEADER>0001047469-18-001732.hdr.sgml : 20180316
<ACCEPTANCE-DATETIME>20180316090440
ACCESSION NUMBER:		0001047469-18-001732
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180503
FILED AS OF DATE:		20180316
DATE AS OF CHANGE:		20180316
EFFECTIVENESS DATE:		20180316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEAP THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001509745
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				274412575
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37990
		FILM NUMBER:		18694331

	BUSINESS ADDRESS:	
		STREET 1:		47 THORNDIKE STREET
		STREET 2:		SUITE B1-1
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617 252 4343

	MAIL ADDRESS:	
		STREET 1:		47 THORNDIKE STREET
		STREET 2:		SUITE B1-1
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Dekkun Corp
		DATE OF NAME CHANGE:	20110107
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2234866zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg12901_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> LEAP THERAPEUTICS, INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=587379,FOLIO='blank',FILE='DISK109:[18ZAY1.18ZAY12901]BA12901A.;5',USER='CHE109864',CD='14-MAR-2018;17:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g18891.jpg" ALT="LOGO" WIDTH="321" HEIGHT="97">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dear Stockholder: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cordially invited to attend the 2018 Annual Meeting of Stockholders of Leap Therapeutics,&nbsp;Inc. which will be held on Thursday, May&nbsp;3, 2018 at 11:00&nbsp;a.m.,
eastern time, at the offices of Morgan, Lewis&nbsp;&amp; Bockius&nbsp;LLP, One Federal Street, Boston, Massachusetts 02110 USA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Details
regarding admission to the Annual Meeting and the business to be conducted are described in the accompanying proxy materials. Also included is a copy of our 2017 Annual Report.
We encourage you to read this information carefully. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote is important. Whether or not you plan to attend the Annual Meeting, we hope you will vote as soon as possible. You may vote over the Internet, by telephone or by mailing a
proxy card. Voting over the Internet, by telephone or by written proxy will ensure your representation at the Annual Meeting regardless of whether or not you attend in person. Please review the
instructions in the Proxy Materials you received in the mail regarding each of these voting options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Thank
you for your ongoing support of Leap Therapeutics,&nbsp;Inc. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Very truly yours,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2> /s/&nbsp;CHRISTOPHER K. MIRABELLI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Christopher K. Mirabelli<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer, President and Chairman of the Board of Directors</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=485190,FOLIO='blank',FILE='DISK109:[18ZAY1.18ZAY12901]BE12901A.;6',USER='CHE109864',CD='14-MAR-2018;17:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g18891.jpg" ALT="LOGO" WIDTH="321" HEIGHT="97">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>47 Thorndike Street<BR>
Suite B1-1<BR>
Cambridge, MA 02141  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS<BR>  </B></FONT><FONT SIZE=2><B>To Be Held on May&nbsp;3, 2018  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2018 Annual Meeting of Stockholders of Leap Therapeutics,&nbsp;Inc. will be held on Thursday, May&nbsp;3, 2018 at 11:00&nbsp;a.m., eastern time, at the
offices of Morgan, Lewis&nbsp;&amp; Bockius&nbsp;LLP, One Federal Street, Boston, Massachusetts 02110 USA. At the Annual Meeting, stockholders will consider and act upon the following matters: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
elect two Class&nbsp;I directors nominated by our board of directors, James Cavanaugh and John Littlechild, each to serve for a term ending in 2021, or until his
successor has been duly elected and qualified; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
ratify the appointment of EisnerAmper&nbsp;LLP, an independent registered public accounting firm, as our independent auditors for the year ending December&nbsp;31,
2018; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders
of record on our books at the close of business on March&nbsp;28, 2018, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual
Meeting or any adjournment or postponement thereof. If you are a stockholder of record, please vote in one of these three ways:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Vote over the Internet</B></FONT><FONT SIZE=2>, by going to the website of our tabulator, Continental Stock Transfer
and Trust Company, at </FONT><FONT SIZE=2><I>www.cstproxyvote.com</I></FONT><FONT SIZE=2>, and following the instructions for Internet voting shown on the enclosed proxy card; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Vote by Telephone</B></FONT><FONT SIZE=2>, by calling 1-866-894-0536 and following the recorded instructions; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Vote by Mail</B></FONT><FONT SIZE=2>, by completing and signing the enclosed proxy card and mailing it in the enclosed
postage prepaid envelope. If you vote over the Internet or by telephone, please do not mail your proxy card. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for
your shares to be voted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directions
to the Annual Meeting are on the back of the proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Whether or not you plan to attend the Annual Meeting in person, we urge you to take the time to vote your shares.</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>By Order of the board of directors,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2> /s/&nbsp;CHRISTOPHER K. MIRABELLI<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Christopher K. Mirabelli<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer, President and Chairman of the Board of Directors</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>March&nbsp;16,
2018 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=849036,FOLIO='blank',FILE='DISK109:[18ZAY1.18ZAY12901]BF12901A.;7',USER='CHE109569',CD='15-MAR-2018;15:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG12901A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg12901_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG12901_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#proxy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2></FONT><FONT SIZE=2><B>PROXY STATEMENT</B></FONT><FONT SIZE=2></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#proxy"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#p1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2></FONT><FONT SIZE=2><B>PROPOSAL NO. 1&#151;ELECTION OF DIRECTORS</B></FONT><FONT SIZE=2></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#p1"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#board"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2></FONT><FONT SIZE=2><B>BOARD OF DIRECTORS AND MANAGEMENT</B></FONT><FONT SIZE=2></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#board"><FONT SIZE=2>9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#corporate_governace"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2></FONT><FONT SIZE=2><B>CORPORATE GOVERNANCE MATTERS</B></FONT><FONT SIZE=2></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#corporate_governace"><FONT SIZE=2>17</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di12901_executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>EXECUTIVE COMPENSATION</B></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di12901_executive_compensation"><FONT SIZE=2>23</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#equity_plan_infor"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2></FONT><FONT SIZE=2><B>EQUITY COMPENSATION PLAN INFORMATION</B></FONT><FONT SIZE=2></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#equity_plan_infor"><FONT SIZE=2>27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di12901_director_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>DIRECTOR COMPENSATION</B></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di12901_director_compensation"><FONT SIZE=2>27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk12901_audit_committee_report"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>AUDIT COMMITTEE REPORT</B></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk12901_audit_committee_report"><FONT SIZE=2>31</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#pr2"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2></FONT><FONT SIZE=2><B>PROPOSAL NO. 2&#151;RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></FONT><FONT SIZE=2></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#pr2"><FONT SIZE=2>32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#security_owner"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2></FONT><FONT SIZE=2><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B></FONT><FONT
SIZE=2></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#security_owner"><FONT SIZE=2>34</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dq12901_certain_relationships_and_related_party_transactions"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CERTAIN RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS</B></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq12901_certain_relationships_and_related_party_transactions"><FONT SIZE=2>38</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dq12901_section_16(a)_benefici__dq102033"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</B></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dq12901_section_16(a)_benefici__dq102033"><FONT SIZE=2>42</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ds12901_general_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>GENERAL MATTERS</B></FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ds12901_general_matters"><FONT SIZE=2>43</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=742590,FOLIO='blank',FILE='DISK109:[18ZAY1.18ZAY12901]BG12901A.;12',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da12901_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Leap Therapeutics,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=2><B>47 Thorndike Street, Suite B1-1<BR>
Cambridge, MA 02141  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B><A NAME="proxy"></A>PROXY STATEMENT FOR 2018 ANNUAL MEETING OF STOCKHOLDERS<BR>  </B></FONT><FONT SIZE=2><B>To Be Held On Thursday, May&nbsp;3, 2018 at 11:00&nbsp;a.m. eastern time</B></FONT><FONT SIZE=2><BR>
At the offices of Morgan, Lewis&nbsp;&amp; Bockius&nbsp;LLP,<BR>
At One Federal Street, Boston, Massachusetts 02110 USA </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
proxy statement and the enclosed proxy card are being furnished in connection with the solicitation of proxies by our board of directors for use at the 2018 Annual Meeting of
Stockholders of Leap Therapeutics,&nbsp;Inc., or the Annual Meeting, to be held on Thursday, May&nbsp;3, 2018 at 11:00&nbsp;a.m., eastern time, at the offices of Morgan, Lewis&nbsp;&amp;
Bockius&nbsp;LLP, One Federal Street, Boston, Massachusetts 02110 USA, and at any adjournment or postponement thereof. You are entitled to vote if you are a stockholder of record as of the close of
business on March&nbsp;28, 2018. As used in this proxy statement,
the terms "Leap," "we," "us," and "our" mean Leap Therapeutics,&nbsp;Inc. unless the context indicates otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
proxies will be voted in accordance with the instructions contained in those proxies. If no choice is specified, the proxies will be voted in favor of the matters set forth in the
accompanying Notice of Annual Meeting of Stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are first mailing this proxy statement and the accompanying proxy card to stockholders on or about April&nbsp;2, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da12901_questions_and_answers___da102375"> </A>
<A NAME="toc_da12901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING AND VOTING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="117pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>Why did I receive these proxy materials?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>We are providing these proxy materials to you in connection with the solicitation by our board of directors, or Board of Directors, of proxies to be voted at our 2018 Annual Meeting of Stockholders, or Annual Meeting, to
be held at the offices of Morgan, Lewis&nbsp;&amp; Bockius&nbsp;LLP, One Federal Street, Boston, Massachusetts 02110 USA on Thursday, May&nbsp;3, 2018 at 11:00&nbsp;a.m., eastern time.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B>What proposals am I voting on?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 There are two proposals scheduled for a vote: </font> <p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2>
 &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2> Proposal&nbsp;1: The election of two directors; and </font> <p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT
 SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2> Proposal&nbsp;2: The ratification of
 the selection of EisnerAmper&nbsp;LLP as our independent registered public accounting firm for the year ending December&nbsp;31, 2018.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Who can vote at the Annual Meeting?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Our board of directors has fixed March&nbsp;28, 2018 as the record date for the Annual Meeting. If you are a stockholder of record on the record date, you are entitled to vote (in person or by proxy) all of the shares
that you held on that date at the Annual Meeting and at any postponement or adjournment thereof.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>On March&nbsp;15, 2018, we had 12,354,014 shares of common stock outstanding. We anticipate that 12,354,014 shares of common stock will be outstanding on the record date.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=46506,FOLIO='1',FILE='DISK109:[18ZAY1.18ZAY12901]DA12901A.;17',USER='CHE108062',CD='15-MAR-2018;20:18' -->
<A NAME="page_da12901_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="117pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>How do I attend the Annual Meeting?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The Annual Meeting will be held on Thursday, May&nbsp;3, 2018 at 11:00&nbsp;a.m., eastern time at offices of Morgan, Lewis&nbsp;&amp; Bockius&nbsp;LLP, One Federal Street, Boston, Massachusetts 02110 USA. If you are a
stockholder of record, you must bring proof of identification. If you are a beneficial owner of shares registered in the name of your broker or other nominee, you must request and obtain a valid proxy from your broker or nominee and bring proof of
identification.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Directions to the Annual Meeting are on the back of the proxy statement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Information on how to vote in person at the Annual Meeting is discussed below.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>What happens if the meeting is postponed or adjourned?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Your proxy may be voted at the postponed or adjourned meeting. You will still be able to change your proxy until it is voted.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>How do I vote?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>
If your shares are registered directly in your name,</B></FONT><FONT SIZE=2> you may vote:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1) </FONT><FONT SIZE=2><B>Over the Internet</B></FONT><FONT SIZE=2>: Go to the website of our tabulator, Continental Stock Transfer and Trust Company, or CST, at </FONT><FONT
SIZE=2><I>www.cstproxyvote.com</I></FONT><FONT SIZE=2>. Use the vote control number printed on your enclosed proxy card to access your account and vote your shares. You must specify how you want your shares voted or your Internet vote cannot be
completed and you will receive an error message. Your shares will be voted according to your instructions. You must submit your Internet proxy before 11:59&nbsp;p.m., eastern time, on May&nbsp;2, 2018, the day before the Annual Meeting, for your
proxy to be valid and your vote to count.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(2) </FONT><FONT SIZE=2><B>By Telephone</B></FONT><FONT SIZE=2>: Call 1-866-894-0536, toll free from the United States, Canada and Puerto Rico, and follow the recorded instructions. You must specify how you want your
shares voted and confirm your vote at the end of the call or your telephone vote cannot be completed. Your shares will be voted according to your instructions. You must submit your telephonic proxy before 11:59&nbsp;p.m., eastern time, on May&nbsp;2,
2018, the day before the Annual Meeting, for your proxy to be valid and your vote to count.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(3) </FONT><FONT SIZE=2><B>By Mail</B></FONT><FONT SIZE=2>: Complete and sign your enclosed proxy card and mail it in the enclosed postage prepaid envelope to CST. CST must receive the proxy card not later than
May&nbsp;2, 2018, the day before the Annual Meeting, for your proxy to be valid and your vote to count. Your shares will be voted according to your instructions.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>If you do not specify how you want your shares voted, they will be voted as recommended by our board of directors.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(4) </FONT><FONT SIZE=2><B>In Person at the Annual Meeting:</B></FONT><FONT SIZE=2> If you attend the Annual Meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which
we will provide to you at the Annual Meeting.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=680372,FOLIO='2',FILE='DISK109:[18ZAY1.18ZAY12901]DA12901A.;17',USER='CHE108062',CD='15-MAR-2018;20:18' -->
<A NAME="page_da12901_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="117pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B> If your shares are held in "street name,"</B></FONT><FONT SIZE=2> meaning they are held for your account by a broker or other nominee, you may vote:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1) </FONT><FONT SIZE=2><B>Over the Internet or by Telephone</B></FONT><FONT SIZE=2>: You will receive instructions from your broker or other nominee if they permit Internet or telephonic voting. You should follow
those instructions.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(2) </FONT><FONT SIZE=2><B>By Mail</B></FONT><FONT SIZE=2>: You will receive instructions from your broker or other nominee explaining how you can vote your shares by mail. You should follow those
instructions.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(3) </FONT><FONT SIZE=2><B>In Person at the Annual Meeting</B></FONT><FONT SIZE=2>: You may contact your broker or other nominee who holds your shares to obtain a broker's proxy and bring it with you to the Annual
Meeting. A broker's proxy is not the form of proxy enclosed with this proxy statement. </FONT><FONT SIZE=2><B>You will not be able to vote shares you hold in street name in person at the Annual Meeting unless you have a proxy from your broker or
other nominee issued in your name giving you the right to vote your shares.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Can I change my vote?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>
If your shares are registered directly in your name,</B></FONT><FONT SIZE=2> you may revoke your proxy and change your vote before or at the Annual Meeting. To do so, you must do one of the following:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1) Vote over the Internet or by telephone as instructed above. Only your latest Internet or telephone vote is counted. You may not change your vote over the Internet or by telephone after 11:59&nbsp;p.m., eastern
time, on May&nbsp;2, 2018, the day before the Annual Meeting.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(2) Sign a new proxy and submit it by mail as instructed above. Only your latest dated proxy that was received by CST by 11:59&nbsp;p.m., eastern time, on May&nbsp;2, 2018 will be counted.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(3) Attend the Annual Meeting, request that your proxy be revoked and vote in person as instructed above. Attending the Annual Meeting will not revoke your Internet vote, telephone vote or proxy, as the case may be,
unless you specifically request it.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> If your shares are held in street name,</B></FONT><FONT SIZE=2> you may submit new voting instructions by contacting your broker or other nominee. You may also vote in person at the Annual Meeting if you obtain a
broker's proxy as described in the answer above.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Will my shares be voted if I do not return my proxy?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>
If your shares are registered directly in your name,</B></FONT><FONT SIZE=2> your shares will not be voted if you do not vote over the Internet, by telephone, by returning your proxy or by ballot at the Annual Meeting.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> If your shares are held in street name,</B></FONT><FONT SIZE=2> your broker or other nominee may, under certain circumstances, vote your shares if you do not timely return your proxy. </FONT><FONT
SIZE=2><B>Brokers and other nominees can vote their customers' unvoted shares on discretionary matters but cannot vote such shares on non-discretionary matters.</B></FONT><FONT SIZE=2> If you do not timely return a proxy to your broker or other
nominee to vote your shares, your broker or other nominee may, on discretionary matters, either vote your shares or leave your shares unvoted.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=1019100,FOLIO='3',FILE='DISK109:[18ZAY1.18ZAY12901]DA12901A.;17',USER='CHE108062',CD='15-MAR-2018;20:18' -->
<A NAME="page_da12901_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="117pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B> The election of directors (Proposal&nbsp;1) is a non-discretionary matter. The ratification of the appointment of our independent auditors (Proposal&nbsp;2)&nbsp;is a discretionary matter.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>We encourage you to provide voting instructions to your broker or other nominee. This ensures that your shares will be voted at the Annual Meeting according to your instructions.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>How many shares must be present to hold the Annual Meeting?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>The holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy must be present to hold
the Annual Meeting and conduct business. This is called a quorum. For purposes of determining whether a quorum exists, we count as present any shares that are voted over the Internet, by telephone or by completion and submission of a proxy or that
are represented in person at the Annual Meeting. Further, for purposes of establishing a quorum, we will count as present shares that a stockholder holds even if the stockholder votes to withhold or abstain or votes on only one of the proposals. In
addition, we will count as present shares held in street name by brokers or other nominees that indicate on their proxies that they do not have authority to vote those shares on Proposal&nbsp;1. If a quorum is not present, we expect to adjourn the
Annual Meeting until we obtain a quorum.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>What vote is required to approve each proposal and how are votes counted?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2><B><BR>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Proposal&nbsp;1&#151;Election of Two Class&nbsp;I Directors</B></FONT><FONT SIZE=2></font> <p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;"> <font size=2> The two nominees for Class&nbsp;I director receiving the highest number of votes FOR
 election will be elected as directors. This is called a plurality. </FONT><FONT SIZE=2><B>Proposal&nbsp;1 is a non-discretionary matter.</B></FONT><FONT SIZE=2> Therefore, if your shares are held in street name and you do not vote your shares, your
 broker or other nominee cannot vote your shares on Proposal&nbsp;1. Shares held in street name by brokers or nominees who indicate on their proxies that they do not have authority to vote the shares on Proposal&nbsp;1 will not be counted as votes FOR
 or WITHHELD from any nominee and will be treated as "broker non-votes." Broker non-votes will have no effect on the voting on Proposal&nbsp;1.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>With respect to Proposal&nbsp;1, you may:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>



<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>vote FOR both
nominees;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>vote FOR one nominee and
WITHHOLD your vote from the other nominee; or</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>



<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2> WITHHOLD your vote from
both nominees.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Votes that are withheld will not be included in the vote tally for the election of directors and will not affect the results of the vote.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=887604,FOLIO='4',FILE='DISK109:[18ZAY1.18ZAY12901]DA12901A.;17',USER='CHE108062',CD='15-MAR-2018;20:18' -->
<A NAME="page_da12901_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="117pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B> Proposal&nbsp;2&#151;Ratification of Appointment of Independent Auditors</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>To approve Proposal&nbsp;2, stockholders holding a majority of the votes cast on the matter must vote FOR the proposal. </FONT><FONT SIZE=2><B>Proposal&nbsp;2 is a discretionary matter.</B></FONT><FONT SIZE=2>
Therefore, if your shares are held in street name and you do not vote your shares, your broker or other nominee may vote your unvoted shares on Proposal&nbsp;2. If you vote to ABSTAIN on Proposal&nbsp;2, your shares will not be voted FOR or AGAINST
the proposal and will also not be counted as votes cast or shares voting on the proposal. Voting to ABSTAIN will have no effect on the voting on Proposal&nbsp;2.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Although stockholder approval of our Audit Committee's appointment of EisnerAmper&nbsp;LLP as our independent registered public accounting firm for the year ending December&nbsp;31, 2018 is not required, we believe
that it is advisable to give stockholders an opportunity to ratify this appointment. As an advisory vote, this proposal is not binding. The outcome of this advisory vote will not overrule any decision by us or our board of directors (or any committee
thereof). However, if this proposal is not approved at the Annual Meeting, our Audit Committee may reconsider its appointment of EisnerAmper&nbsp;LLP as our independent registered public accounting firm for the year ending December&nbsp;31,
2018.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B>How does the board of directors recommend that I vote?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:left;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Our board of directors unanimously recommends that you vote your shares: </font> <p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2> </font> <p align=left
 style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>"FOR" the nominees for election as director listed in Proposal&nbsp;1;
 and </font> <p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;"> <font size=2> </FONT><FONT SIZE=2> </font> <p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:0pt;"><font size=2> &#149;</font></p> <p align=left
 style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>"FOR" the ratification of the appointment of EisnerAmper&nbsp;LLP as our independent registered public accounting firm for the year ending December&nbsp;31, 2018.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>How many votes do I have?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>On each matter to be voted upon, you have one vote for each share of common stock you owned as of March&nbsp;28, 2018.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Are there other matters to be voted on at the Annual Meeting?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>We do not know of any matters that may come before the Annual Meeting other than the election of two Class&nbsp;I directors and the ratification of the appointment of our independent registered public accounting firm.
If any other matters are properly presented at the Annual Meeting, the persons named in the accompanying proxy will vote, and otherwise act, in accordance with their judgment on the matter.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Is my vote confidential?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Proxy instructions, ballots, and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within Leap or to third
parties, except as necessary to meet applicable legal requirements, to allow for the tabulation of votes and certification of the vote, or to facilitate a successful proxy solicitation.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Where can I find the voting results?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>We will report the voting results in a Current Report on Form&nbsp;8-K within four business days following the adjournment of the Annual Meeting.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=409323,FOLIO='5',FILE='DISK109:[18ZAY1.18ZAY12901]DA12901A.;17',USER='CHE108062',CD='15-MAR-2018;20:18' -->
<A NAME="page_da12901_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="117pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>What are the costs of soliciting these proxies?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>We will bear all expenses of this solicitation, including the cost of preparing and mailing these proxy materials. Directors, officers and employees of Leap may also solicit proxies in person or by other means of
communication. Such directors, officers and employees will not be additionally compensated but may be reimbursed for reasonable out-of-pocket expenses in connection with such solicitation. We may engage the services of a professional proxy
solicitation firm to aid in the solicitation of proxies from certain brokers, bank nominees and other institutional owners. Our costs for such services, if retained, will not be significant.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>What are the implications of being an "emerging growth company?"</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>We are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups (JOBS) Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. These
reduced reporting requirements include reduced disclosure about Leap's executive compensation arrangements and no non-binding advisory vote on executive compensation. The Company may take advantage of these exemptions up until the last day of the
fiscal year following the fifth anniversary of the date that the Company's common stock became publicly traded or such earlier time that it is no longer an emerging growth company. The Company would cease to be an emerging growth company if it has
more than $1.07&nbsp;billion in annual revenue, has more than $700.0&nbsp;million in market value of its stock held by non-affiliates (and has been a public company for at least 12&nbsp;months, and has filed one annual report on Form&nbsp;10-K), or
it issues more than $1.0&nbsp;billion of non-convertible debt securities over a three-year period.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Q.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;</B></FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Who may I contact if I have any additional questions?</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> A.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>If you hold your shares directly, please call Douglas E. Onsi, Secretary of the Company, at (617)&nbsp;714-0360. If your shares are held in street name, please contact the telephone number provided on your voting
instruction form or contact your broker or nominee holder directly.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=270140,FOLIO='6',FILE='DISK109:[18ZAY1.18ZAY12901]DA12901A.;17',USER='CHE108062',CD='15-MAR-2018;20:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc12901_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<!-- BOXING PARAGRAPH(S) -->
 </FONT></P>
<DIV style="width:100%;border:solid #000000 1pt;margin-right:1pt;padding-top:12pt;padding-right:14pt;padding-bottom:13pt;padding-left:15pt;">

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc12901_important_notice_regarding_ava__imp04212"> </A>
<A NAME="toc_dc12901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPORTANT NOTICE REGARDING AVAILABILITY OF PROXY MATERIALS    <BR>    <BR>    For the 2018 Annual Meeting of Stockholders on May&nbsp;3, 2018    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>This proxy statement and the 2017 Annual Report to Stockholders are available for viewing, printing and downloading at  </B></FONT><FONT
SIZE=2><B><I>http://www.cstproxy.com/leaptx/2018.</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>A copy of our Annual Report on Form&nbsp;10-K (including financial statements and schedules) for the year ended December&nbsp;31, 2017, as filed with the
Securities and Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder after written or oral request to:</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B> Leap Therapeutics,&nbsp;Inc.<BR>
Attn: General Counsel<BR>
47 Thorndike Street, Suite B1-1<BR>
Cambridge, Massachusetts 02141 USA<BR>
Telephone: +1 (617)&nbsp;714-0360<BR> </B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>This proxy statement and our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017 are also available on the SEC's website,  </B></FONT><FONT SIZE=2><B><I>www.sec.gov</I></B></FONT><FONT SIZE=2><B>.</B></FONT></P>
 <p style="font-family:times;margin-bottom:-11pt;"></p>
</DIV>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=562919,FOLIO='7',FILE='DISK109:[18ZAY1.18ZAY12901]DC12901A.;9',USER='CHE109863',CD='15-MAR-2018;15:16' -->
<A NAME="page_dc12901_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="p1"></A>PROPOSAL NO. 1&#151;ELECTION OF DIRECTORS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with Leap's amended and restated certificate of incorporation and amended and restated bylaws, the Board of Directors is divided
into three classes of directors of approximately equal size. The members of each class of directors are elected to serve a three-year term with the term of office of each class ending in successive
years. James Cavanaugh and John Littlechild are the Class&nbsp;I directors whose terms expire at Leap's 2018 Annual Meeting of stockholders. Each of James Cavanaugh and John Littlechild has been
nominated for, and has agreed to stand for, re-election to the Board to serve as a Class&nbsp;I director of Leap for three years until the 2021 Annual Meeting of Stockholders of Leap and until their
successors are duly elected and qualified or until their earlier death, resignation or removal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is intended that, unless you give contrary instructions, shares represented by proxies will be voted for the election of each of the two nominees listed above as director nominees.
Leap has no reason to believe that any nominee will be unable to serve. In the event that one or more nominees is unexpectedly not available to serve, proxies may be voted for another person nominated
as a substitute by the Board, or the Board may reduce the number of directors to be elected at the Annual Meeting. Information relating to each nominee for election as director and for each continuing
director,
including his or her period of service as a director of Leap, principal occupation and other biographical material, is included below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dc12901_vote_required"> </A>
<A NAME="toc_dc12901_2"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


VOTE REQUIRED    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A plurality of the votes cast at the meeting will be required for the election of the Class&nbsp;I director nominees. The two nominees for
director with the highest number of affirmative votes will be elected as directors. Broker non-votes and abstentions will not be treated as votes cast for this purpose and, therefore, will not affect
the outcome of the election. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" EACH<BR>
OF THESE NOMINEES FOR CLASS I DIRECTOR.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>(PROPOSAL NO. 1 ON YOUR PROXY CARD)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=939729,FOLIO='8',FILE='DISK109:[18ZAY1.18ZAY12901]DC12901A.;9',USER='CHE109863',CD='15-MAR-2018;15:16' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de12901_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="board"></A>BOARD OF DIRECTORS AND MANAGEMENT  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="de12901_information_regarding___de102200"> </A>
<A NAME="toc_de12901_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Regarding Directors and Director Nominees    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors currently consists of seven members divided into three classes with staggered three-year terms. Our amended and restated
certificate of incorporation and amended and restated bylaws provide that the number of our directors shall be fixed from time to time by a resolution of the majority of our Board of Directors. Any
additional directorships resulting from
an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class shall consist of one third of the board of directors. In addition, our
amended and restated certificate of incorporation and amended and restated bylaws each of which became effective upon consummation of the merger with Macrocure&nbsp;Ltd. on January&nbsp;23, 2017,
provide that a director may be removed only for cause and only by the affirmative vote of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast in an
annual election of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
division of our Board of Directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in
control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms
of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2018 for Class&nbsp;I directors, 2019 for
Class&nbsp;II directors, and 2020 for Class&nbsp;III directors. Currently, Class&nbsp;I consists of James Cavanaugh and John Littlechild, each with a term expiring at this annual meeting of
stockholders to be held in 2018. Class&nbsp;II consists of William Li and Thomas Dietz, each with a term expiring at the annual meeting of stockholders to be held in 2019. Class&nbsp;III consists
of Joseph Loscalzo, Nissim Mashiach and Christopher Mirabelli, each with a term expiring at the annual meeting of stockholders to be held in 2020. Our Board of Directors has nominated
Dr.&nbsp;Cavanaugh and Mr.&nbsp;Littlechild for election at the Annual Meeting as Class&nbsp;I directors, each to serve until the annual meeting to be held in 2021. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Qualifications  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table and biographical descriptions provide information as of March&nbsp;15, 2018 relating to each director and director
nominee, including his age and period of service as a director of our company; his board of directors committee memberships; his business experience during the past five years, including directorships
at other public companies; his or community activities; and the other experience, qualifications, attributes or skills that led our Board of Directors to conclude he should serve as a director of our
company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=201580,FOLIO='9',FILE='DISK109:[18ZAY1.18ZAY12901]DE12901A.;17',USER='CHE109569',CD='15-MAR-2018;15:17' -->
<A NAME="page_de12901_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board of Directors Tenure, Principal Occupation,<BR>
Other Business Experience<BR>
During the Past Five Years and Other Directorships </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Class&nbsp;I Director Nominees to be elected at the 2018 Annual Meeting (terms expiring in 2021)</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Cavanaugh<BR></FONT> <FONT SIZE=2><I>Nominating and Corporate Governance<BR>
Committee Member and Chair</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>81</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Cavanaugh, age 81, has served as a member of our Board of Directors since January 2016. Dr.&nbsp;Cavanaugh has been a managing
director of HealthCare Ventures since 1989. He was previously President of SmithKline&nbsp;&amp; French Laboratories-U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. Dr.&nbsp;Cavanaugh had been president of SmithKline
Beckman's clinical laboratory business and President of Allergan International. He has been a board member of a number of private and public pharmaceutical and biotechnology companies and was Chairman of The Shire Pharmaceutical Group,&nbsp;plc. He
served as staff assistant to President Nixon for Health Affairs and then deputy director of the president's Domestic Council. Under President Ford, he was a deputy assistant to the President for domestic affairs and deputy chief of the White House.
He has served as deputy assistant secretary for health and scientific affairs in the United States Department of Health, Education and Welfare, special assistant to the Surgeon General, United States Public Health Services, and director, Office of
Comprehensive Health Planning. He began his career as a member of the faculty of the Graduate College and the College of Medicine at the University of Iowa where he received his Master's and Doctorate degrees.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We believe that Dr.&nbsp;Cavanaugh's experience with working in government, combined with his clinical and pharmaceutical industrial
experience and background, make him qualified to serve as a member of our Board of Directors.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=305802,FOLIO='10',FILE='DISK109:[18ZAY1.18ZAY12901]DE12901A.;17',USER='CHE109569',CD='15-MAR-2018;15:17' -->
<A NAME="page_de12901_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board of Directors Tenure, Principal Occupation,<BR>
Other Business Experience<BR>
During the Past Five Years and Other Directorships </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Littlechild<BR></FONT> <FONT SIZE=2><I>Audit Committee Member</I></FONT><BR>
<FONT SIZE=2><I>Compensation Committee Member and Chair</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mr.&nbsp;Littlechild, age 66, has served as a member of our Board of Directors since January 2016. Mr.&nbsp;Littlechild has been a managing director of
HealthCare Ventures since 1992. He has been in the venture capital industry since 1980 when he joined Citicorp Venture Capital in London. He subsequently joined the Advent Group, opening the London office of Advent U.K. and becoming an early general
partner of Advent International in Boston. Prior to his career in venture capital, he held marketing and financial management positions with Rank Xerox and ICI. Mr.&nbsp;Littlechild holds a B.Sc. in Engineering from the University of Manchester and
an MBA from Manchester Business School.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We believe that Mr.&nbsp;Littlechild's experience with our Company, combined with his venture capital industry experience and technical
background, make him qualified to serve as a member of our Board of Directors.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Class&nbsp;II Directors (terms expiring in 2019)</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Li<BR></FONT> <FONT SIZE=2><I>Audit Committee Member</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Li, age 55, has served as a member of our Board of Directors since January 2017. Dr.&nbsp;Li is a co-founder of the Angiogenesis
Foundation in Cambridge, Massachusetts, of which he has been the President since April 2000 and Medical Director since December 1994. Dr.&nbsp;Li has extensive expertise in the field of angiogenesis and its therapeutic development and clinical
applications. He trained with Dr.&nbsp;Judah Folkman, who pioneered the field of angiogenesis research. Through the Angiogenesis Foundation, Dr.&nbsp;Li has worked in association with the National Institutes of Health, and other major governmental
and academic institutions, and industry leaders on angiogenesis-related programs. Dr.&nbsp;Li received his M.D. degree from University of Pittsburgh School of Medicine. He completed his clinical training in internal medicine at the Massachusetts
General Hospital in Boston. Dr.&nbsp;Li has also served on the faculties of Harvard Medical School, Tufts University School of Veterinary Medicine and Dartmouth Medical School.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We believe that Dr.&nbsp;Li's experience with working with companies and foundation in the cancer field, combined with his medical training
and background, make him qualified to serve as a member of our Board of directors.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=258795,FOLIO='11',FILE='DISK109:[18ZAY1.18ZAY12901]DE12901A.;17',USER='CHE109569',CD='15-MAR-2018;15:17' -->
<A NAME="page_de12901_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board of Directors Tenure, Principal Occupation,<BR>
Other Business Experience<BR>
During the Past Five Years and Other Directorships </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Dietz<BR></FONT> <FONT SIZE=2><I>Audit Committee Member and Chair</I></FONT><BR>
<FONT SIZE=2><I>Compensation Committee Member</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>54</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Dietz, age 54, has served as a member of our Board of Directors since January 2016. Dr.&nbsp;Dietz is currently chairman and CEO of Waypoint
Holdings,&nbsp;LLC, a diversified financial-holdings and services company. Previously, Dr.&nbsp;Dietz was co-CEO and then CEO and a director of Pacific Growth Equities,&nbsp;LLC, a San Francisco-based investment bank and institutional brokerage firm
from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr.&nbsp;Dietz served as head of the investment banking division at Wedbush until November 2010. Prior to taking the CEO role at Pacific Growth, Dr.&nbsp;Dietz served as the
company's director of equities research and was an award-winning biotechnology and biopharmaceutical analyst. He joined Pacific Growth in 1993. Previously, he was a member of the research faculty in the Department of Medicine, University of
California, San Francisco and the VA Medical Center. Dr.&nbsp;Dietz is currently Chairman of Eiger Biopharmaceuticals,&nbsp;Inc. (NASDAQ: EIGR) and privately held AgBiome,&nbsp;LLC. He also serves as a director and member of the compensation
committee and audit committee of Paratek Pharmaceuticals (NASDAQ: PRTX) and several other private companies. Dr.&nbsp;Dietz previously served as a director of Transcept Pharmaceuticals,&nbsp;Inc. (NASDAQ: TSPT) Dr.&nbsp;Dietz holds a Ph.D. in
molecular biology and biochemistry from Washington University, St.&nbsp;Louis, and was a National Science Foundation Post-Doctoral Fellow.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We believe that Dr.&nbsp;Dietz's experience with Leap, combined with his business, financial and leadership expertise and financial industry
background, make him qualified to serve as a member of our Board of directors.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=177600,FOLIO='12',FILE='DISK109:[18ZAY1.18ZAY12901]DE12901A.;17',USER='CHE109569',CD='15-MAR-2018;15:17' -->
<A NAME="page_de12901_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board of Directors Tenure, Principal Occupation,<BR>
Other Business Experience<BR>
During the Past Five Years and Other Directorships </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Class&nbsp;III Directors (terms expiring in 2020)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joseph Loscalzo<BR></FONT> <FONT SIZE=2><I>Nominating and Corporate Governance Committee Member</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Joseph Loscalzo, age 66, has served as a member of our Board of Directors since January 2016. He is currently the Hersey Professor
of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine and Physician-in-Chief at Brigham and Women's Hospital. In 1994, Dr.&nbsp;Loscalso joined the faculty of Boston University, first as Chief of
Cardiology and, in 1997, as Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. In July 2005, he returned to Harvard Medical School and Brigham and Women's Hospital, where he had
previously worked. He is an editor-at-large of the New England Journal of Medicine, former Chair of the Cardiovascular Board of the American Board of Internal Medicine, former Chair of the Research Committee of the American Heart Association, former
Chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in Cardiovascular Sciences, and former Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of
Health. He is past Editor-in-Chief of Circulation, a current senior editor of Harrison's Principles of Internal Medicine, a former member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a former member of the Council of
Councils of the National Institutes of Health. Dr.&nbsp;Loscalzo received his AB degree, </FONT><FONT SIZE=2><I>summa cum laude</I></FONT><FONT SIZE=2>, his PhD in biochemistry, and his MD from the University of Pennsylvania and completed his
clinical training at Brigham and Women's Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine. Dr.&nbsp;Loscalzo is currently a member of the board of directors of Ionis
Pharmaceuticals&nbsp;Inc. (IONS: Nasdaq).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We believe that Dr.&nbsp;Loscalzo's vast experience as a scientist, clinician, and educator and his background in science and medicine, make
him qualified to serve as a member of our Board of directors.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=11513,FOLIO='13',FILE='DISK109:[18ZAY1.18ZAY12901]DE12901A.;17',USER='CHE109569',CD='15-MAR-2018;15:17' -->
<A NAME="page_de12901_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board of Directors Tenure, Principal Occupation,<BR>
Other Business Experience<BR>
During the Past Five Years and Other Directorships </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nissim Mashiach<BR></FONT> <FONT SIZE=2><I>Audit Committee Member</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>57</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mr.&nbsp;Mashiach, age 57, has served as a member of our Board of Directors since January 2017. He served as the President and Chief Executive Officer of
Macrocure,&nbsp;Ltd. from June 2012 until its merger with Leap in January 2017. He is also currently a member of the board of directors at Chemomab&nbsp;Ltd. He also previously served as General Manager at Ethicon, a Johnson&nbsp;&amp; Johnson
company, from January 2009 to January 2012. Prior to then, he served as President and Chief Operating Officer at Omrix Biopharmaceuticals,&nbsp;Inc., a public company acquired by Johnson&nbsp;&amp; Johnson in 2008. Prior to Omrix, Mr.&nbsp;Mashiach
held leadership positions at several pharmaceutical companies. He has been a board and audit committee member of Mediwound&nbsp;Ltd. (NASDAQ: MDWD) sicne June 2017. He holds an MBA from the University of Manchester, England, an MPharmSc from the
Hebrew University, Jerusalem, Israel, and a BSc, Chemical Engineering from the Technion-Israel Institute of Technology, Haifa, Israel.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We believe that Mr.&nbsp;Mashiach's experience with working with a number of biopharmaceutical companies, combined with his pharmaceutical
industry experience and background, make him qualified to serve as a member of our Board of Directors.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=721687,FOLIO='14',FILE='DISK109:[18ZAY1.18ZAY12901]DE12901A.;17',USER='CHE109569',CD='15-MAR-2018;15:17' -->
<A NAME="page_de12901_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Board of Directors Tenure, Principal Occupation,<BR>
Other Business Experience<BR>
During the Past Five Years and Other Directorships </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christopher K. Mirabelli<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer</I></FONT><BR>
<FONT SIZE=2><I>President</I></FONT><BR>
<FONT SIZE=2><I>Chairman of the board of directors</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Mirabelli, age 63, has served as the Chairman of our Board of Directors since January 2016 and has also served as our President, Chief Executive
Officer and a director since our inception in January 2011. Dr.&nbsp;Mirabelli has been a managing director of HealthCare Ventures&nbsp;LLC since August 2000. From December 1999 to May 2000, Dr.&nbsp;Mirabelli served as president of pharmaceutical
research and development and member of the board of directors of Millennium Pharmaceuticals,&nbsp;Inc., following its merger with LeukoSite&nbsp;Inc., where Dr.&nbsp;Mirabelli had been serving as president, chief executive officer and chairman of the
board of directors since 1993. He was a co-founder of Ionis Pharmaceuticals,&nbsp;Inc. (NASDAQ: IONS), where he held several positions including senior vice president of research, from 1989 until 1993.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline&nbsp;Plc) R&amp;D Division. He is a
member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr.&nbsp;Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in
molecular pharmacology from Baylor College of Medicine and a B.S. degree in biology from State University of New York at Fredonia.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We believe that Dr.&nbsp;Mirabelli's experience with Leap from serving as our President, Chief Executive Officer and Chairman, leadership in
a number of biopharmaceutical companies, combined with his venture capital industry experience and scientific background, make him qualified to serve as a member of our Board of Directors and its chair.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="de12901_executive_officers_who_are_not_directors"> </A>
<A NAME="toc_de12901_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers Who Are Not Directors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain information regarding our executive officers who are not also directors, as of March&nbsp;15, 2018, is set forth below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="119pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Positions(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>Augustine K. Lawlor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Chief Operating Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>Douglas E. Onsi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Chief Financial Officer, General Counsel, Treasurer and Secretary</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Augustine Lawlor.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Lawlor, age 61, has served as our Chief Operating Officer since January 2016. Mr.&nbsp;Lawlor has
been a managing
director of HealthCare Ventures&nbsp;LLC since June 1999, including serving as the chief executive officer of GITR,&nbsp;Inc. prior to its merger into Leap. Prior to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=468945,FOLIO='15',FILE='DISK109:[18ZAY1.18ZAY12901]DE12901A.;17',USER='CHE109569',CD='15-MAR-2018;15:17' -->
<A NAME="page_de12901_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>joining
HealthCare Ventures, Mr.&nbsp;Lawlor served as Chief Operating Officer of LeukoSite&nbsp;Inc., a biotechnology company, from 1997 to 1999. Before joining LeukoSite, Mr.&nbsp;Lawlor
served as Chief Financial Officer and Vice President of Corporate Development of Alpha-Beta Technology,&nbsp;Inc., a biotechnology company. He was also previously Chief Financial Officer and Vice
President, Business Development, of BioSurface Technologies Corporation, a biofilm company. Mr.&nbsp;Lawlor serves on the board of directors of Cardiovascular Systems,&nbsp;Inc. and Catalyst
Biosciences,&nbsp;Inc., each a publicly-traded biopharmaceutical company, and a number of private companies. He received a B.A. from the University of New Hampshire and a master's degree in
management from Yale University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Douglas E. Onsi.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Onsi, age 49, has served as our Chief Financial Officer, Treasurer and Secretary since our inception
in January 2011.
Mr.&nbsp;Onsi has been at HealthCare Ventures since August 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics,&nbsp;Inc. which was
sold to Roche Holdings,&nbsp;Inc. in 2016. Prior to joining HealthCare Ventures, Mr.&nbsp;Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President,
Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of
Tolerx,&nbsp;Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx,&nbsp;Inc., he was in business development at LeukoSite, a publicly traded
biopharmaceutical company that was acquired by Millennium Pharmaceuticals,&nbsp;Inc. He began his career as an attorney at Bingham Dana&nbsp;LLP. Mr.&nbsp;Onsi currently serves as a member of
the board of directors of Vaxxas Pty&nbsp;Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences
from Cornell University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no family relationships among any of our directors or executive officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=20,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=197546,FOLIO='16',FILE='DISK109:[18ZAY1.18ZAY12901]DE12901A.;17',USER='CHE109569',CD='15-MAR-2018;15:17' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg12901_1_17"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="corporate_governace"></A>CORPORATE GOVERNANCE MATTERS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors believes that good corporate governance is important to ensure that our company is managed for the long-term benefit of
our stockholders. The following sections describes key corporate governance guidelines and practices that we have adopted. Complete copies of our Audit Committee Charter, Compensation Committee
Charter, Nominating and Corporate Governance Committee Charter and our Code of Business Conduct and Ethics are available on the Investor Relations section of our website, </FONT> <FONT SIZE=2><I>www.investors.lptx.com,</I></FONT><FONT SIZE=2> at
"Corporate Governance". Alternatively, you can request a copy of any of these documents by writing us at: Leap
Therapeutics,&nbsp;Inc., Attn: Secretary, 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts 02141 USA. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_corporate_governance_guidelines"> </A>
<A NAME="toc_dg12901_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Governance Guidelines    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has adopted Corporate Governance Guidelines to assist it in the exercise of its duties and responsibilities and to serve
the best interests of our company and our stockholders. These principles, which set forth a framework for the conduct of our Board of Directors' business, provide
that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the principal responsibility of the directors is to oversee our management and to hold our management accountable for the pursuit of our
corporate objectives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> except as otherwise required by the rules and regulations of the Nasdaq Stock Market, a majority of the members of our Board of Directors must
be independent directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the independent directors meet regularly in executive session; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> directors have full and free access to management and, as necessary and appropriate, independent advisors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> new directors participate in an orientation program and all directors are encouraged to attend director education programs. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_director_independence"> </A>
<A NAME="toc_dg12901_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rule&nbsp;5605 of the NASDAQ Listing Rules requires a majority of a listed company's board of directors to be comprised of independent
directors within one year of listing. In addition, the NASDAQ Listing Rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and
corporate governance committees be independent under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Audit committee members must also satisfy independence criteria set forth in
Rule&nbsp;10A-3 under the Exchange Act, and compensation committee members must also satisfy the independence criteria set forth in Rule&nbsp;10C-1 under the Exchange Act. Under
Rule&nbsp;5605(a)(2), a director will only qualify as an "independent director" if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the
exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule&nbsp;10A-3, a member of an audit committee of a listed
company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory,
or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. In order to be considered
independent for purposes of Rule&nbsp;10C-1, the board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a
director has a relationship to such company which is material to that director's ability to be independent from management in connection with the duties of a compensation committee member, including,
but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director; and whether the director is affiliated
with the company or any of its subsidiaries or affiliates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=21,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=540848,FOLIO='17',FILE='DISK109:[18ZAY1.18ZAY12901]DG12901A.;12',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<A NAME="page_dg12901_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Cavanaugh
and Messrs.&nbsp;Littlechild and Mashiach are the current members of our audit committee; Drs. Dietz and Li and Mr.&nbsp;Littlechild are the current members of
our compensation committee; and Drs. Cavanaugh and Loscalzo are the current members of our nominating and corporate governance committee. In March 2018, our Board of Directors undertook a review of
the composition of our Board of Directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her
background, employment and affiliations, including family relationships, our Board of Directors has determined that (i)&nbsp;each of our directors, except for Christopher Mirabelli, qualifies as an
"independent director" as defined under NASDAQ Listing Rules, (ii)&nbsp;each of our audit committee members was independent pursuant to Rule&nbsp;10A-3 under the Exchange Act, and
(iii)&nbsp;each of our compensation committee members was independent pursuant to Rule&nbsp;10C-1 under the Exchange Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
making such determinations, our Board of Directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances our
Board of Directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_director_nomination_process"> </A>
<A NAME="toc_dg12901_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nomination Process    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee evaluates director candidates and selects or recommends for selection by the Board of
Directors, director nominees. The process followed by the nominating and corporate governance committee to identify and evaluate director candidates may include requests to Board of Directors' members
and others for recommendations, meetings from time to time to evaluate biographical information and background material relating to potential candidates, and interviews of selected candidates by
members of the Board of Directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Criteria and Diversity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In considering whether to recommend any particular candidate for inclusion in the Board of Directors' slate of recommended director nominees,
the nominating and corporate governance committee applies certain criteria as set forth in our Corporate Governance Guidelines. These criteria include the candidate's business experience and skills,
independence, character, wisdom, judgment, integrity, ability to make independent analytical inquiries, understanding of our business environment, the ability to commit sufficient time and attention
to board activities, and the absence of potential conflicts with our interests. The Board of Directors does not assign specific weights to particular criteria and no particular criterion is a
prerequisite for any prospective nominee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
corporate governance committee and Board of Directors do not have a formal policy with respect to diversity, but an objective of board composition is to bring to our company a
variety of perspectives and skills derived from high quality business and professional experience. Our Board of Directors recognizes its responsibility to ensure that nominees for our Board of
Directors possess appropriate qualifications and reflect a reasonable diversity of personal and professional experience, skills, backgrounds and perspectives. We believe that the backgrounds and
qualifications of our directors, considered as a group, should provide a composite mix of experience, knowledge and abilities that will allow our Board of Directors to promote our strategic objectives
and to fulfill its responsibilities to our stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
director biographies on pages 10-15 indicate each director's experience, qualifications, attributes and skills that led the Board of Directors to conclude that each should continue
to serve as a member of our Board of Directors. Our nominating and corporate governance committee and Board of Directors believes that each of the directors has had substantial achievement in his or
her professional and personal pursuits and possesses the background, talents and experience that our Board of Directors desires and that will contribute to the best interests of our company and to
long-term stockholder value. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=22,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=803149,FOLIO='18',FILE='DISK109:[18ZAY1.18ZAY12901]DG12901A.;12',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<A NAME="page_dg12901_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
additional information regarding stockholder nominations and other proposals see "Stockholder Proposals for 2018 Annual Meeting." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<A NAME="bm"></A>Board of Directors Meetings and Attendance  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors met 6 times during 2017, either in person or by teleconference. During 2017, each of our directors attended at least 75%
of the aggregate number of the meetings of the Board of Directors and the committees on which they served. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Corporate Governance Guidelines provide that our directors are invited and encouraged to attend our annual meeting of stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_board_of_directors_leadership_structure"> </A>
<A NAME="toc_dg12901_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Leadership Structure    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Christopher Mirabelli is the Chairman of our Board of Directors. Dr.&nbsp;Mirabelli has authority, among other things, to call and preside
over meetings of our Board of Directions and set meeting agendas. As a result of Dr.&nbsp;Mirabelli's extensive history with and knowledge of Leap Therapeutics, he is able to provide valuable
insight and help ensure that the Board of Directors and management act with a common purpose. If Dr.&nbsp;Mirabelli is ever not present at a meeting of the board
of directors, an independent director is appointed to chair such meetings. In general, the agenda for every regularly scheduled board of directors meeting includes a meeting of the "Independent
Directors" in executive session. In any event, the non-management directors meet in executive session at least semi-annually to discuss, among other matters, the performance of the Chief Executive
Officer. The director who presides at these meetings is a non-management director selected by a majority of the non-management directors. There have been 4 meetings of the Independent Directors in
executive session in 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have a separate chair for each committee of our Board of Directors. The chairs of each committee are expected to report to our Board of Directors on the activities of their committee
in fulfilling their responsibilities as detailed in their respective charters, if any. Our Board of Directors delegates substantial responsibilities to the committees, which report their activities
and actions back to the full Board of Directors. We believe this structure represents an appropriate allocation of roles and responsibilities for our company at this time because it strikes an
effective balance in the participation of management and independent leadership in our Board of Directors' proceedings. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_board_of_directors_committees"> </A>
<A NAME="toc_dg12901_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Committees    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of
which operates pursuant to a charter adopted by our Board of Directors. The composition and functioning of all of our committees complies with all applicable requirements of the Sarbanes-Oxley Act of
2002, rules and regulations of the Nasdaq Stock Market and the SEC. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
composition and responsibilities of each of the committees of our Board of Directors are described below. Members serve on these committees until their resignation or until otherwise
determined by our Board of Directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our audit committee are Thomas Dietz, John Littlechild, and Nissim Mashiach with Thomas Dietz serving as chairman. The financial
literacy requirements of the Commission require that each member of our audit committee be able to read and understand fundamental financial statements. In addition, at least one member of our audit
committee must be qualified as an audit committee financial expert, as defined in Item&nbsp;407(d)(5) of Regulation&nbsp;S-K
promulgated under the Securities Act, and have financial sophistication in accordance with the NASDAQ stock market rules. Our Board of Directors has determined that Mr.&nbsp;Dietz qualifies as an
audit committee financial expert. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=23,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=154762,FOLIO='19',FILE='DISK109:[18ZAY1.18ZAY12901]DG12901A.;12',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<A NAME="page_dg12901_1_20"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary purpose of our audit committee is to assist the Board of Directors in the oversight of the integrity of our accounting and financial reporting process, the audits of our
financial statements, and our compliance with legal and regulatory requirements. The functions of our audit committee will include, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> hiring the independent registered public accounting firm to conduct the annual audit of our financial statements and monitoring its
independence and performance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving the planned scope of the annual audit and the results of the annual audit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pre-approving all audit services and permissible non-audit services provided by our independent registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing the significant accounting and reporting principles to understand their impact on our financial statements </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing our internal financial, operating and accounting controls with management, our independent registered public accounting firm and our
internal audit provider; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing with management and our independent registered public accounting firm, as appropriate, our financial reports, earnings announcements
and our compliance with legal and regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing potential conflicts of interest under and violations of our Code of Conduct; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing procedures for the treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters
and confidential submissions by our employees of concerns regarding questionable accounting or auditing matters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving related-party transactions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and evaluating, at least annually, our audit committee's charter. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee operates under a written charter that satisfies the applicable standards of the Nasdaq Stock Market and the SEC and which is available on our website at </FONT> <FONT SIZE=2><I>www.investors.lptx.com</I></FONT><FONT SIZE=2> at
"Corporate Governance". The Audit Committee met 5 times during 2017, either in person or by teleconference.
 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our compensation committee are Thomas Dietz, John Littlechild, and William Li, with John Littlechild serving as chairman. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary purpose of our compensation committee is to assist our Board of Directors in exercising its responsibilities relating to compensation of our executive officers and employees
and to administer our equity compensation and other benefit plans. In carrying out these responsibilities, this committee will review all components of executive officer and employee compensation for
consistency with its compensation philosophy, as in effect from time to time. The functions of our compensation committee will include, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> designing and implementing competitive compensation policies to attract and retain key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and formulating policy and determining the compensation of our executive officers and employees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and recommending to our board of directors the compensation of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> administering our equity incentive plans and granting equity awards to our employees and directors under these plans; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=24,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=405212,FOLIO='20',FILE='DISK109:[18ZAY1.18ZAY12901]DG12901A.;12',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<A NAME="page_dg12901_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if required from time to time, reviewing with management our disclosures under the caption "Compensation Discussion and Analysis" and
recommending to the full board its inclusion in our periodic reports to be filed with the Commission; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if required from time to time, preparing the report of the compensation committee to be included in our annual proxy statement; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> engaging compensation consultants or other advisors it deems appropriate to assist with its duties; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and evaluating, at least annually, our compensation committee's charter. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee operates under a written charter that satisfies the applicable standards of the Nasdaq Stock Market and which is available on our website at </FONT> <FONT SIZE=2><I>www.investors.lptx.com</I></FONT><FONT SIZE=2> at "Corporate
Governance". The Compensation Committee met 1 time during 2017 in person or by teleconference. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_compensation_committee__dg102476"> </A>
<A NAME="toc_dg12901_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No member of our compensation committee has ever been an executive officer or employee of ours. None of our executive officers currently serves,
or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more executive officers serving as a member of our Board of
Directors or compensation committee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_nominating_and_corporate_governance_committee"> </A>
<A NAME="toc_dg12901_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our nominating and corporate governance committee are James Cavanaugh and Joseph Loscalzo, with James Cavanaugh serving as
chairman. Our Board has determined that each of James Cavanaugh and Joseph Loscalzo satisfies the NASDAQ independence standards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary purpose of our nominating and corporate governance committee is to assist our Board of Directors in promoting the best interests of our company and our stockholders through
the implementation of sound corporate governance principles and practices. The functions of our nominating and corporate governance committee will include, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identifying, reviewing and evaluating candidates to serve on our board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> determining the minimum qualifications for service on our board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and recommending to our board an annual self-evaluation process for our board and overseeing the annual self-evaluation process; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing, as appropriate, a set of corporate governance principles, and reviewing and recommending to our board any changes to such
principles; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> periodically reviewing and evaluating our nominating and corporate governance committee's charter. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee operates under a written charter that satisfies the applicable standards of the Nasdaq Stock Market and which is available on our
website at </FONT><FONT SIZE=2><I>www.investors.lptx.com</I></FONT><FONT SIZE=2> at "Corporate Governance". The nominating and corporate governance committee did not meet separately from the Board of
Directors during 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_board_of_directors__role_in_risk_oversight"> </A>
<A NAME="toc_dg12901_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors' Role in Risk Oversight    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors oversees the management of risks inherent in the operation of our business and the implementation of our business
strategies. Our Board of Directors performs this oversight role by using several different levels of review. In connection with its review of the operations and corporate functions of our company, our
Board of Directors addresses the principal risks </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=25,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=585452,FOLIO='21',FILE='DISK109:[18ZAY1.18ZAY12901]DG12901A.;12',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<A NAME="page_dg12901_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>associated
with those operations and corporate functions. In addition, our Board of Directors reviews the risks associated with our business strategies periodically throughout the year as part of its
consideration of undertaking any such business strategies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures,
including guidelines and policies to govern the process by which risk assessment and management are undertaken. Our audit committee also monitors compliance with legal and regulatory requirements, in
addition to oversight of the performance of our internal audit function and whistleblower protections. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee assesses and monitors the extent to which our incentive compensation policies and programs for all employees may encourage excessive risk-taking and the
relationship between risk management policies and practices and compensation, and evaluates compensation policies and practices that could mitigate any such risk. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_communicating_with_the_directors"> </A>
<A NAME="toc_dg12901_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Communicating with the Directors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors will give appropriate attention to written communications that are submitted by stockholders and other interested
parties, and will respond if and as appropriate. The General Counsel is primarily responsible for monitoring communications from stockholders and other interested parties and for providing copies or
summaries of such communications to the directors as he considers appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
procedures approved by our Board of Directors, communications are forwarded to all directors if they relate to important substantive matters and include suggestions or comments
that our General Counsel considers to be important for the directors to know. In general, communications relating to corporate governance and corporate strategy are more likely to be forwarded than
communications relating to ordinary business affairs, personal grievances and matters that are duplicative communications. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders
and other interested parties who wish to send communications on any topic to the Board of Directors should address such communications to: Board of Directors, c/o General
Counsel, Leap Therapeutics,&nbsp;Inc., 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts 02141 USA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
we have established a confidential process for reporting, investigating and resolving employee and other third party concerns related to accounting, auditing and similar
matters under the Sarbanes-Oxley Act of 2002. Stockholders and other interested parties may confidentially provide information to one or more of our directors by using the confidential and anonymous
financial concern hotline that is operated by an independent, third party service. Within the United States and Canada,
the Ethics Hotline can be reached by telephone, toll-free, at 1-844-413-0900, e-mailing the Company at&nbsp;LPTX@openboard.info, or visiting http://www.openboard.info/LPTX/. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dg12901_code_of_business_conduct_and_ethics"> </A>
<A NAME="toc_dg12901_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a Code of Business Conduct and Ethics (the "Code of Conduct") that is applicable to all of our employees, executive officers and
directors. The Code of Conduct is available on our website at www.investors.leaptx.com at "Corporate Governance". The nominating and corporate governance committee of our Board of Directors will be
responsible for overseeing the Code of Conduct and the General Counsel or Board of Directors approve any waivers of the Code of Conduct for employees, executive officers or directors. We expect that
any amendments to the Code of Conduct, or any waivers of its requirements, will be disclosed on our website or in a current report on Form&nbsp;8-K. We shall provide to any person without charge,
upon request, a copy of the Code of Conduct. Any such request must be made in writing to Leap Therapeutics&nbsp;Inc., c/o Investor Relations, 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=26,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=467937,FOLIO='22',FILE='DISK109:[18ZAY1.18ZAY12901]DG12901A.;12',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di12901_1_23"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di12901_executive_compensation"> </A>
<A NAME="toc_di12901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di12901_overview"> </A>
<A NAME="toc_di12901_2"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following discussion relates to the compensation of our Chief Executive Officer and President, Christopher Mirabelli, and our next two most
highly compensated persons serving as executive officers as of December&nbsp;31, 2017. Each year, our Compensation Committee reviews and determines the compensation of our executive officers. Our
executive compensation program is designed to attract and retain a highly skilled team of key executives and to align the compensation of
our executives with the interests of our stockholders by rewarding the achievement of short- and long-term strategic financial goals, which we believe serves to enhance short- and long-term value
creation for our stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="sum"></A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di12901_summary_compensation_table"> </A>
<A NAME="toc_di12901_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents compensation awarded in 2017 to our principal executive officer and our other executive officers as of
December&nbsp;31, 2017, or compensation paid to or accrued for those executive officers for services rendered during 2017. We refer to these executive officers as our "named executive officers". </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Awards<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Total ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Christopher K. Mirabelli</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>397,048</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>112,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,115,971</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,524</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>(4)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,659,543</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Executive Officer and President</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Augustine Lawlor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
397,048</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
112,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2,115,971</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
32,941</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR></FONT><FONT SIZE=2><B>(5)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2,657,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Operating Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Douglas E. Onsi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
397,048</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
112,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2,115,971</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
33,413</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR></FONT><FONT SIZE=2><B>(6)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2,658,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Financial Officer, Treasurer and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Secretary</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christopher K. Mirabelli</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
350,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
33,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR></FONT><FONT SIZE=2><B>(4)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
383,880</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Executive Officer and President</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Augustine Lawlor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
350,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
32,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR></FONT><FONT SIZE=2><B>(5)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
382,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Operating Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Douglas E. Onsi</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
350,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
31,301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR></FONT><FONT SIZE=2><B>(6)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
381,301</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Financial Officer, Treasurer and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Secretary</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
2016 base salary for each named executive officer became effective January&nbsp;1, 2016. Upon the consummation of the merger on January&nbsp;23, 2017, the
base salary for each of Christopher K. Mirabelli, Augustine Lawlor and Douglas E. Onsi was increased to $400,000.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>This
column represents a cash incentive bonus for 2017, which was paid in 2018 to each executive.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>This
column reflects the aggregate fair value of equity awards granted in 2017 as of the grant date for each such award, and is calculated in accordance with ASC
718, using the Black-Scholes option-pricing model. Assumptions used in the calculations for these amounts are set forth in Note&nbsp;10 to our financial statements included in our Annual Report on
Form&nbsp;10-K filed with the SEC on February&nbsp;23, 2018. In connection with the consummation of the merger with Macrocure&nbsp;Ltd., in January 2017, we made an option grant to each
executive to purchase 330,303 shares of Leap's common stock pursuant to our Amended and Restated 2012 Equity Incentive Plan. These options vested 33% on the first anniversary of the date of grant, and
thereafter in equal monthly installments over a period of two years, generally subject to the executive's continued employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>For
2017, other compensation includes 401(k) matching ($15,055), payment of medical insurance ($16,936) and dental insurance ($1,296) and life insurance ($1,237).
For 2016, other compensation includes 401(k) matching ($11,667), payment of medical insurance ($16,002) and dental insurance ($1,037) and life insurance ($5,174). </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=849920,FOLIO='23',FILE='DISK109:[18ZAY1.18ZAY12901]DI12901A.;17',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<A NAME="page_di12901_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>For
2017, other compensation includes 401(k) matching ($14,165), payment of medical insurance ($16,243) and dental insurance ($1,296) and life insurance ($1,237).
For 2016, other compensation includes 401(k) matching ($11,667), payment of medical insurance ($16,002) and dental insurance ($1,037) and life insurance ($3,338).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>For
2017, other compensation includes 401(k) matching ($14,900), payment of medical insurance ($16,936) and dental insurance ($1,296) and life insurance ($281). For
2016, other compensation includes 401(k) matching ($12,250), payment of medical insurance ($16,002) and dental insurance ($1,037) and life insurance ($2,012). </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di12901_elements_of_executive_compensation"> </A>
<A NAME="toc_di12901_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Elements of Executive Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The compensation of our named executive officers consists of base salary, annual cash bonuses, equity awards and employee benefits that are made
available to all salaried employees. Our named executive officers are also entitled to certain compensation and benefits upon certain terminations of employment and certain change of control
transactions pursuant to employment agreements. In addition to the factors discussed below, the compensation committee also considers recommendations from Dr.&nbsp;Mirabelli, who as our Chief
Executive Officer regularly discusses compensation issues with the chairperson of the compensation committee and meets with our compensation committee to discuss these matters. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following describes the material terms of the elements of our executive compensation program during fiscal year 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive compensation program is based on a pay-for-performance philosophy. We designed our executive compensation program to achieve the
following primary objectives: provide compensation and benefit levels that will attract, retain, motivate and reward a highly talented executive team within the context of responsible cost management;
establish a direct link between our individual/team performance and results and our executives' compensation; and align the interests and objectives of our executives with those of our stockholders by
linking executive equity awards to stockholder value creation. Compensation for our executive officers is composed primarily of the following three main components: base salary, annual cash incentive
bonuses, and long-term equity incentives. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base Salary  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salaries are determined on a case-by-case basis for each executive officer (including our three named executive officers), including
consideration of each officer's experience, expertise and performance, as well as market compensation levels for similar positions. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016<BR>
Base Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Christopher K. Mirabelli</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>350,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Executive Officer and President</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Augustine Lawlor</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
350,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Operating Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Douglas E. Onsi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
350,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Financial Officer,</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Treasurer and Secretary</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
2017 base salary for each named executive officer became effective January&nbsp;23, 2017.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=792997,FOLIO='24',FILE='DISK109:[18ZAY1.18ZAY12901]DI12901A.;17',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<A NAME="page_di12901_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Cash Incentive Bonuses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual cash incentive bonuses are contingent upon our achievement of certain operational and financial objectives, which for 2017 are expected
to consist entirely of corporate goals. Each executive officer's target bonus amount is expressed as a percentage of the officer's base salary and is intended to be commensurate with the officer's
position and responsibilities. Target bonuses for each officer are 35% of base salary for the year ended December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long-term Equity Incentives  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe equity awards in the form of options to purchase shares of our common stock provide an incentive for our executive officers to focus
on driving growth in our stock price and long-term value creation and help us to attract and retain key talent. In addition, the granting of options helps ensure that the interests of our officers are
aligned with those of our stockholders as the options only have value if the value of our common stock increases after the date the option is granted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
officers are entitled to certain benefits if the officer's employment terminates in certain circumstances or if a change of control occurs. Our Board of Directors and our
compensation committee review our officers' overall compensation packages on an annual basis or more frequently as it deems appropriate. From time to time, we may retain independent compensation
consultants as we consider appropriate to help identify appropriate peer group companies and to obtain and evaluate current executive compensation data. In 2016, we retained compensation consultants
in designing our executive compensation programs. Moving forward, we expect that our compensation committee will retain independent compensation consultants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<A NAME="emp"></A>Employment Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into employment agreements with each of our executive officers (including our named executive officers), Messrs.&nbsp;Lawlor
and Onsi and Dr.&nbsp;Mirabelli, on the same terms. The following is a summary of the material terms of each employment agreement including terms related to severance and payments upon termination
or change of control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive employment agreements do not include a specified term as their employment is "at-will". The agreements provide that each executive receives an annual base salary, initially
established at $400,000, and that he is eligible for an annual incentive bonus, with his target bonus being 35% of his base salary. The compensation committee of the Board of Directors determines the
executive's actual bonus amount based on its assessment of the satisfaction of performance criteria to be established by the compensation committee within the first three months of each fiscal year.
The agreement also provides for the executive to participate in our benefit programs made available to our employees generally. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
each executive's agreement, if his employment is terminated by us without cause or if the executive resigns with good reason (as such terms are defined in the agreement), in either
case prior to
a change in control or one year after a change in control (as such term is defined in the agreement), he will be entitled to receive cash severance equal to his annualized base salary; a pro-rata
bonus, payable within two and one-half months following the end of the fiscal year in which the termination or resignation occurs; any accrued or earned, but unpaid or unreimbursed, base salary,
expenses, benefits, bonus, rights to indemnification, or vacation pay; reimbursement of his COBRA premiums for 12&nbsp;months; and acceleration of vesting on any outstanding equity awards along with
extension of the time period to exercise the outstanding equity awards to one year. In the event that such termination or resignation occurs during the one-year period immediately following a change
in control, the executive will also receive, an increase in the cash severance amount to double his annualized base salary, an extension of the time period during which Leap will reimburse COBRA
premiums to 18&nbsp;months, and extension of the time period to exercise all outstanding equity awards to two years. An </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=810867,FOLIO='25',FILE='DISK109:[18ZAY1.18ZAY12901]DI12901A.;17',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<A NAME="page_di12901_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>executive's
right to receive these severance benefits is subject to his providing a release of claims in favor of Leap and return of all company property. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that a change in control occurs within two years of the effective date of an executive's employment agreement, and the severance and other benefits provided in the agreement
are considered "parachute payments" within the meaning of 280G of the Code and are subject to the excise tax imposed by Section&nbsp;4999 of the code, then the executive will be entitled to receive
an additional gross-up payment. This payment shall be in an amount equal to the excise tax and taxes imposed on such payment. Additionally, in the event that such change in control occurs more than
two years after the effective date of the executive's employment agreement and the same conditions above are applicable, the executive's severance and other benefits constituting parachute payments
will be either (i)&nbsp;delivered in full or (ii)&nbsp;delivered to a lesser extent which would result in no portion of such severance being subject to excise tax under Section&nbsp;4999 of the
Code, whichever provides the greatest amount to the executive. If any reduction in severance and other benefits constituting parachute payments is necessary to achieve the effect of clause&nbsp;(ii)
above, then the reduction will occur first from cash severance payments, next from cancellation of accelerated vesting of equity awards and third from reduction of continued employee benefits. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
executive's employment agreement incorporates the terms and provisions of a customary employee proprietary information, invention, non-competition and non-solicitation between Leap
and the executive. This agreement includes a noncompetition covenant during the period of the executive's employment and for one year thereafter. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di12901_stock_option_and_other_compensation_plans"> </A>
<A NAME="toc_di12901_5"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Option and Other Compensation Plans    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the consummation of the merger with Macrocure&nbsp;Ltd., in January 2017, we made an option grant to each executive to
purchase 330,303 of shares of Leap's common stock pursuant to our Amended and Restated 2012 Equity Incentive Plan, which is described in further detail below. This option grant is at an exercise price
$9.90 per share. Each option granted to an executive will vest 33% on the first anniversary of the date of grant, and thereafter in equal monthly installments over a period of two years, generally
subject to the executive's continued employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di12901_outstanding_equity_awards_at_fiscal_year-end"> </A>
<A NAME="toc_di12901_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at Fiscal Year-End    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding equity awards held by our named executive officers as of December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Christopher K. Mirabelli</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/20/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>330,303</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/20/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Executive Officer and President</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Augustine Lawlor</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/20/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
330,303</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/20/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Operating Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Douglas E. Onsi</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/20/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
330,303</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/20/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Financial Officer,</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Treasurer and Secretary</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=30,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=747874,FOLIO='26',FILE='DISK109:[18ZAY1.18ZAY12901]DI12901A.;17',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<A NAME="page_di12901_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="di12901_retirement_benefits"> </A>
<A NAME="toc_di12901_7"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Retirement Benefits    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a defined contribution employee retirement plan, or 401(k) plan, for our employees. Our named executive officers are also eligible
to participate in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a tax-qualified plan under Section&nbsp;401(k) of the Code. The plan provides
that each participant may contribute up to the statutory limit, which is $18,000 for calendar year 2017. Participants that are 50&nbsp;years or older can also make "catch-up" contributions, which in
calendar year 2017 may be up to an additional $6,000 above the statutory limit. In general, eligible compensation for purposes of the 401(k) plan includes an employee's earnings reportable on IRS
Form&nbsp;W-2 subject to certain adjustments and exclusions required under the Code. We also make matching employer contributions in cash to each employee's 401(k) plan at a rate of 100% of the
first 3% of earnings contributed by each such employee and 50% of the next 2% of earnings contributed. Employees participating in the 401(k) plan are fully vested in our matching contributions, and
investments are directed by employees. The 401(k) plan currently does not offer the ability to invest in our securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="equity_plan_infor"></A>EQUITY COMPENSATION PLAN INFORMATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table contains information about our equity compensation plans as of December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="97pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="94pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="97pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon<BR>
exercise of<BR>
outstanding stock<BR>
options, warrants<BR>
and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted average<BR>
exercise price of<BR>
outstanding options,<BR>
warrants and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available<BR>
for future issuance<BR>
under equity<BR>
compensation plans </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders</FONT><FONT SIZE=2><B>(1)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,257,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>(2)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>258,287</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>(3)</B></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans not approved by security holders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,257,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>(2)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>258,287</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><B>(3)</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
information regarding our Amended and Restated 2012 Equity Incentive Plan, our 2016 Equity Incentive Plan and the assumed Macrocure 2013 Plan and 2008 Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;277,889 shares of Leap common stock issued in connection with the exchange of Macrocure options and the assumption of the Macrocure 2013 Plan and
2008 Plan (ii)&nbsp;1,380,677 shares issued pursuant to the Amended and Restated 2012 Equity Incentive Plan and (iii)&nbsp;599,055 shares issued pursuant to the Leap 2016 Equity Incentive Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
255,266 shares reserved for issuance under the Leap 2016 Equity Incentive Plan and 3,021 shares reserved for issuance under the Leap Amended and Restated
2012 Equity Incentive Plan.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di12901_director_compensation"> </A>
<A NAME="toc_di12901_8"> </A>
<BR></FONT><FONT SIZE=2><B>  DIRECTOR COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our director compensation program, we pay our non-employee directors retainers in cash. We do not pay any compensation to our President
and Chief Executive Officer in connection with his service on our Board and, consequently, he is not included in the table. The compensation that we pay to our President and Chief Executive Officer is
discussed in the "Executive Compensation" section of this Proxy Statement. Each non-employee director receives a cash retainer for service on the Board and for service on each committee(s) on which
the director is a member. The chairmen of each committee receive higher retainers for such service. These fees are payable semi-annually in arrears. Each </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=31,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=191415,FOLIO='27',FILE='DISK109:[18ZAY1.18ZAY12901]DI12901A.;17',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<A NAME="page_di12901_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>non-employee
director shall be paid an annual fee of $40,000 and such additional fees as set out in the following table: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Non-Employee Director

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual<BR>
Fee ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chairman of audit committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Member of audit committee (other than chairman)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chairman of compensation committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Member of compensation committee (other than chairman)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chairman of governance and nominating committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Member of governance and nominating committee (other than chairman)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also continue to reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending Board and committee meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, under our director compensation program, each non-employee director elected to our Board will receive an option to purchase 15,000 shares of our common stock, with each of
these options vesting in equal quarterly installments over a three-year period measured from the date of grant, subject to the non-employee director's continued service as a director, and becoming
exercisable in full upon a change in control of our Company. Further, we expect to make a grant of options to purchase 7,500 shares of common stock around the time of Leap's 2018 Annual Meeting of the
Stockholders, to all Directors whose service will continue. These option grants will be at an exercise price equal to the fair market value of Leap's common stock on the date of grant and will vest
quarterly over a one-year period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
policy is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our
directors' interests with those of our stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current director compensation arrangements have been in effect since Leap became a public company in January 2017. Prior to that time, we did not have a formal non-employee director
compensation policy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information regarding compensation earned by our non-employee directors during fiscal year 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-4pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR style="line-height:0pt;"><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="100.00%" style="font-family:times;"><div style="width:100.00%;"></div></TD>
<TD WIDTH="12.0pt" style="font-family:times;"><div style="width:12.0pt;"></div></TD>
<TD WIDTH="3.96pt" style="font-family:times;"><div style="width:3.96pt;"></div></TD>
<TD WIDTH="5.0pt" ALIGN="RIGHT" style="font-family:times;"><div style="width:5.0pt;"></div></TD>
<TD WIDTH="22.52pt" style="font-family:times;"><div style="width:22.52pt;"></div></TD>
<TD WIDTH="3.96pt" style="font-family:times;"><div style="width:3.96pt;"></div></TD>
<TD WIDTH="17.0pt" style="font-family:times;"><div style="width:17.0pt;"></div></TD>
<TD WIDTH="6.56pt" style="font-family:times;"><div style="width:6.56pt;"></div></TD>
<TD WIDTH="5.0pt" ALIGN="RIGHT" style="font-family:times;"><div style="width:5.0pt;"></div></TD>
<TD WIDTH="27.50pt" style="font-family:times;"><div style="width:27.50pt;"></div></TD>
<TD WIDTH="6.56pt" style="font-family:times;"><div style="width:6.56pt;"></div></TD>
<TD WIDTH="12.0pt" style="font-family:times;"><div style="width:12.0pt;"></div></TD>
<TD WIDTH="23.82pt" style="font-family:times;"><div style="width:23.82pt;"></div></TD>
<TD WIDTH="5.0pt" ALIGN="RIGHT" style="font-family:times;"><div style="width:5.0pt;"></div></TD>
<TD WIDTH="17.52pt" style="font-family:times;"><div style="width:17.52pt;"></div></TD>
<TD WIDTH="23.82pt" style="font-family:times;"><div style="width:23.82pt;"></div></TD>
<TD WIDTH="12.0pt" style="font-family:times;"><div style="width:12.0pt;"></div></TD>
<TD WIDTH="5.0pt" ALIGN="RIGHT" style="font-family:times;"><div style="width:5.0pt;"></div></TD>
<TD WIDTH="27.50pt" style="font-family:times;"><div style="width:27.50pt;"></div></TD>
<TD WIDTH="12pt" style="font-family:times;"><div style="width:12pt;"></div></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="white-space:nowrap;font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="white-space:nowrap;font-family:times;"><FONT SIZE=1>&#8203;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="white-space:nowrap;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned($) </B></FONT></TH>
<TH style="white-space:nowrap;font-family:times;"><FONT SIZE=1>&#8203;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="white-space:nowrap;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards(1)($) </B></FONT></TH>
<TH style="white-space:nowrap;font-family:times;"><FONT SIZE=1>&#8203;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="white-space:nowrap;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Other<BR>
Compensation(2)($) </B></FONT></TH>
<TH style="white-space:nowrap;font-family:times;"><FONT SIZE=1>&#8203;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="white-space:nowrap;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total($) </B></FONT></TH>
<TH style="white-space:nowrap;font-family:times;"><FONT SIZE=1>&#8203;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James&nbsp;Cavanaugh</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>57,500</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2><B>(3)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#8203;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>171,254</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>1,963</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>230,717</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas&nbsp;Dietz</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2><B>(4)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#8203;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>171,254</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>4,995</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>236,249</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William&nbsp;Li</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>38,917</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2><B>(5)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#8203;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>98,721</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>137,638</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John&nbsp;Littlechild</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2><B>(6)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#8203;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>171,254</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>990</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>232,244</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joseph&nbsp;Loscalzo</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>45,000</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2><B>(7)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#8203;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>171,254</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>216,254</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nissim&nbsp;Mashaich</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>40,167</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2><B>(8)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B>&#8203;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>98,721</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>656</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;" COLSPAN=2><FONT SIZE=2>139,544</FONT></TD>
<TD VALIGN="BOTTOM" style="white-space:nowrap;font-family:times;"><FONT SIZE=2>&#8203;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>This
column reflects the aggregate fair value of equity awards granted in 2017 as of the grant date for each such award, and is calculated in accordance with ASC
718, using the Black-Scholes option-pricing model. Assumptions used in the calculations for these amounts are set forth in Note&nbsp;10 to our financial statements included in our Annual Report on
Form&nbsp;10-K filed with the SEC on February&nbsp;23, 2018. Upon the effectiveness of the merger with Macrocure&nbsp;Ltd., we made an option grant to each non-employee director to purchase
15,000 shares of common stock, which vest on a quarterly basis over a three-year period. In addition, immediately prior to the merger with Macrocure&nbsp;Ltd., we made an option grant to James
Cavanaugh, Thomas Dietz, John </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=32,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=11188,FOLIO='28',FILE='DISK109:[18ZAY1.18ZAY12901]DI12901A.;17',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<A NAME="page_di12901_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>Littlechild
and Joseph Loscalzo, to purchase 11,000 shares of common stock, all of which were immediately vested.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
the amount of expenses reimbursed in connection with travel to and from Board meetings.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$40,000 for annual fee as non-employee director, $7,500 for annual fee as a member of the Audit Committee (member of audit committee until 10/1/17) and
$10,000 for annual fee as Chairman of the Governance&nbsp;&amp; Nominating Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$40,000 for annual fee as non-employee director, $15,000 for annual fee as Audit Committee Chairman and $5,000 for annual fee as a member of the
Compensation Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$37,667 for annual fee as a non-employee director (1/23/17 start date) and $1,250 for annual fee as a member of the Compensation Committee (Appointed
10/1/17).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$40,000 for annual fee as non-employee director, $10,000 for annual fee as member of the Audit Committee and $10,000 for annual fee as Chairman of the
Compensation Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$40,000 for annual fee as non-employee director and $5,000 for annual fee as a member of the Governance&nbsp;&amp; Nominating Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
$37,667 for annual fee as a non-employee director (1/23/17 start date) and $2,500 for annual fee as a member of the Audit Committee (Appointed 10/1/17). </FONT></DD></DL>
 </DIV>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth, as of December&nbsp;31, 2017, the aggregate number of exercisable and unexercisable option awards outstanding held by our non-employee directors at that
time. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Cavanaugh</FONT><FONT SIZE=2><B>(1)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Dietz</FONT><FONT SIZE=2><B>(2)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Li</FONT><FONT SIZE=2><B>(3)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Littlechild</FONT><FONT SIZE=2><B>(4)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joseph Loscalzo</FONT><FONT SIZE=2><B>(5)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nissim Mashiach</FONT><FONT SIZE=2><B>(6)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>186,991</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
the effectiveness of the merger with Macrocure&nbsp;Ltd., we made an option grant to James Cavanaugh to purchase 15,000 shares of common stock, which vest on
a quarterly basis over a three-year period. In addition, immediately prior to the merger with Macrocure&nbsp;Ltd., we made an option grant to James Cavanaugh to purchase 11,000 shares of common
stock, all of which were immediately vested on the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
the effectiveness of the merger with Macrocure&nbsp;Ltd., we made an option grant to Thomas Dietz to purchase 15,000 shares of common stock, which vest on a
quarterly basis over a three-year period. In addition, immediately prior to the merger with Macrocure&nbsp;Ltd., we made an option grant to Thomas Dietz to purchase 11,000 shares of common stock,
all of which were immediately vested on the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
the effectiveness of the merger with Macrocure&nbsp;Ltd., we made an option grant to William Li to purchase 15,000 shares of common stock, which vest on a
quarterly basis over a three-year period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
the effectiveness of the merger with Macrocure&nbsp;Ltd., we made an option grant to John Littlechild to purchase 15,000 shares of common stock, which vest on
a quarterly basis over a three-year period. In addition, immediately prior to the merger with </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=33,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=316356,FOLIO='29',FILE='DISK109:[18ZAY1.18ZAY12901]DI12901A.;17',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<A NAME="page_di12901_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>Macrocure&nbsp;Ltd.,
we made an option grant to John Littlechild to purchase 11,000 shares of common stock, all of which were immediately vested on the grant date.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
the effectiveness of the merger with Macrocure&nbsp;Ltd., we made an option grant to Joseph Loscalzo to purchase 15,000 shares of common stock, which vest on
a quarterly basis over a three-year period. In addition, immediately prior to the merger with Macrocure&nbsp;Ltd., we made an option grant to Joseph Loscalzo to purchase 11,000 shares of common
stock, all of which were immediately vested on the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
the effectiveness of the merger with Macrocure&nbsp;Ltd., we made an option grant to Nissim Mashaich to purchase 15,000 shares of common stock, which vest on
a quarterly basis over a three-year period. In addition, he was granted 183,241 options pursuant to the 2008 and 2013 Macrocure&nbsp;Ltd. Stock Option Plans prior to the merger with
Macrocure&nbsp;Ltd., all of which were vested at December&nbsp;31, 2017.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=34,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=522769,FOLIO='30',FILE='DISK109:[18ZAY1.18ZAY12901]DI12901A.;17',USER='CHE106795',CD='16-MAR-2018;07:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk12901_1_31"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk12901_audit_committee_report"> </A>
<A NAME="toc_dk12901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  AUDIT COMMITTEE REPORT    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>The report of the Audit Committee is not "soliciting material," is not deemed "filed" with the SEC and is not to be incorporated by reference into any filing of the Company
under the Securities Act of 1933 or the Securities Exchange Act of 1934, both as amended.</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee has reviewed the Leap audited consolidated financial statements for the year ended December&nbsp;31, 2017 and has discussed these statements with management and
EisnerAmper&nbsp;LLP, or EisnerAmper, the Company's independent registered public accounting firm. Leap management is responsible for the preparation of the Company's financial statements and for
maintaining an adequate
system of disclosure controls and procedures and internal control over financial reporting for that purpose. The independent registered public accounting firm audits the annual consolidated financial
statements prepared by management, expresses an opinion as to whether those consolidated financial statements present fairly the consolidated financial position, results of operations and cash flows
of Leap Therapeutics,&nbsp;Inc. in conformity with U.S. generally accepted accounting principles and discusses any issues they believe should be raised with us. The Audit Committee is responsible
for providing independent, objective oversight of the Company's accounting functions and internal controls. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee also received from, and discussed with, EisnerAmper the written disclosures and other communications that the Company's independent registered public accounting firm
is required to provide to the Audit Committee, including the matters required to be discussed by Statement on Auditing Standards No.&nbsp;61, as amended (Communication with Audit Committees), as
adopted by the Public Company Accounting Oversight Board, or PCAOB, in Rule&nbsp;3200T. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EisnerAmper
also provided the Audit Committee with the written disclosures and the letter required by Rule&nbsp;3526 of the PCAOB requiring independent registered public accounting
firms to annually disclose in writing all relationships that, in their professional opinion may reasonably be thought to bear on independence, to confirm their perceived independence and to engage in
a discussion of independence. The Audit Committee has reviewed this disclosure and has discussed with EisnerAmper their independence from Leap. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on its discussions with management and our independent registered public accounting firm as outlined above, and its review of the representations and information provided by
management and our independent registered public accounting firm, the Audit Committee recommended to the Board of Directors that the audited consolidated financial statements be included in the Leap
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2017, for filing with the Securities and Exchange Commission. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Respectfully
submitted by the Audit Committee, </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
Thomas Dietz, Chair<BR>
/s/ John Littlechild<BR>
/s/ Nissim Mashiach </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=558465,FOLIO='31',FILE='DISK109:[18ZAY1.18ZAY12901]DK12901A.;8',USER='CHE109864',CD='14-MAR-2018;17:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dm12901_1_32"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="pr2"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> PROPOSAL NO. 2<BR>
RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED<BR>
PUBLIC ACCOUNTING FIRM  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee has appointed the firm of EisnerAmper&nbsp;LLP, or EisnerAmper, an independent registered public accounting firm, to audit
our books, records and accounts for the year ending December&nbsp;31, 2018. This appointment is being presented to the stockholders for ratification at the Annual Meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EisnerAmper&nbsp;LLP
has audited our financial statements since the fiscal year ended December&nbsp;31, 2015. EisnerAmper has no direct or indirect material financial interest in our
company or our subsidiaries. Representatives of EisnerAmper are expected to be present at the Annual Meeting and will be given
the opportunity to make a statement on the firm's behalf if they so desire. The representatives also will be available to respond to appropriate questions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proxies
solicited by management will be voted for ratification unless stockholders specify otherwise. Ratification by the stockholders is not required. Although we are not required to
submit the appointment of EisnerAmper to a vote of the stockholders, our board of directors believes it is appropriate as a matter of policy to request that the stockholders ratify the appointment of
EisnerAmper as our independent registered public accounting firm. As an advisory vote, this proposal is not binding. The outcome of this advisory vote will not overrule any decision by us or our Board
of Directors (or any committee thereof). However, if the stockholders do not ratify the appointment, the Audit Committee will investigate the reasons and consider whether to retain EisnerAmper or
appoint another independent registered public accounting firm. Even if the appointment is ratified, our Board of Directors and the Audit Committee in their discretion may direct the appointment of a
different independent registered public accounting firm at any time if they determine that such a change would be in the best interests of our company and our stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="poa"></A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent
Registered Public Accounting Firm  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with requirements of the SEC and the Public Company Accounting Oversight board of directors regarding auditor independence, our Audit
Committee is responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. In recognition of this responsibility, our Audit Committee
(or the chair if such approval is needed on a time urgent basis) generally pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm.
These services may include audit services, audit-related services, tax services and other services. The Audit Committee determined that the provision of the non-audit services by EisnerAmper described
above is compatible with maintaining EisnerAmper's independence. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=36,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=988011,FOLIO='32',FILE='DISK109:[18ZAY1.18ZAY12901]DM12901A.;6',USER='CHE109864',CD='14-MAR-2018;17:53' -->
<A NAME="page_dm12901_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<A NAME="pri"></A>Principal Accounting Fees and Services  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth all fees paid or accrued by us for professional audit services and other services rendered by
EisnerAmper&nbsp;LLP during the years ended December&nbsp;31, 2017 and 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Nature of Service

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Fees </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 Fees </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>142,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>214,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>163,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit
Fees consist of fees for professional services in connection with the audit of our financial statements, review of our quarterly financial statements, and
related services that are normally provided in connection with registration statements, including the registration statement on Form&nbsp;S-4 in connection with our merger with Macrocure&nbsp;Ltd.
and the registration statement on Form&nbsp;S-3 in connection with our 2017 private placement.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit-Related
Fees consist of fees for professional services that are reasonably related to the performance of the audit or review of our financial statements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Tax
Fees consist of fees for professional services in connection with tax compliance, tax planning, and tax advice, including foreign tax return preparation and
requests for rulings or technical advice from tax authorities.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>All
other Fees consists of professional services performed related to Form&nbsp;8-K filings.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dm12901_vote_required"> </A>
<A NAME="toc_dm12901_1"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


VOTE REQUIRED    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of a majority of shares of our common stock, present in person or represented by proxy at the Annual Meeting and entitled
to vote, is required to ratify the selection of our independent auditors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE<BR>
"FOR" THE RATIFICATION OF THE APPOINTMENT OF EISNERAMPER&nbsp;LLP AS THE<BR>
COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (PROPOSAL NO. 2 ON YOUR PROXY CARD)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=37,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=737362,FOLIO='33',FILE='DISK109:[18ZAY1.18ZAY12901]DM12901A.;6',USER='CHE109864',CD='14-MAR-2018;17:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do12901_1_34"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="security_owner"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information as of March&nbsp;15, 2018 (unless otherwise specified), with respect to the beneficial
ownership of our Common Stock by each person who is known to own beneficially more than 5% of the outstanding shares of our Common Stock, each person currently serving as a director, each named
executive officer, and all directors and executive officers as a group. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have determined beneficial ownership in accordance with the SEC's rules. Shares of our Common Stock subject to options or other rights to purchase which are now exercisable or are
exercisable within 60&nbsp;days after March&nbsp;15, 2018, are to be considered outstanding for purposes of computing the percentage ownership of the persons holding these options or other rights,
but are not to be considered outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have
sole voting and investment
power with respect to all shares shown as beneficially owned by them, subject to any applicable community property laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;15, 2017, there were 12,354,014 shares of our common stock outstanding. Except as otherwise noted below, the address for each person or entity listed in the table is
c/o Leap Therapeutics,&nbsp;Inc., 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Address of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount and<BR>
Nature of<BR>
Beneficial Ownership </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Ownership (%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5% or Greater Stockholders:</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HealthCare Ventures, and affiliates(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,593,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eli Lilly and Company(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,301,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lilly Corporate Center Indianapolis, IN&nbsp;46285</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Directors and Named Executive Officers</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christopher&nbsp;K. Mirabelli(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,731,067</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Executive Officer, President and Chairman</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Douglas E. Onsi(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,112,661</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer, General Counsel, Treasurer and Secretary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Augustine Lawlor(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,731,067</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>57.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James Cavanaugh(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,635,656</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Dietz(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Li(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Littlechild(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,635,656</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joseph Loscalzo(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nissim Mashiach(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>189,491</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Directors and Executive Officers as a Group (nine&nbsp;persons)(12)(13)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,271,062</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58.7 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than one percent of our outstanding common stock. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=225955,FOLIO='34',FILE='DISK109:[18ZAY1.18ZAY12901]DO12901A.;15',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<A NAME="page_do12901_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;2,618,406 shares of common stock held by HealthCare Ventures&nbsp;VIII,&nbsp;L.P., (ii)&nbsp;4,631,145 shares of common stock held by
HealthCare Ventures&nbsp;IX,&nbsp;L.P. (including 1,057,769 shares of common stock that may be acquired upon the exercise of warrants), and (iii)&nbsp;343,889 shares of common stock held by
HealthCare Ventures Strategic Fund,&nbsp;L.P. Christopher&nbsp;K. Mirabelli, James H. Cavanaugh, Ph.D., John W. Littlechild, Harold Werner and Augustine Lawlor (collectively, the "HCPVIII
Directors") are the Managing Directors of HealthCare Partners&nbsp;VIII,&nbsp;LLC ("HCPVIII&nbsp;LLC"), which is the General Partner of HealthCare Partners&nbsp;VIII,&nbsp;L.P. ("HCPVIII"),
which is the General Partner of Health Care Ventures&nbsp;VIII,&nbsp;L.P. Each of the HCPVIII Directors, HCPVIII&nbsp;LLC and HCPVIII beneficially own and share voting and dispositive power with
respect to all of the securities owned by HealthCare Ventures&nbsp;VIII,&nbsp;L.P. and each disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary
interest in these securities. Christopher&nbsp;K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCPIX Directors") are the Managing Directors of HealthCare
Partners&nbsp;IX,&nbsp;LLC ("HCPIX&nbsp;LLC") which is the General Partner of HealthCare Partners&nbsp;IX,&nbsp;L.P. ("HCPIX"), which is the General Partner of HealthCare
Ventures&nbsp;IX,&nbsp;L.P. Each of the HCPIX Directors, HCPIX&nbsp;LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by
HealthCare Ventures&nbsp;IX,&nbsp;L.P. and each disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.
Christopher&nbsp;K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCSP Directors") are the Managing Directors of HealthCare Strategic Partners,&nbsp;LLC ("HCV
Strategic&nbsp;LLC"), which is the General Partner of HealthCare Ventures Strategic Fund,&nbsp;L.P. Each of the HCSP Directors and HCV Strategic&nbsp;LLC beneficially own and share voting and
dispositive power with respect to all of the securities owned by HCV Strategic Fund,&nbsp;L.P. and each disclaims beneficial ownership of these shares except to the extent of his proportionate
pecuniary interest in these securities.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
821,693 shares of common stock that may be acquired upon the exercise of warrants.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;2,618,406 shares of common stock held by HealthCare Ventures&nbsp;VIII,&nbsp;L.P., (ii)&nbsp;4,631,145 shares of common stock held by
HealthCare Ventures&nbsp;IX,&nbsp;L.P. (including 1,057,769 shares of common stock that may be acquired upon the exercise of warrants), (iii)&nbsp;343,889 shares of common stock held by
HealthCare Ventures Strategic Fund,&nbsp;L.P., and (iv)&nbsp;137,627 shares of common stock subject to stock options that were exercisable as of March&nbsp;15, 2018, or that will become
exercisable within 60&nbsp;days after that date. Christopher&nbsp;K. Mirabelli, is a Managing Director of HCPVIII&nbsp;LLC, which is the General Partner of HealthCare
Partners&nbsp;VIII,&nbsp;L.P. ("HCPVIII"), which is the General Partner of HealthCare Ventures&nbsp;VIII,&nbsp;L.P. Christopher&nbsp;K. Mirabelli shares voting and dispositive power with
respect to all of the securities owned by HealthCare Ventures&nbsp;VIII,&nbsp;L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest
in these securities. Christopher&nbsp;K. Mirabelli is a Managing Director of HCPIX&nbsp;LLC which is the General Partner of HealthCare Ventures&nbsp;IX,&nbsp;L.P. ("HCPIX"), which is the
General Partner of HealthCare Ventures&nbsp;IX,&nbsp;L.P. Christopher&nbsp;K. Mirabelli beneficially owns and shares voting and dispositive power with respect to all of the securities owned by
HealthCare Ventures&nbsp;IX,&nbsp;L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. Christopher&nbsp;K.
Mirabelli is a Managing Director of HCV Strategic&nbsp;LLC, which is the General Partner of HealthCare Ventures Strategic Fund,&nbsp;L.P. Christopher&nbsp;K. Mirabelli, Ph.D. beneficially owns
and shares voting and dispositive power with respect to all of the securities owned by HCV Strategic Fund,&nbsp;L.P. and disclaims beneficial ownership of these shares except to the extent of his
proportionate pecuniary interest in these securities.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;4,631,145 shares of common stock held by HealthCare Ventures&nbsp;IX,&nbsp;L.P. (including 1,057,769 shares of common stock that may be
acquired upon the exercise of warrants), </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=39,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=714386,FOLIO='35',FILE='DISK109:[18ZAY1.18ZAY12901]DO12901A.;15',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<A NAME="page_do12901_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<UL>

<P style="font-family:times;"><FONT SIZE=2>(ii)&nbsp;343,889
shares of common stock held by HealthCare Ventures Strategic Fund,&nbsp;L.P. and (iii)&nbsp;137,627 shares of common stock subject to stock options that were exercisable as of
March&nbsp;15, 2018, or that will become exercisable within 60&nbsp;days after that date. Douglas E. Onsi is a Managing Director of HCPIX&nbsp;LLC which is the General Partner of HCPIX, which is
the General Partner of HealthCare Ventures&nbsp;IX,&nbsp;L.P. Douglas E. Onsi beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HealthCare
Ventures&nbsp;IX,&nbsp;L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. Douglas E. Onsi is a Managing
Director of HCV Strategic&nbsp;LLC, which is the General Partner of HealthCare
Ventures Strategic Fund,&nbsp;L.P. Douglas E. Onsi beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HCV Strategic Fund,&nbsp;L.P. and
disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;2,618,406 shares of common stock held by HealthCare Ventures&nbsp;VIII,&nbsp;L.P., (ii)&nbsp;4,631,145 shares of common stock held by
HealthCare Ventures&nbsp;IX,&nbsp;L.P. (including 1,057,769 shares of common stock that may be acquired upon the exercise of warrants), (iii)&nbsp;343,889 shares of common stock held by
HealthCare Ventures Strategic Fund,&nbsp;L.P., and (iv)&nbsp;137,627 shares of common stock subject to stock options that were exercisable as of March&nbsp;15, 2018, or that will become
exercisable within 60&nbsp;days after that date. Augustine Lawlor is a Managing Director of HCPVIII&nbsp;LLC, which is the General Partner of HCPVIII, which is the General Partner of HealthCare
Ventures&nbsp;VIII,&nbsp;L.P. Augustine Lawlor shares voting and dispositive power with respect to all of the securities owned by HealthCare Ventures&nbsp;VIII,&nbsp;L.P. and disclaims
beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. Augustine Lawlor is a Managing Director of HCPIX&nbsp;LLC which is the General
Partner of HCPIX, which is the General Partner of HealthCare Ventures&nbsp;IX,&nbsp;L.P. Augustine Lawlor beneficially owns and shares voting and dispositive power with respect to all of the
securities owned by HealthCare Ventures&nbsp;IX,&nbsp;L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.
Augustine Lawlor is a Managing Director of HCV Strategic&nbsp;LLC, which is the General Partner of HealthCare Ventures Strategic Fund,&nbsp;L.P. Augustine Lawlor beneficially owns and shares
voting and dispositive power with respect to all of the securities owned by HCV Strategic Fund,&nbsp;L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate
pecuniary interest in these securities.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;17,250 shares of common stock subject to stock options that were exercisable as of March&nbsp;15, 2018, or that will become exercisable within
60&nbsp;days after that date, and (ii)&nbsp;2,618,406 shares of common stock held by HealthCare Ventures&nbsp;VIII,&nbsp;L.P. James H. Cavanaugh, is a Managing Director of HCPVIII&nbsp;LLC,
which is the General Partner of HCPVIII, which is the General Partner of HealthCare Ventures&nbsp;VIII,&nbsp;L.P. James Cavanaugh beneficially owns and share voting and dispositive power with
respect to all of the securities owned by HealthCare Ventures&nbsp;VIII,&nbsp;L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest
in these securities.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
17,250 shares of common stock subject to stock options that were exercisable as of March&nbsp;15, 2018, or that will become exercisable within
60&nbsp;days after that date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
6,250 shares of common stock subject to stock options that were exercisable as of March&nbsp;15, 2018, or that will become exercisable within
60&nbsp;days after that date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
(i)&nbsp;Includes 17,250 shares of common stock subject to stock options that were exercisable as of March&nbsp;15, 2018, or that will become
exercisable within 60&nbsp;days after that date, and (ii)&nbsp;2,618,406 shares of common stock held by HealthCare Ventures&nbsp;VIII,&nbsp;L.P. John Littlechild is a Managing Director of
HCPVIII&nbsp;LLC, which is the General Partner of HCPVIII, which is the General Partner of HealthCare Ventures&nbsp;VIII,&nbsp;L.P. John Littlechild beneficially owns and share </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=40,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=672102,FOLIO='36',FILE='DISK109:[18ZAY1.18ZAY12901]DO12901A.;15',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<A NAME="page_do12901_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">

<UL>

<P style="font-family:times;"><FONT SIZE=2>voting
and dispositive power with respect to all of the securities owned by HealthCare Ventures&nbsp;VIII,&nbsp;L.P. and disclaims beneficial ownership of these shares except to the extent of his
proportionate pecuniary interest in these securities.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
17,250 shares of common stock subject to stock options that were exercisable as of March&nbsp;15, 2018, or that will become exercisable within
60&nbsp;days after that date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
189,491 shares of common stock subject to stock options that were exercisable as of March&nbsp;15, 2018, or that will become exercisable within
60&nbsp;days after that date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of clarification, (i)&nbsp;each of the 2,618,406 shares of common stock owned by HealthCare Ventures&nbsp;VIII,&nbsp;L.P. (and indirectly owned
by each of Christopher&nbsp;K. Mirabelli, Augustine Lawlor, James H. Cavanaugh, and John W. Littlechild) have only been counted one time in calculating the number of shares of Common Stock
beneficially owned by all executive officers and directors, (ii)&nbsp;each of the 4,631,145 shares of common stock (including 1,057,769 shares of common stock that may be acquired upon the exercise
of warrants) held by HealthCare Ventures&nbsp;IX,&nbsp;L.P. (and indirectly owned by each of Christopher&nbsp;K. Mirabelli, Douglas E. Onsi and Augustine Lawlor) have only been counted one time
in calculating the number of shares of common stock beneficially owned by all executive officers and directors, and (iii)&nbsp;each of the 343,889 shares of common stock owned by HealthCare Ventures
Strategic Fund,&nbsp;L.P. (and indirectly owned by each of Christopher&nbsp;K. Mirabelli, Douglas E. Onsi and Augustine Lawlor) have only been counted one time in calculating the number of shares
of Common Stock beneficially owned by all executive officers and directors.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
677,622 shares of common stock subject to stock options held by our directors and named executive officers that were exercisable as of March&nbsp;15,
2018, or that will become exercisable within 60&nbsp;days after that date.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=41,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=38027,FOLIO='37',FILE='DISK109:[18ZAY1.18ZAY12901]DO12901A.;15',USER='CHE106795',CD='16-MAR-2018;06:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq12901_1_38"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq12901_certain_relationships_and_related_party_transactions"> </A>
<A NAME="toc_dq12901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of transactions since January&nbsp;1, 2017, in which we were a party and the amount involved exceeded or will
exceed $120,000, and in which any of our executive officers, directors, or holders of more than 5% of any class of our voting securities, or an affiliate or immediate family member thereof, had or
will have a direct or indirect material interest. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were
comparable to terms available or amounts that would be paid or received, as applicable, in arm's-length transactions with unrelated third parties. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_notes"> </A>
<A NAME="toc_dq12901_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notes    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As set forth in the table below, we issued promissory notes to holders of 5% or more of our capital stock. The interest rate on each note is
eight percent (8%) per annum beginning on either the date the note was entered into or, if the note contains drawdown dates, commencing to accrue with respect to any principal amount outstanding on
the applicable drawdown date of such principal amount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
issued a convertible promissory note to HealthCare Ventures VIII,&nbsp;L.P., HealthCare Ventures&nbsp;IX,&nbsp;L.P. and HealthCare Strategic Fund,&nbsp;L.P. The note was
originally issued by Leap to the payees on September&nbsp;1, 2015, in the original principal amount of up to $1,500,000, but was thereafter amended such that the maximum principal amount available
to Leap under the note was $31,000,000 and HealthCare Ventures Strategic Fund,&nbsp;L.P. was an additional payee party thereunder. The interest rate on the note was eight percent (8%) per annum,
commencing to accrue with respect to any principal amount outstanding on the applicable drawdown date of such principal amount. The note automatically converted into 1,950,768 shares of common stock
on January&nbsp;20, 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_recapitalization_and_conversion"> </A>
<A NAME="toc_dq12901_3"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recapitalization and Conversion    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the consummation of the merger with Macrocure&nbsp;Ltd., all outstanding Notes and Preferred Stock converted into common
stock. On January&nbsp;20, 2017 a 1-for-19.86754 reverse stock split of the Company's common stock outstanding was effected. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_voting_agreements_in_connection_with_the_merger"> </A>
<A NAME="toc_dq12901_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Agreements in Connection with the Merger    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the execution of the merger agreement, on August&nbsp;29, 2016, Leap entered into a voting agreement with each of Ze'ev
Bronfeld, a director of Macrocure, David Ben Ami, a director of Macrocure, Ranan Groban, a director of Macrocure, Vaizra Ventures, Viatcheslav Mirilasvili, Shlomo Kalish,, Pontifax (Israel)
II&#151;Individual Investors&nbsp;L.P., Pontifax (Israel) II&nbsp;L.P., Pontifax (Cayman)&nbsp;II&nbsp;L.P., and Nissim Mashiach, the chief executive officer of Macrocure (the
"equityholders"), under which each such equityholder agreed to vote in favor of the merger and against any alternative acquisition proposal, agreement or transaction. As of August&nbsp;29, 2016,
these entities collectively beneficially owned or controled approximately 54.28% of the voting power of Macrocure on an as-converted to common stock basis. These voting agreements granted Leap
irrevocable proxies to vote any Macrocure ordinary shares over which each such equityholder had voting power in favor of the Macrocure merger proposal and against any alternative acquisition proposal,
agreement or transaction. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in connection with the execution of the merger agreement, on August&nbsp;29, 2016, HealthCare Ventures VIII,&nbsp;L.P., HealthCare Ventures IX,&nbsp;L.P., HealthCare
Ventures Strategic Fund,&nbsp;L.P. and Eli Lilly and Company, who collectively beneficially owned or control 100% of Leap's outstanding common stock as of August&nbsp;29, 2016, each entered into a
voting agreement with Macrocure&nbsp;Ltd. under which each such stockholder has agreed to (i)&nbsp;vote in favor of the Leap proposals that relate to the merger and against any alternative
acquisition proposal, agreement or transaction and (ii)&nbsp;take certain actions necessary to approve and implement certain other requirements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=42,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=761688,FOLIO='38',FILE='DISK109:[18ZAY1.18ZAY12901]DQ12901A.;5',USER='CHE109864',CD='14-MAR-2018;17:54' -->
<A NAME="page_dq12901_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
Leap upon which Macrocure's obligation to consummate the transactions contemplated in the merger agreement is conditioned. Each of these voting agreements granted Macrocure&nbsp;Ltd. irrevocable
proxies to vote any shares of Leap common stock over which each such stockholder has voting power in favor of (i)&nbsp;each of the Leap proposals and against any alternative acquisition proposal,
agreement or transaction and (ii)&nbsp;each such other approval necessary to satisfy certain other requirements of Leap upon which Macrocure's obligation to consummate the transactions contemplated
in the merger agreement were conditioned. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
voting agreements terminated upon the effective time of the merger on January&nbsp;23, 2017. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_equity_investment"> </A>
<A NAME="toc_dq12901_5"> </A></FONT> <FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Investment    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;20, 2017, pursuant to the terms of the merger agreement and their respective voting agreements, HealthCare Ventures
IX,&nbsp;L.P. invested approximately $10.0&nbsp;million into Leap by purchase of 1,010,225 shares of common stock of Leap. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_royalty_agreement"> </A>
<A NAME="toc_dq12901_6"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Royalty Agreement    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;20, 2017, Leap declared a special distribution of certain royalty rights to each of its holders of common stock outstanding
immediately prior to the effective time of the merger with Macrocure. The royalty rights were set forth in a royalty agreement, referred to herein as the Royalty Agreement, by and between Leap and a
special purpose vehicle formed by those holders of Leap's common stock prior to the merger, specifically, HealthCare Ventures VIII,&nbsp;L.P., HealthCare Ventures&nbsp;IX,&nbsp;L.P., HealthCare
Ventures Strategic Fund,&nbsp;L.P. and Eli Lilly and Company. These holders collectively beneficially owned or controlled 100% of Leap's outstanding common stock as of the date of the merger. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Royalty Agreement, Leap will pay to the special purpose vehicle (i)&nbsp;5% of Leap's net sales of products incorporating its TRX518 compound and (ii)&nbsp;2% of
Leap's net sales of products incorporating its DKN-01 compound. Net sales will be calculated as the gross amount invoiced by Leap, its affiliates, assignees or sublicensees to a third party, but shall
be reduced by any discounts, refunds, rebates, product returns, bad debts, sales taxes, VAT and other similar taxes. The calculation of the gross amount invoiced shall also be discounted in the event
that Leap's product is sold as part of a combination product. Royalties will be payable by Leap to the special purpose vehicle every calendar quarter. Among other customary terms for licensing
transactions of this type, the special purpose vehicle will have the right no more than once a year to have an independent certified public accountant audit Leap's records to determine the accuracy of
royalty payments received. The Royalty Agreement has an indefinite term, and neither Leap nor the special purpose vehicle has the right to terminate. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_registration_rights_agreement"> </A>
<A NAME="toc_dq12901_7"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights Agreement    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leap entered into a Registration Rights Agreement with each of its holders of common stock outstanding immediately prior to the effective time
of the merger. In addition, to the former holders of Leap's common stock, certain larger holders of Leap's common stock following the merger (who were among the largest holders of Macrocure ordinary
shares prior to the merger) are parties to the Registration Right Agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_pipe_transaction_and_voting_agreement"> </A>
<A NAME="toc_dq12901_8"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PIPE Transaction and Voting Agreement    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;14, 2017, Leap entered into purchase agreements (collectively, the "Purchase Agreement") with certain existing and new
institutional accredited investors and strategic partners (collectively, the "Purchasers"), including HealthCare Ventures IX,&nbsp;L.P. and Eli Lilly and Company. Each of the Purchase Agreements was
on terms and conditions substantially similar to each other Purchase Agreement and pursuant to such Purchase Agreements, the Company, in a private placement, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=43,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=771094,FOLIO='39',FILE='DISK109:[18ZAY1.18ZAY12901]DQ12901A.;5',USER='CHE109864',CD='14-MAR-2018;17:54' -->
<A NAME="page_dq12901_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>agreed
to issue and sell to the Purchasers an aggregate of 2,958,094 shares (the "Shares") of unregistered common stock, par value $0.001 per share, of the Company (the "Common Stock"), at a price per
share of $6.085, each share issued with a warrant (the "Warrants") to purchase one share of Common Stock (the "Warrant Shares") at an exercise price of $6.085 (the "Exercise Price") with an exercise
period expiring seven years after closing (the "Term"), for gross proceeds of approximately $18.0&nbsp;million (the "Private Placement"). If all of the Warrants are exercised at the Exercise Price
during the Term, the Company will receive proceeds of approximately $18.0&nbsp;million in cash and will issue an aggregate of 2,958,094 Warrant Shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HealthCare
Ventures IX,&nbsp;L.P. and Eli Lilly and Company, each a more than 5% direct holder of our Common Stock prior to the closing of the Private Placement, purchased Common Stock
and Warrants pursuant to a Purchase Agreement in the Private Placement. Each of HealthCare Ventures&nbsp;IX,&nbsp;L.P. and Eli Lilly and Company agreed to purchase the Common Stock and Warrants on
the same terms and conditions as the other Purchasers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Christopher
K. Mirabelli, our Chief Executive Officer, Douglas E. Onsi, our Chief Financial Officer, General Counsel, Treasurer and Secretary, and Augustine Lawlor, our Chief Operating
Officer (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX,&nbsp;LLC ("HCPIX&nbsp;LLC"), which is the General Partner of HealthCare Partners IX,&nbsp;L.P.
("HCPIX"). HCPIX is the General Partner of HealthCare Ventures IX,&nbsp;L.P. Each of the HCVIX Directors, HCPIX&nbsp;LLC and HCPIX indirectly beneficially own and share voting and dispositive
power with respect to all of the securities owned by HealthCare Ventures IX,&nbsp;L.P. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrants include full ratchet anti-dilution protection provisions. The inclusion of such provisions was subject to stockholder approval. Therefore, the Company held a special meeting
of stockholders for the stockholders to approve the full ratchet anti-dilution protection. In connection with such approval, the Company, on November&nbsp;14, 2017, entered into a voting agreement
with HealthCare Ventures VIII,&nbsp;L.P., HealthCare Ventures IX,&nbsp;L.P. and HealthCare Ventures Strategic Fund,&nbsp;L.P. (collectively, the "HealthCare Parties"), which together hold a
majority of the shares entitled to vote at the special meeting of stockholders, pursuant to which the HealthCare Parties agreed to vote all of their beneficially owned shares in favor of the any
approval proposed at the special meeting of stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_indemnification_agreements"> </A>
<A NAME="toc_dq12901_9"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification Agreements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into indemnification agreements with each of our directors and certain executive officers. These agreements require us to
indemnify these individuals and, in certain cases, affiliates of such individuals, to the fullest extent permissible under Delaware law against liabilities that may arise by reason of their service to
us or at our direction, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation also provides that we will indemnify each of our executive officers and directors to the fullest extent permitted by the Delaware
General Corporation Law against liabilities that may arise by reason of their service to us or at our direction, and to advance expenses to each indemnitee in connection with any proceeding in which
indemnification is available. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, we have been informed that in the opinion of the SEC such
indemnification is against public policy and is therefore unenforceable. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="dq12901_related_party_transaction_approval_policy"> </A>
<A NAME="toc_dq12901_10"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Related Party Transaction Approval Policy    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the completion of the merger with Macrocure&nbsp;Ltd., we adopted a related party transactions policy that requires all
future transactions between us and any director, executive officer, holder of 5% or more of any class of our capital shares or any member of the immediate family of, or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=44,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=39046,FOLIO='40',FILE='DISK109:[18ZAY1.18ZAY12901]DQ12901A.;5',USER='CHE109864',CD='14-MAR-2018;17:54' -->
<A NAME="page_dq12901_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>entities
affiliated with, any of them, or any other related persons (as defined in Item&nbsp;404 of Regulation&nbsp;S-K) or their affiliates, in which the amount involved is equal to or greater
than $120,000, be approved in advance by our nominating and corporate governance committee. Any request for such a transaction must first be presented to our General Counsel who will promptly notify
our nominating and corporate governance committee for their review, consideration and approval. In approving or rejecting any such proposal, our nominating and corporate governance committee is to
consider the relevant facts and circumstances available and deemed relevant to the nominating and corporate governance, including, but not limited to, the extent of the related party's interest in the
transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances. The
nominating and corporate governance committee has reviewed certain interested transactions and determined that they are pre-approved. These pre-approved interested transactions include, subject to
certain limitations, employment or compensation of executive officers, director compensation, certain transactions with other companies, certain company charitable contributions, transaction sin which
all shareholders receive proportional benefits and transactions involving competitive bids. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
of the transactions described above were entered into prior to the adoption of this written policy but each such transaction was approved by our Board of Directors. Prior to our
Board of Directors' consideration of a transaction with a related person, the material facts as to the related person's relationship or interest in the transaction were disclosed to our board of
directors, and the transaction was not approved by our Board of Directors unless a majority of the disinterested directors approved the transaction. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=45,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=95802,FOLIO='41',FILE='DISK109:[18ZAY1.18ZAY12901]DQ12901A.;5',USER='CHE109864',CD='14-MAR-2018;17:54' -->
<A NAME="page_dq12901_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq12901_section_16(a)_benefici__dq102033"> </A>
<A NAME="toc_dq12901_11"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers and beneficial owners of more than 10% of our common stock
to file reports of holdings and transactions in our common stock and our other securities with the Securities Exchange Commission. Our directors, executive officers and beneficial owners of more than
10% of our common stock did not become subject to such Section&nbsp;16(a) reporting requirements until January&nbsp;20, 2017. Based solely on our review of reports that reporting persons have
filed with the SEC and furnished to us and written representations that no other reports were required, we believe that during 2017, other than as set
forth below, our directors, executive officers and beneficial owners of more than 10% of our common stock timely complied with all applicable filing requirements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that HealthCare Partners IX,&nbsp;L.P., the general partner of HealthCare Ventures IX,&nbsp;L.P., inadvertently did not file&nbsp;a Form&nbsp;3 with the SEC in
connection with becoming a more than 10% owner of our common stock on January&nbsp;20, 2017. Immediately upon recognition of this error, on November&nbsp;16, 2017, HealthCare Ventures
IX,&nbsp;L.P. filed an amended Form&nbsp;3 to include HealthCare Partners IX,&nbsp;L.P. as a reporting person. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=46,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=408953,FOLIO='42',FILE='DISK109:[18ZAY1.18ZAY12901]DQ12901A.;5',USER='CHE109864',CD='14-MAR-2018;17:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds12901_1_43"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds12901_general_matters"> </A>
<A NAME="toc_ds12901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  GENERAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds12901_stockholder_proposals_and_nominations"> </A>
<A NAME="toc_ds12901_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Proposals and Nominations    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Requirements for Stockholder Proposals to be Considered for Inclusion in our Proxy Materials.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under Rule&nbsp;14a-8(e) of the Exchange
Act, to
submit a proposal for inclusion in our Proxy Statement for the 2019 Annual Meeting of Stockholders, stockholder proposals must be received by December&nbsp;3, 2018 by our Secretary at our principal
executive offices at 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts&nbsp;02141. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Requirements for Stockholder to bring Business and Nominations Before the 2019 Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated bylaws provide
that, for
stockholder nominations to the Board or other business to be considered at the 2019 Annual Meeting of Stockholders, the stockholder must have given timely notice thereof in writing to the Secretary at
Leap Therapeutics,&nbsp;Inc., 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts&nbsp;02141. To be timely for the 2019 Annual Meeting of Stockholders, the stockholder's notice must be
delivered to or mailed and received by us not earlier than the close of business on the 120th&nbsp;day nor later than the close of business on the 90th&nbsp;day prior to the anniversary date of
the previous year's annual meeting of stockholders, or, if later, the 10th&nbsp;day following the day on which we first provide notice or public disclosure of the date of the 2019 Annual Meeting of
Stockholders. Therefore, notice must be received not earlier than January&nbsp;3, 2019 and not later than February&nbsp;2, 2019. Such notice must provide the information required by
Section&nbsp;2.4 and 2.5 of our amended and restated bylaws with respect to each nomination or matter the stockholder proposes to bring before the 2019 Annual Meeting of Stockholders and must be
sent to our Secretary at our principal executive offices at 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts&nbsp;02141. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds12901_householding_of_proxy_materials"> </A>
<A NAME="toc_ds12901_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Householding of Proxy Materials    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC has adopted rules that permit companies and intermediaries, such as brokers or other nominees, to satisfy delivery requirements for
annual reports and proxy statements with respect to two or more stockholders sharing the same address by delivering a single annual report and/or proxy statement addressed to those stockholders. This
process, which is commonly referred to as "householding," potentially provides extra convenience for stockholders and cost savings for companies. We and some brokers or other nominees household annual
reports and proxy materials, delivering a single annual report and/or proxy statement to multiple stockholders sharing an address unless contrary instructions have been received from the affected
stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
you have received notice from your broker or other nominee or us that they or we will be householding materials to your address, householding will continue until you are notified
otherwise or until you revoke your consent. You may request to receive at any time, and we will then promptly deliver, a separate copy of our annual report or proxy statement, by sending a written
request to us at: Leap Therapeutics,&nbsp;Inc., Attn: Secretary, 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts&nbsp;02141 USA or calling us at: (617)&nbsp;714-0360. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any time, (1)&nbsp;you no longer wish to participate in householding and would prefer to receive a separate annual report and/or proxy statement in the future or (2)&nbsp;you
and another stockholder sharing the same address wish to participate in householding and prefer to receive a single copy of our annual report and/or proxy statement, please notify your broker or other
nominee if your shares are held in a brokerage account or us if you hold registered shares. You can notify us by sending a written request to us at: Leap Therapeutics,&nbsp;Inc., Attn: Secretary, 47
Thorndike Street, Suite B1-1, Cambridge, Massachusetts&nbsp;02141 USA or calling us at: (617)&nbsp;714-0360. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=47,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=370613,FOLIO='43',FILE='DISK109:[18ZAY1.18ZAY12901]DS12901A.;12',USER='CHE109569',CD='15-MAR-2018;15:24' -->
<A NAME="page_ds12901_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="ds12901_miscellaneous"> </A>
<A NAME="toc_ds12901_4"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Miscellaneous    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if you plan to attend the Annual Meeting in person, please complete, sign, date and return the enclosed proxy promptly. Should you attend
the Annual Meeting, you may revoke the proxy and vote in person. A postage-paid, return-addressed envelope is enclosed for your convenience. No postage need be affixed if mailed in the United States.
Your cooperation in giving this your immediate attention will be appreciated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>You may obtain a copy of our Annual Report on Form&nbsp;10-K (without exhibits) filed with the Securities and Exchange Commission for the year ended
December&nbsp;31, 2017 without charge upon written request to: Leap Therapeutics,&nbsp;Inc., Attn: Secretary, 47 Thorndike Street, Suite B1-1, Cambridge, Massachusetts&nbsp;02141
USA.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=48,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=813039,FOLIO='44',FILE='DISK109:[18ZAY1.18ZAY12901]DS12901A.;12',USER='CHE109569',CD='15-MAR-2018;15:24' -->
<A NAME="page_ds12901_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this proxy statement, we know of no matter not specifically referred to above as to which any action is expected to be taken at the Annual Meeting. The persons named as
proxies will vote the proxies, insofar as they are not otherwise instructed, regarding such other matters and the
transaction of such other business as may be properly brought before the Annual Meeting, as they determine to be in the best interest of our company and our stockholders. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Christopher Mirabelli<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer, President<BR>
and Chairman of the Board of Directors</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Cambridge, Massachusetts<BR>
March&nbsp;16, 2018<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=49,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=938715,FOLIO='45',FILE='DISK109:[18ZAY1.18ZAY12901]DS12901A.;12',USER='CHE109569',CD='15-MAR-2018;15:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="du12901_directions_to_morgan,_lewis_____dir03207"> </A>
<A NAME="toc_du12901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DIRECTIONS TO MORGAN, LEWIS&nbsp;&amp; BOCKIUS&nbsp;LLP<BR>  ONE FEDERAL STREET<BR>  BOSTON, MASSACHUSETTS 02110    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="du12901_address_"> </A>
<A NAME="toc_du12901_2"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Address:    <BR>    </B></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>One
Federal Street<BR>
Boston, Massachusetts 02110-1726<BR>
Tel:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;617.341.7700<BR>
Fax:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;617.341.7701 </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><A
NAME="du12901_directions_"> </A>
<A NAME="toc_du12901_3"> </A></FONT> <FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directions:    <BR>    </B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FROM POINTS NORTH:  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> From I-93 South and the Tobin Bridge, take Exit 23 (Purchase Street/South Station). </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Upon exiting, proceed on Purchase Street and turn right onto Pearl Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Turn left onto Franklin Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Then turn right onto Federal Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Parking Garage entrance is on the left at the corner of Federal and Milk Streets. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FROM POINTS SOUTH:  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Take I-93 North to Exit 20 (Mass. Turnpike/South Station); stay in left lane. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> While on this long ramp, follow the sign for South Station/Chinatown. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Continue straight; at the 4th&nbsp;traffic light, turn right onto Summer Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Take next left onto High Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Then take first left onto Federal Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Parking Garage entrance is on the left at the corner of Federal and Milk Streets. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FROM POINTS WEST:  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Take the Mass. Turnpike (I-90) to Exit 24-A (South Station), following signs for Atlantic Avenue. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> At the 3rd&nbsp;traffic light, turn left onto Summer Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Continue on Summer Street through 2 traffic lights. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Turn right onto High Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Then take first left onto Federal Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Parking Garage entrance is on the left at the corner of Federal and Milk Streets. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FROM LOGAN AIRPORT:  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Follow the "exit" signs from the airport to the Summer Tunnel. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Stay in the left lane of the tunnel. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> At the end of the tunnel, bear left and follow signs for Government Center. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Turn left onto Congress Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Follow Congress Street to Purchase Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Turn right onto Purchase Street. </FONT></DD></DL>
</UL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=50,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=200406,FOLIO='blank',FILE='DISK109:[18ZAY1.18ZAY12901]DU12901A.;4',USER='CHE109864',CD='14-MAR-2018;17:54' -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Follow Purchase Street to Summer Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Turn right onto Summer Street </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Turn right at the next set of lights (High Street). </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> On High Street, take first left onto Federal Street. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Parking Garage entrance is on the left at the corner of Federal and Milk Streets. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FROM THE MBTA RED LINE, AMTRAK, AND COMMUTER RAIL (SOUTH STATION):  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Coming out of South Station onto Sumer Street, cross Surface Road and walk straight onto Federal Street. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Continue on Federal Street, eventually crossing over Franklin Street. One Federal Street is on the left side of the street. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PARKING INSTRUCTIONS AT GARAGE:  </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Enter the Parking Garage, taking a ticket from the machine to open the gate. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Drive to the first level. A Parking Attendant will park your vehicle after issuing a valet check, to be used for retrieving your vehicle when
leaving the building. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Upon leaving the Parking Garage, present your ticket to the cashier. </FONT></DD></DL>
</UL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=51,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=234768,FOLIO='blank',FILE='DISK109:[18ZAY1.18ZAY12901]DU12901A.;4',USER='CHE109864',CD='14-MAR-2018;17:54' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg12901a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="la12901_appendix_a"> </A>
<A NAME="toc_la12901_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Appendix&nbsp;A    <BR>    </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=52,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=770645,FOLIO='blank',FILE='DISK109:[18ZAY1.18ZAY12901]LA12901A.;5',USER='CHE105948',CD='15-MAR-2018;21:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">YOUR VOTE IS   IMPORTANT. PLEASE VOTE TODAY. Vote by Internet or Telephone &#150; QUICK EASY   IMMEDIATE &#150; 24 Hours a Day, 7 Days a Week or by Mail LEAP THERAPEUTICS, INC.   Your telephone or Internet vote authorizes the named proxies to vote your   shares in the same manner as if you marked, signed and returned your proxy   card. Votes submitted electronically over the Internet or by telephone must   be received by 11:59 p.m., Eastern Time, on May 2, 2018. INTERNET/MOBILE &#151;   www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy   card available when you access the above website. Follow the prompts to vote   your shares. PHONE &#151; 1 (866) 894-0536 Use a touch-tone telephone to vote your   proxy. Have your proxy card available when you call. Follow the voting instructions   to vote your shares. MAIL &#151; Mark, sign and date your proxy card and return it   in the postage-paid envelope provided. FOLD HERE DO NOT SEPARATE INSERT IN   ENVELOPE PROVIDED PROXY THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; ITEMS   1 AND 2. Please mark your votes like this 1. Election of Class I Directors   (1) James Cavanaugh (2) John Littlechild 2. Ratification of the appointment   of EisnerAmper LLP as the independent registered public accounting firm of   the Company for the fiscal year ending December 31, 2018. FOR AGAINST ABSTAIN   FOR all Nominees listed to the left WITHHOLD AUTHORITY to vote (except as   marked to the contrary for all nominees listed to the left) (Instruction: To   withhold authority to vote for any individual nominee, strike a line through   that nominee&#146;s name in the list above) CONTROL NUMBER Signature Signature, if   held jointly Date , 2018. Note: Please sign exactly as name appears hereon.   When shares are held by joint owners, both should sign. When signing as   attorney, executor, administrator, trustee, guardian, or corporate officer,   please give title as such. X PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE   VOTING ELECTRONICALLY OR BY PHONE. </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="680" height="880" src="g82292bgi001.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=53,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=278483,FOLIO='',FILE="DISK110:[18ZAY2.18ZAY12902]8229-2-BG_ZAY12902.CHC",USER="CGONCE",CD='Mar 16 03:13 2018' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Internet Availability of Proxy Materials for the Annual   Meeting of Shareholders The Proxy Statement is available at:   http://www.cstproxy.com/leaptx/2018 FOLD HEREDO NOT SEPARATEINSERT IN   ENVELOPE PROVIDED PROXY THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF   DIRECTORS LEAP THERAPEUTICS, INC. The undersigned appoints Christopher K.   Mirabelli and Douglas E. Onsi, and each of them, as proxies, each with the   power to appoint his substitute, and authorizes each of them to represent and   to vote, as designated on the reverse hereof, all of the shares of common   stock of Leap Therapeutics, Inc. held of record by the undersigned at the   close of business on March 28, 2018 at the Annual Meeting of Stockholders of   Leap Therapeutics, Inc. to be held on May 3, 2018, or at any adjournment   thereof. THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS INDICATED. IF NO   CONTRARY INDICATION IS MADE, THE PROXY WILL BE VOTED IN FAVOR OF PROPOSAL 1   AND 2, AND IN ACCORDANCE WITH THE JUDGMENT OF THE PERSONS NAMED AS PROXY   HEREIN ON ANY OTHER MATTERS THAT MAY PROPERLY COME BEFORE THE ANNUAL MEETING.   THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS. (Continued, and   to be marked, dated and signed, on the other side) </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="680" height="880" src="g82292bgi002.gif" alt="GRAPHIC"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=54,EFW="2234866",CP="LEAP THERAPEUTICS, INC.",DN="1",CHK=511104,FOLIO='',FILE="DISK110:[18ZAY2.18ZAY12902]8229-2-BG_ZAY12902.CHC",USER="CGONCE",CD='Mar 16 03:13 2018' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g18891.jpg
<DESCRIPTION>G18891.JPG
<TEXT>
begin 644 g18891.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@!#35),3%]'4D%02$E#4SI;3$5!4%]4
M2$5205!%551)0U-?24Y#74Q%05!?5$A%4D%0155?1$Q?-$-?3$]'3RY%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" !A 4$# 2(  A$! Q$!_\0 '@ !  (!!0$!              <(
M"0$"!08*! /_Q !-$  !! (! P(# P8&#@H#   # 0($!0 &!P@1$A,A"10Q
M%2)1%C(W=I&U(T%A<8&V%Q@E-38X0G)UH;&TPM$D,S125F*"E;+!U>'P_\0
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M?**,86$/X=D(]@AM<J=T8WOVS'?N^]632010DR.H:.3>Q4Q.2C 1H,9 (Y8
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MHE&O@AV I9H2O&U'<H^,>/A)&?3-/!;''X1GY>E60XXX'X[X]H:^O#KE-;7
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MW000V\$%LKLSF.*(-(Y#3R2F.+M]#I^EVVFJXAWN\F-\LA!<@>%&U555!).
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MN5$17.<B(JJB)W]U1.ZY]W9$^B(F,NPPK!$L*EBJ@@%L;OB)8YP /)^55'
M^556Z7>.=@U/BW8=5W_7BUI+?8K5YZJ<6'(;,J+"CJ*\J$6!+E"4,CT94=S%
M*TG9KE5K45JK&L'C?G3I[N;HG$\.!R#Q_:REFIK<^2UEG#5&M$%7A?)@E2>
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..F,8Q2F,8Q2F,8Q2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g82292bgi001.gif
<DESCRIPTION>G82292BGI001.GIF
<TEXT>
begin 644 g82292bgi001.gif
M1TE&.#EAJ )P _8   ,  08)"0D%!@L'" X*"P\1$1$-#A,/$!41$A<8&!D5
M%AL7&!X:&QXA(2$='B,?("4B(B<I*2@D)2LG*"TJ*B\O,"\P,#$M+C,O,#4R
M,S<X.3DU-CLW.#TZ.T ]/D(_0$5"0T=(2$E%1DI'2$U*2T]/4$]04%%.3E)/
M4%524U=965E65EI76%A85UU:6U]@86%>7F)?8&5B8V9H:&EF9VIG:&UJ:W!N
M;W)O<'!P;W9S='=X>'AV=WIW>'UZ>X!^?X%_@(6"@X>(B(B&AXF'B(V*BY".
MCY&/D)63DYB6EYF7F)V;FY^@H*">GZ&?H*2CHZBGIZFGJ*RKJ["OK[&OL+2R
ML[BWM[FWN+R[N[^_P,"_O\"_P,3#P\?(R,C'Q\C'R,S+S,_0T-#/S]#/T-33
MT]C7U]C7V-O;V^#?W^#?X.3CY.?HY^CGY^CGZ.SL[/#O[_#O\/3T]/CW]_CW
M^/[^_@                                           "'Y!
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M _T6@0,.4NJ  Q*V58BL#SCH> 0=/0 0!8&>'H"!S3I\+-82!GA@ !C*(2&
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M "!E4M>6JFSR6M+R'O (42,/1$&.2_#=&1B0 CI08 -)P14-S@"<U%   DN
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M/D&,X3\"."D :B"()0"@"720XIT@Y@$!&  #-I#3&R[ @ '(M:>%D,$T.<"
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MF9N)F(P9F)7)F99YEX5YF(KIEXT9EP-0@6;Y$'-@!K 9F[(YF[19F[89FV<
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M !0@ RX@ %3B0((@ 4>E>PL0.AE@ X%S!>U' ?W"'S9  Q=P!JAT "L@!68
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M? @QHL2)%"M:O*@PC@,==)HP@.&!CA<*+A[0@?+Q QTN)"7,.<1#E<:8DW
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M;:<*FZ@0Z^8%0P9X)_<#LX CZM)PAFB $"!NEBAVJO $'&%3@QB+!1<'&8
M>#8,/8  [<. V?5/W)$$!R !$G  '35J%^  MI)='W@ #N!^%@B#$  !"7B%
MXV()]I,**3"!T( ""W"-P>@ 43@)PI1&-6B# O" P[$ #28!V <%O^A''_B!
M ! ,C\  :;2 "6C^"5WH6@C@ /2 #&/@  A@/VXPA3Z""->879Y5! 8PD-DV
MAA*0 BO@ 1]X+U_!)PK0 2N0 @U& +/@=0:)D.>87LDX$%'0"="@5&.( 2NP
M A>@  KP .XG+*R 6:= !@K@.A.!64E!;SS@ *]H#(M!.%E1@!9%/O.',%'E
M$+S%B@S!"F60(V(@ +E&=A4Q![I%)O@SB03W!MG2CKG0 ]$H!:/'>(T'>72P
M @3 #0;PDQ"8+2+P'V3@!6HC6V,G?.5' PK@ &F9>VX@3"?I%B1 AM!  @I
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M I"(1)EI-A 2>E+#-SP$<X  ;JH&1KDXM(C =, #RB0T5W!OHTINF+MVKG4
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M4*/BY'&XMY)F.6,$[< T7+$.-&O$K)8;"O24L3L@HA:9($BH+8(230<C6)_
M1"-'!]I".D$$=)"%C0X8!0ILV&($8L$*1>"2Z=S)LZ<HD*9T+"#DLZC1HTB3
M*EW*M*G3ISJ/D0BU3. H%_(H9," X0*%!PA<&+MP8"I H**8.<O)3R,=$M>R
MT;&60>XG3&TQO?'@P  E.F88.(#0=6L&"6"K;,3WA XAH'E%_9A%*:>4:#]
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M@&QTN$  FBFD($%?'H3"ZT!5.?!G%1 <$$PT"A!0 S4/S2)!NX,:$"\=;S@
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MQ ((@ D 32B)5T"P 6?H *T*6$ RXP""P7B,!@@X:UJ?TP,!* (+ %#,64&
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M[HDX<"'6%07<K76.ZY:_/.:J#KK0AWYJ03-+ %8PS@_,P&]6UWKG.)  & Y
M!#64034@)@X.E-T('C! +K*EP\FS_/5%>"#&;R#!!3+PFE?3P0$P8 ,9SA#,
M*[@@Q#<F0&-HO0@P2Z1;4KB (L!M# :0 P0,(T/'U$ &-:SV$UB8P,6< 8*#
MO<'P=#A[D0P;A&&'P@U0&,$!U'"&'$N,822@@"I/COA*"& *5E>#-TIY@0ML
M\*Z$=@;)W9+N1J=\$3J0N@&(('?'A^*C7D'^"0.6WG2^VSH;40># 8K >#70
MD^C8S[[V7Z<#!;@: %(@06I$PC <E-W\M58 '=IJH!Z48;L>,$.WLLH9 <A
M#43 NP(<;(8#P$ -0P  H=,#1S95;]4804  57 &/H!3)  #<: $B65"9
M01 '9V  _Q> T-0(>R$!P=5E ) (,&  K]$!&> K*0 ![;=MC@$"%" 6(DB"
M)C@7#, %5[!;:E K&'0&%W"!/,4&9X!I9L<P")!641 WF3<V<4 !(* &5> #
M;\ %$" %;@ "$G![ZB<%F^48"X NTZ, +F A7PA\ZL<"#]""GT"%5HB%,O8
M#L( #",4M59VW;?^?FD(!CW@@MO7AW[XAYQB'=@!6U4P!AV  "S0 V?T X-X
M'=G0 Q2 *3)P&A>@&&20 0J0 C50,< G 3V &AX3!Q,P*W2 !1W@ !005V<0
M1G3@!0J !7)&"7$0!!!P<1E!!1R &CJ %CB (G1P!:>8BJ*0@"'U!!3@ !V
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MIHL 60] CPXF"F60 IM* HK IV446$7@ )1  6%***'C!C"P !,@1F""B2D
M Q" 06"P 9MJ U]* U>ZG9"541( AK8A >)7!'/@ @Q  6*4 JLR%9#H:@B
M!5C  '#!!45  46@IKL()C^U 8!&!0_  #;0>E!ZK_A*1J=% V4@ NEE!AR@
MCSS  G&@678B 0M@31TP 72  @3P W-# *2W -@:! P;!0!  V9PH6_^ 82E
M908 D 3F(!.@4'D_8E]<]@D$* =S0&(->X-<P "34X'?\@'M]AS^1B U(  >
M4 8R, !N( 4=H :(16<LI@9A%0170 "A$R;8.@04T&4"4'4R( "6=AXT8 !0
M2 $XU0'Q0HR+$VTN8TT;$+4I\(1DX "*00'Q]P2$PK$Z0+ &^V!A9 85)K54
M:[5[0@ @T#LK( )GD+8+N #_!S@!5X%7< 7+Y2N%)0-G$ 0 0$,4X*54H%=J
MD YJD(!&DZ^<V[FAX'6>8'2L1@C=8P,(-G9>]Q8WB[$ B&8]( .)=04"\"?6
MPP76X"L2X %1X$7/8:_V^AS2AR &T'BF]P3^AG4& _ M?O<<25@+:%,+4$
MSN &9C $PF*O;T !AZ@.?:H#KPM^+G!&",, *'H>47  ., %X.-W#B"D8!!M
M#""DP?<2*Y ^%26[Q.%M2%*ZI^M@(/<6EG=R()%/C3$&B)@^>2-V_KMS8R
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MQ08 !@[  C]RO>@6HA!P1E)  +N,*JYA*$!F!LDY7W'&3!(38[.5#0%("0X
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MFD9D0S\!ZOU!'K0:"BX09IC0! YP32!!!/U$FNQY0XL&&(WJY5Z.":T7!SV
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M("!OTLY=/^.\H4 /=(A%!Q@V;'"! 0\M@!H=-BAT$6 PF9.!#M^0(<5]F_2
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MEPTP\(,G>$ -:O# $UR0(6R0H&1Q@.&!S$@#'+H!C%\!8QDP\H$-D&"!U<"
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MP".;H 8*L $/P9$9D %OX(&4A 25X (*\ 3^<\!=*="..(21:Z,UNL #&.
M>=2.V_<*;N  %S"1*2 64[5J#;F53N$O&>(! + FGM8#,9E'%R !ZO(&#*
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M J!!#  !'L !)>)3$P$!,M!/9.!/=.!Q(*  &> &\'@!'U!/:L!=$Y R(O
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MLV$D#S#;#, 65$#^ >.K)R7R SI@(&!  _5S$4D  "L0!#3P$"F@ $%P 1>
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M<'^R!;5S><_XCO_UI:]/<Y #0* #+\#Z,L#Z*F $'V P[8"/+OC:FZ"71@(
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M*R!(N*0@2!0!;*0 4',&P080'T!TD">GFX QB\Q,4$.'01 9-LXXJ&+@2A4
M/A7Q4(".0&01#$ HTL$ '=5&CC5*=BJWNO7KV+-KW\Z]>\,73.R6=1-$B-&R
M8>F \$!G,!4U.(,DIA-G\402#B"+F*R* 0D) +AP24D\T/$ #[_IHL!IJ75@
MQD10=+5(%1@DTED5)!3APAD ^$:57L/=8D#^9*I!4$4Y6TGQX7V/I<8?.V.
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M@$1HVJ6)R( !MO" M_CD!C=TH$\_$, 0Z. " $@D!0Z84D#'2M:RTN "79
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M4(.9@'SM6,^[WNFQ!/9410(C<042#(G=)\A:#1X0 1?>T%S)80T+1YCD1#Q
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MFI>@5ST0O 2+MMC[(SLAFLAE2G2 !1"P>.])!T-P)2!P4B1P8D60 6.A!@\
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M L'[(#;  6#%#4<  E6   S@F%%R ,3)=QTPM!%S!++D 9>@?LI8!(4_!V1
M2K>@#BZE"2-_[3T="T40">O;./Q! _=X:(E  B<BC+:P <*M!B)@!2*0*VH
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M8$7!*CI0@,IV;KX)9YQRSDGG)E4 8(4A-D  @0V$F'$! S*@0,LP-BC@ #(
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ME@("  !:AA4+8PAGX8$@2 =LL $#> $G<X'^&3A]%   "L@? #  ][<*)0@
M6E((/""!D45^1W@Z8! !.<B$30@  2 $E# "'5 &"Y0!V"8%_5(((O E4D N
M7' &[H$"'Q4K!L409S J:C &#*9\DS &'4  &X _/L  2P( #:($ & &:F
M.' 6KE!C2R!20$(&!F!=^72':-6 2"  4G &&! +I"0 <F@Y-K  400 V/ !
M'[!4)X$% % $O#"&96  .N &), !EH>$JT@P&_B$$# #16 $12 $.- ! 1
M &!SCP "7T((/8  \R$ )T$(O9@K&0 219!4=,  -M !0 (% K!* H :BR!X
MWP,2<:  (S!:]^;^ +]18PV"! /P!D'  !*C<%SX!F<P<H7@ :Y4"U8@ .)(
MCCK@ /Z@ U^1!!?0C<4#&2NU@?@Q A0@!#Y00U  %:5@C^@8>:SHD(53!$\8
M %-S-B:0@\@H"2.0 41'! P0'?SR 5PH @RP$PN0'M1#!@) 4W S8FS@A6I@
M!@A0$1X  AUP,I/P!@#" [54/%=  ,E#! L  @M ;3B01@!  3Y! @^@
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MQ?,OM<"%\T$N7A"&!% *(Y(>%RAM!&H 1W &:P@&3#5R$B=QKS>G'F<Y/?
MJGD%!H -\N@32$  ?@8M9^ !$Q ;"% 2#.!.I'9\,B( ?QJH28  140 +J &
M)*"E&  L->0/EG@&28"A:@  $S &2   1_")TR #@?HL44"HQHFDL7HP$;.$
M$1 "%H"K%@  _54)&_ 1Q<. _;<!KB ' 2B!*Q U!/ =>3@ 9G & F   V@
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M!E>@!D*'!24+#%8S4BZ"!%-D!8<>!U% #6-0!+47%A7UX%PT#%0P?%2 ,5+
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M]P#+K6O[S,$9; HJ6 NYDH#RAH%O*#B'N^: >PL7&,![;DSTAH(OF2"@.\C
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M#] 1D0"AZ8B$G:W%TH1P P1B[ 819" #(" %%Q:P 0NM DX8]0 %SF (#WA
M I6A7864%6&!P. D<)J"I"% Q^"1P4$( <$&0,T9&AB %#(X]F]Z(  <S '2
MR0NTI L]YFI;>W-D0,(31ED8,B"-(4MH#!=&(X4S](T-2A WAJA@ABK^(($4
M<X@"9[!0!%6%5=[F*%R^X:UO?A0!$2:<&AW*(/!:>.!%^^@/G+*M!L7]!@M+
M4! 5D+"9\DB-'Q@:0WEJH31@J0$) )?<&]P A7U X46$((/ "6X+-RAA:OK.
M7*_^?>V:V_SFS2C;&7"0W6K1#>= #[K=SJ$+LH459V:S'-*/;C8S1LX75:!
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M;V^ (*Z@ P:19=9U%!O@'6I 921@8@AR:0HSBZ]P".X@>00 &%[ 1$6Q"FH
M 2\2!%$1"F-  :X  T[A II !@[ 1!P@"#W&$!0@CJ'P!,O! 5.P7PO^D0*V
MN!Q5H0,3P!DN 0&A4 5E4%O#> !JD 0[44268  +4011X0&"@ #Z@3BI^)%A
MYP-' 0+Z(0]D8@\TD!PP,54TH -J,"&;D K[X &I@!,@!B$=T $P@"&'X0U@
M54;FY)(P20@>4 [72),G:4Y@90/@( -NU@0$Y VKP!9 M1JRH T9H :U11)7
MM0':  %!L 3^<6J$< %6$$QSL#_L@%1DLI)CE&DDT $DD!LPQ$8+809(4 ,7
M<!3/,0@@,!F4T0U$D $>$ 2: Y*(.69@( )ET &D8))Y4D)TD01A5$TZ$$P4
M@I3[$%KL=5G\@ 00(!\)XI//& Z7^0 44G_^(#![1TD5* E64Z4&3Y "*H8.
M4[D<\F252D #6. PZ\65JW -W!4$3Z!MJQ$*-H #1?8/8 4&#T /45$5U'4+
M8_ $'' 4[#5/8' !14 &5U5.[B #4) $3R".;R %.'"0B;F>U8:<*!!"2- O
M-D:+)Q$EI%D21Y%)]D$ OS@4=-"99X $.P$".-!*K@"4-E P!5%+XV0?%CD"
MCG"-\>D&\ZF4IOD&'8 BX/$A*<D0C_0>B4@]+D " B<#T"(&#T"/@A!@@Z #
MN5$+5V!FH8(%#H (*' 23P !% H"!7-=H6 %(T */  3E[5>:D #)T$&"A 0
MP"6('A *12 ((C#^!71@!@:@*J7'GEHZ45*@ (!#@A!@ U * #7P!#OCA*1Q
M$EC  (7H '@B%:FP .AS"'%@A KPI,&D &YP555Z 0P@ R3PA%%X 5,# P!0
M!&>P  8"IF+Z#SM1B^9Q !" &[]1! "@"1\H 2YV"^<A/2B0AB%DJ XU @_P
M "1@."PP 81P!!+P  0E"2*@ "10 S"!IB7C @I@0;158 1&!OE4B"C  LX1
MHC;P08M"!U"@ 'L8H8ZUI<Y:6'$ ?;7P:Q&#5@:X?71@;B37>&Y  =J0<J0P
M!JEI(&Z0&9QA!F!P?0KH&-?7?1+(>%Z@E1!(K8. K;UG0FAE"W*0KZ[^X05_
M9X #D7V9%J_FD!FYD *&IAM6N:\4BB+WVD"9,23U-PAD$()<H)4V,8.^)WR#
M@*X YWW/&K)CYP8,( )#D $@*!T_5W18H08KL  *J'BU)[(T^W9R$PIEP(0_
MP 84!3==!WM>9WHL:WD/%3, -G59@38FL[(UV[1.^[10&[74PK1W0[52>[58
MF[5:N[5<V[5>^[5@.[5 RQ56.[9):[9:4;8RN[9"V[8]Z[9A&[=R.[=TZQ7S
M@A!WB[=ZBQ 2L[=ZF[> R[=\.R]WF[>#N[>&6[B"2[B(N[B-V[>""[F,*[F.
M2[F06[F*>[B7V[>!Z[>'F[F8Z[F@R[F/^[C^HVNZFGNYAFNYH]NYJANYF=NZ
MJ7NZK"NZLZNW=5MM8R !O-N[OON[P!N\P)N&PEN\QGN\Q'N\RKN\S-N\RIN\
MO@N]SCN]U%N]UGN]V)N]U3L!#O!YN1MF[, %F)$9Y%N^YGN^Z)N^ZKN^[-N^
M[ON^\!N_\CN_]%N_]GN_^)N_^NN^8N %2_IZWSM1!?%W 9Q?<>   5' B$40
ME;0J62<[.!,YE$=[E(=U$FQY$-QT&4Q[%$QU&ZQT24<R8#/!2E?!5W?"&OS
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M2/FS8:&9I;,$T&$+.WC:T^'+5L' !+PX ,"F#B  "J &9H#.[H$# .  WHT
M )<"!&"1 E$%X.T ".#>2W#>#G#?!% )%P8& L  'W0 "/"B\"&I Z!-M@ &
M!'!,5D4 !@(?!O  !,  1JD #Z  !L"FS=I>!G#?#@  G\#?;,H #R  0T $
M _  "(  $#  1> # Y H!  7 H#>#C  &5 Q#^#AA0  _4<H;&H ?"0!.@
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M*= #"H2C)7R@&R#02!PN8!['-<(&.)@#!*JBC,0\P@6"TTI3!LD1!\!G0QF
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MN*<,(#H#]E;$1YQASW%00"NE8(#5^HH,;-_'I:RQ1 $LG9T R&8<$,"9:>,
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M<Q ''X  1# %2# ! $ 0TR-@$KL$$J92P[%#9S88/PH"5: $%_!7<_ $RH8
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M! #0VA5] 89J=""P'?XR*M:" &KP ZSR""+@4I!2 Q3@!@[ &22@ */^\@
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M3 8%*7RX,)M(QD@7)B.*'DT:(2$P$G:5?B@&P))N8 ! H4, I+!F7,P(6.
M+X%TX1)%$8!!M1L7 Q0\$$ !BSD;!@@^ 7#F#("7+ ! T%3%  ('" !<<!X.
MS.[>#HB>$9#2 7@U/0"@=Z  &P@!] 4@,3;^_>N8Z[C0D<( 9_!RP $0#+#
M:W1LL($C @ H $AD4$" ! @@(,AT\!"R!'5F ) 27@? IQU>"#RU008'84$!
M?@H,X((F'W[5"@7"$-*$?'@I(  5W?S7A$%Q$%!#-X04"9)4 ,"3! ,$0'"
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MW.<":(Q._>^ @#/=X!#(P 8ZT'SMXQ_SD#0]A@1'&QVR8-^@1[OAK<Y]KY+
M5TZ3 8),L!LZX,G\'LC"AMROA3",H0P)![FQS= TN(  P[IWAE&! 0(+9(L,
MXG+#(B($-7""W0=S1T'=.7&)2]S=\=B2/"K^(D^*R%M=%)W81"A2L8E=M*(8
M@V<.)981BV+,XNS R$4SDI&-9-3B&MO(1B_"D8YMM",>[_A&-^X1CZQ[ P/*
ML3\LP"!=<0B"%W!@@S+0@0CF @,1$F%(1$H '@[;U\6P, 2?%>,)+& 0?Z+P
MA!5(@1!(@((G*^DA(-&!#4%@0Q$J00:E5($"NX /#.HR!RFL( HV.-(*C?C
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MK.B*8Z*,J&$&_I4('T$%TJ@A(K ?X1")$S !HO $UJ@ NX:/N-B&(01:7^4
M$[  &;.)HL@-15 6;K !0R !T, <#, !AN@ $N"(3T:1#&!K#J$& ; =8PAV
MA) $    'C Y'D8(6R4*%36!IV,ETC0&#""/= !SE@ !T*",W; $94('&; ?
M.C0]<R ',Q !)F#^A1XA35KR!'B%"%& 9Z^2 0) !E"@C#"09G.@7X/ !1/@
M!CE"!Q2P&5>  F/R&JSC 8T1!7N( B[0 7>5&G0  YNQB2[ #83 !9'&8)*%
M-D^0 1; !-U0 T>" M>19'2P! *P%]*&DQZRDSV9"$F@C*IAEKP  #SQDX1
MD]V0 H-IDR2P&6J@ %P@!3B9"#3),TI6" X@!T^@C,%&!5,PFHG"53Q0)ES5
M3V]IE2@@+@C@'$5P6 ZYFDV3 4?RDZ\R ?5P%T9Y$(() $!P0A]Y=7<&  $
M"3C$ WE!"TN@C(1  SB04'0(F.PH='1  JZ0 0X9!0H@ A[0"5"0GBG^X %L
M, <4D $BD &"$ Y ,)( H )L 9Z0U0,]$!>7V1B/L0$K0 -/4";$^4.[8$QT
M@ 49T"K"0 (4, (9D#$@( -5P (@8 87X 8@T @5Y0$KP '.$05Z@0%2@T3V
MP  DL $T5PQNP #Z61<)MPDI<&^^TFX9D +P\ 3IZ0&TT)XB\)YZI00[>0R-
M80,DX %<L!7%0*'UF3$BL (Z2@=:"0W0J(\=P T?\!K"0 ,JQ@%24 42( 5(
ML$Y4@  @T*4$\083\ -4P '2-)\IL &OL: / %D@ 0)*< :/U00XJ9->N0$B
M@ &"\)-KM4.T4P4!,)T!$&_/B76$L /2.9W^#1!$'I%QKT&HV]F=#C H_ED#
MXBD"," %/?";%  %2W +Q+8$!  D<!H$4( $4D,(FED  ! !NN.?,@"@ CJ3
M!+I6'6>E=+"@%48^>6*$I;1K('"J25 /)# !'D "C$4 .,  <8%72Y!>#*8
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MU4_]! #(0$)8%R#XR@^(?O_'?FZ@!OAW!J]\U&;]$&# !>\7T9S<>W2  P!
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MTO;0Y93>&X*@CO2A.63NZ0]4)Y,"*)P"QRW6*)'"[IZB)V!S*-6/)^S^7C[
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M87'F!%X_\2P=''R3?.<XM.XP(R#$ZR#WM6,%8!#.$UQ3+#JD+A]0 !W>I+
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MD $5,F Q]9!2D4UP01"D\*R:U61S[2 ! A 0!%?0@00N^H"X",$&!6 A,7$
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M^,(8YK /4F  R4&8(!!-BD0)T;P:>J$58B0$.1\A AVX 0"$=4,&GH6"%>#
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M!I+SA#D(DA]Y(5= 4W/ @@I)DR&YD_"W?&E8CST)A_4!D3=UDECP""?Y"&:
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M%![0 YP) B@P!L7#<3W@ 5:! OI$ L$0!.PT FY0 QF07#>A3CFG!'.P CU
M RY2!-X$ V< ;3]0 ^JD SS!"&[P+7+E!BS *230E"0P!"0@$.'I C4@!1A
M VI /##P6$MP 47P!"E !#!P*S^*7FX  U!F7S50A&K0 4@1!##@ ]M3!!10
M!%7  UCP $7@!L(A!=*Z :F9 N&ZIR)PJCI0IB+ 6EO!!1WP ZW5"="AK550
M!1,@ Z\A!11 JB2@ RO 664%K;QYLRQ 6#B0 CK@ ;/A ;3#;>[I H_^=03&
MT0%1ZR)#0 %$@ 4>X ,H$%TLX#!%T*YREP+90RDT8*X9**Y;(0-[^U1N  (R
M8$)?9:%)8 ,P( ']*0V".P2^0@.;X@)#X+B^@@-D$ 15\ ,\ #-+L */@07[
M$PU16K!(QP)#8 .SL00I +KPFAGK2A,V8 4]4 /$BC9(\);-D )QZ0(&NP13
M) *H$C<R@!1AT@,\P0)OD )(H08>H"SX(0.)! 9Z5P0^0 8NP@AJD)MBA 1[
M61=@X+PI +..L %5X ;OP+-@=1XJ<A/\6@XD\ 1L,+11P&W+XP)S\ 3<!@-3
M$ 5;80,E85<:&PT_8!5 I!0R  (44',\$0?^,L!(X<$%^U,['>L!Y? VSD<$
MGH68V$,&LWHP#N(K:M WZX049_ !M.$UQ1,'%;Q.<3H"J,(!HI<4Y4 %G6$#
MA'4%*;#"VP(#5" %^DL%4<!(+*PP_UH>PJ$&(S (!#0"%.0"GD4"MR(#8<-9
MA& #R24"0U7%."7"W39%,  &Q0.^XM8,2L "4@ "9" %*'"]*/ $*X#&98 #
M8,"S:B  4= #4; $G8$%>^2/27#&:<P#YZ #4I#'3> K5[!'K46WD1JS=H$
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MC#$"1HY6,!.V)B&U6( 1==[>1M0!+( #CY#*//"D(/!.>03G<E[9.,60L4R
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M"P#.\Y4/( $US_5"/P(((%E?*1=;_P%E;_-GG_90+_<_R@A10  E>0UD0
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M\80J0.%7W'"# BK%@"(T 8*2I,-&Z% \(%6!!U9 %Q%\"85XD" *7,!0[HH
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M!MS;!N!5P<P-37E\T]\'D>Y8:Q[JC@_](Z 0ID%489^2I^VE=XEP$FB[K6#
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M(BQ\I[9E)KQ 2GC^:B$,PF;ZN/?R5I"B W#G2G-%!SRP/^B@6=\2B@?AE87
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MIAD8]E<G30  D4$/EGW9F&W9-- 7 . 6_O0&#( !.$ #F5W:F&T#"@!3::(
M%S#:IOW:F[T JNW.PS/'BE,%$F Y)+"*H2P7(/ A]E%O##QB-PDDB5P(;U!O
MI3P&T6,&&3 %4K !S"(*(]#)F;AC5V!3P7&3K<$G3_,#XD1^ET$%;" %8X %
M9C &MIB1]K$2FX!=IS %214B38!.QL=&5##?4M $6D,M JF<(:*);K K8'!4
M*UV(/2%<H, %&[U+U-,35]!:9S!GQB<%S37@5<"K'5H%9. @2] #8*" 20 ]
M7I"'?Z0&)  #(!#^IJN28I36I5[F-C#  B( 0<_H1X7 +#;P7*_]VC@ SWFD
M83W^VDHRRV(:!*X]Y*:- T9.VX%#N7(]'C62=7[-UW4M"Z"V#6_ !L^&Y<B6
M"8(G:V;GV(!-")D4V>HHC.(Q%V/ G/W 5#04(AV.T:#P!&- +1I57=ULY]02
M8-5E#^=]$QG>*QQ13+"@QS,9!7+@!DFP'IA#!4I)!5'0?,W%WV5 %1,>(HQA
M!CEYDS=9TM2RM18)!AL=#Q$)X]T@YGJ!ZC<D=*P.LYFFUDX^Z[0NA_Q["*>'
MC;5>:?TP!UC@D:VQBG,@!Q9^"UZ@@T]06BN-";*%!98*";UR"LW^80S^+@U+
M )'C0 938 6W, 7@- :%L 1),09N0.I9D@C0<P5D4.ZH8 \&;@7GKI[D;@\I
MR.S&9P8-KFZOGH2[7FD@+',QG')8N'( +WPH// P#/ H7/#]?FDHE4D-3]O[
M'N,"F;.A)PI8V R/XH11>$O^Q 5:R$887V5<6%K9^ @8KX\SR[S4:"H;2*81
M'_,R/_/E9W.B1YLLCW\ZGWI@4%A 2W.+<#\^N]D=#_-05@A4  )X,5L]+TLR
MI'-O("1WCO _+UI8X"+=1?-:O_5<3WZJTIVB=1*!<1)!GWC;D$GR"';;L.ZP
MIFY'$9-*8);_P!.!5%@YII5PZ098E0U 01/^4MD+ZAYL_0!VC))J7"0+K3D3
M+F,4)/ &4&26I (0AA"8@XD*U94(QB"6B$HR)V/(JX )$/CW8(<3J# -CA"5
M6.[W(5&<7CG7F8"8=O* X]?UM%_[MI\6%#F7CE4FP[.0Y. &9K >-*%J47 +
M()@)>0U<[B"ZPB,%?QP33$L'YJ!N)U* (N #(. @"Q(C?@)V,N#E@C &'.0!
M;J$$UV\\XH,$<= !1[)+KA.AH8@='V KK@0#<$D"'G %53#^)&BT8%:T@!#U
M).(#0D4W1C)$4D7G2 1AQ65#E]*#TT,GY='#82:5$D0B18>41#='1Z1$QT5#
M9Q-;0Z?&TD-#N93^$13G"!M+Z>;!PS(+-KRB0U>$1-?!LT))]IQ!Z7N-G:V]
MS=WM_0T>+CY.7FY^CIZNOL[>3AXGI7:%]4;T,^7NK2;%I?8$AB6(&BQ7W("I
M(I!.#S!<HH"AX\9'E2)5L*BQ0H^.%3-<JKBIXH,(K4/YP*6:1">)#(TK90B,
M(L&-(S4IKJ4B@856!SI-5EYQ02M%G ]GZ,AX0D8FD95(5EI9Z6*@,E2E6'50
M0^?*BC<U'9VDI)*ET9<Q';D!BN6'&@Q)Y[SQ@!4,&3 RB[Q"TBP5F)9CO(P@
M<V9#DS</Q>Q<4L0K'2PDR)CAL(0.7#HDW*RXHHH2DLB32;S18649#JK^)4N;
M/HTZM>K5K%OGBU,E"98E8[C$:[WOBAHHCCM"D1*%5!6L5,B06A('-IB'49!@
M2?(02Y0E6)Z<X4?GS1/7V+!H;H9%&0D>-G@@Z84*ADR]8V1@I;-BSA+PRL[(
M..L([QP6-&0HP[O8:$@T000IOFP61U=NJ ?4-=Z50A]EY)F'GAHKM$()%R1D
MT ,9,*"2BAHNT ##?\WX(@,80"6!@@\V!/%0$23T  (=\Y&&1 H_V/ #&6^P
MX B#6*%TQ!+[.>*"94..QEV33CX)99123OF.%%* 884;5#QA1FMG/''(&55$
M@45'7(Q!2A)%<7G(=G% X047=/P&AFY953'^Q7)C@$G'FU!B,4L1B3W(0A39
M&4K5#S+TX@4&9LC "A<[)3$H)2+&D8$7=+ P1@J8]< 4>)9NL))BID@FIQ(P
MO'&A8EB\<D2EFQKZ!J*T7(@%#VZ<"((5),@91!4LA.;#*\R0]@0$AD;1H$=+
MK#1&!G0H<:(CS#IBQ1F6.;)"'$&P8D.@D775[0^GQ$(:E>JNRVZ[[KZ+S1Q@
MS'$E(K:U9A 9\#CK!A>8^2/%&W1,T<\2,LUY!1MT/%0O(F^@2<L83<0Q1DZI
M-*F&!T@\<0H7F:A!0@HKR.G+'#V,  ,,#[E!@@L?/*1$9%SP0(L-;H3B01":
MC.!2)DMTG D=+@S^4;*-K'@!@@N>N5&J+QD?P7$K'X<\,E5,2TV'#BP,O3 (
M*30C!<]!^!S9Q6I0\%X07HMTU@HN^L/*Q72HO0+;I=['<HD_I/3$''>[D: +
M/= ,;^&&'XYXXHJKVT^4;K@Q1RJ1.Q*'&@=CXX8:Z/6IAL @HH+>'"+. ;E9
M6*TG.7HU/'1-'!>_H3GHV3P^!WJV6XY-+Y/3HK CL%^<.42?^T)&TQ"I<7'E
M<LCANMR^9)X\Y91CI7LJMI=25!,^I+MX]]Y_#W[XI3G?#?DF>7^Q^=U<G8WZ
MOTSI/C=J=$ R]T5O$[\X38   PJ7BP_   IP@.V3'%4F%SG)&3!]!*3^4OY>
M\PVYE:Y\Y'C@.N+P/RA!KX$<[* '/^@DYS%0,?>SH+M,6#CRH1"$+&RA"U^H
MFBG(H@8TK*$-;UA#&N" !^^!X6GBP! LL.Y^).0&^=B0015B0QZ]<\09W.>&
M*PS1#4)43.>>9P7/^7"+7.RB%[61"AL 8(8X+",-<2$" (S!?NVX @A& ((X
MRG&.=*0C'#&3PH5Q2 >X6"$;J8*$Q*!04CA806@6PX$,SB0%-AB!SEC62)'0
MX0P<8%T5DL$",GQQDYSL) A[ ('-D4,*!-"D'\_W! !X0 1U;"4=1> ! &SG
M<.&AB@X20P<R5*$H?>("%M#CA8)D1PT<@4C^1I"@A#,,T5\RB<,9N*!%'.2D
M"A_Z 0@JHXTBY(0.?[G1'*(BA0^ @'4P.$001')*3ZISG>P,8=88$+K/,1"!
MGWO" #1YFBB4\AQD(("ATND:E/1B6U0@ 1%(L$89N  &0"F""WR0 GEUP <H
MJ($-5O"*)XS@!Q[8CD,A*B\*X*"'$&G*0[S -)+&RRANT,$V;= /-_!@FV2@
M 1)LULZ<ZG2G44J%#AP@RG%$00#X+$DJH$#4="FQ:*D@@P"@@#@NC"9$0"'!
M$]3P Q0\825SN (90& 1%NC@#"*@Q0AZ08(Y/.%#:A#!&$30CV24X15+1$(0
MFN"+).'/1CISJ2/^<$ RF.:G!T]@!$\/B]C$FD8'\"Q'*J)PSS^N8ZA%)8=3
M_PFO5&AAJG3P @O>\($@U( '5CB5'%H!@B#8H =< (.E/B2T:9WH*"3X00U8
MZ]IT:9$$[XG*-KR%2QN\]*5R4@,(4F&&$2AVN<QMKCAX %3'SBFIXZ,#9?GY
M5,1A@4ET$ %40;!&CA0T.ZO#IA?F8BD@54*MRN6"#,P@ IF 00RYE5LYZ: %
M$*"'!2KUR@]F28<G*(,F!Y-F=EQ0E#',PKD,;G!S?=I8<UPWGP-8HSDN*UEU
MC8$#"F4!*Q;F 1;(H"A!$('* ASB#-%,#7>;0Q1PX8&'0*$#+,A0T)S^IM 4
MH>A@0UC/,BZ@M104108I  %F6>L(,"3M/F_0F8.?#&6=_C2HYX.L*8UJ7>J6
M8PP"L)7A,H>[YUW1$4@4\_7Z)+W(/<[,TL,&[$2YN2+T$(-J4 ,;)!=FRLD-
M=@(C793_#.@O^C2Z$M9R:: 0V0MW.</A Z@XU#<'+#@ZT)2NM!=3P8/&IG/"
M6.:T90< 54N+>M2DEC*AQ_'8R$ZZ&]=-)QE S>A2RWK6M";@E*6+Z,JZXZB)
M1G4N%UWK8 M[V. ;-)7#8674Y!J[F"6VLY\-[74Q]MC>.*JA=YUE78OCU:&.
MMK>_#6[48#K"Y1BJA4UC;F;'.MSL;K>[MW'^ZPIFVS2/O;8XN-SM=^M[W_R&
M,+6_L>S3!+P<&%XUOP^.\$K'V]?)-GC[YGUA6"=\XA0?-J9/30Y/EZ35!!]
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M(N,&;P !/_"5V^$ /@ &!P %;B  0_"5>^, 9T %%Y"6"."-US $FO0 >.4
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M8[ 34G !+(  1P#^$2"@ (VA"0X  =N##6!0B1S0! "L $-P-AOP 3SB#%%
M!@H@)^C( 19C(QZ  M@41I0P"G20 4$IC42@ !:)" S  !Z !1RB -:P AW
M $^ ! XPJ*DP GB%+E2  %NC#"+0CN_H"&2P )GHB3V@ +/05D;;$<C8%6_
M <HM$TU  0S0D0KA 5XS! 9@#2E "LG=C'6! !;I!J;]%W/#J96(G%21 B3
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MA;B!2[?7;LMMMN9RZVTYY9Z;#KK?(BN%1HJQ&R^R[:[;[;[\IMN/MO#&N^W
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M8,U:VO)N,LC+'-R $$/   ..? ,2%#"%42$  M6)PRM:$9M+O($8'L@**$#
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M0BX(>G !\CX7;U)XP">3<P8B0!9;%&D)&2# $Q)8.)UB)8=AR4"!$=&!!)I
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M.Q+'@/O@<<SG#HO%E8-SD'14,D1H1QEWE<Y#*C)@8B_R>+=@.DK@ CY0'7+
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MEM 5<9 ""J  5, %"P !6N(Q'%)/+94!_R0"IRD!"X ,C4!,05">N.(&(R
M&4!3OQ433P &N!8+*=!CK- #;T &!T &50 !=*8)2# K-G !B40"[]0L):DX
M5J  ") "WO &#' &5) 702  9V &!@ %4B  9J %[ 19*9 "2]5=&Y =#%"7
M7' !9# &$Y!33R9F*^I(A@ ./V!/4' 3X8I1EC!<VT "J$ .&_ $;C  0X"J
M)L( 97 &!N"&!""KM(H)V^  ;_ &$/!/D8-D=@4&2/!/#M $:N  3Z &&= A
M]_JK%<,")(!>H$#^ S;@!IO2&<^P ![  ,3DI_6 !3^%"C6@ V?P #RA;[&0
M" "V*'':K!  "J7@$)>0LZY0 T'0H9;C!DD@ @;@#"::;S<% 9(  7,@!QM5
M!33@ 2. "9T!5AW@#!!P%$D@ 4'P PX 3D^F78* +&"U 5,@!1 0!$'  %(@
M!9> 3KGP784@"U$@7;I !U";7> 2"9/ $S30&?>Z!!?6L$&A4;"@)@[@) Y@
M!F20BD.0 =5U,>:R KLF :!0 Y%F4W.0 BP0!0O&L?!1 ZZB!@9P!CJP#1)&
M9,E &(O@!@@@!9!@!F4@ 3PA6<DQ"DX+"4O #;TD.6<  L@1!'R!43G^0@=B
MH #-*@%4@5%#0 %OT+>\4&.%M0P;]03@2@9<,)_U1 EY5@YQ0 &%-0L3$*Z"
MT02H( &"P0/U:@BN906<>X-9*[C0JU&2J[NDT!D_X'*FP;)V$ZCAJP;%>0C+
M  '_Z@!88 9<\)@9(P,D &[)=&*N8@,E914. 1"Z @4 L (X( *H  ,P<19I
ML184< 1TL (T0+NL(0"790 NL">-!P&S,A2?L0%#X&&F>S@DL  8?&QT8 !C
MH :^Y0((H 8L$9L(8 9#D!=[00H+D!47D $V  #+,!FMT &W<0: ,G 2X:FJ
M 1F$81P=X 9+ ! _< P(\%WRZPR&@1C$1![^L,K$RB3#<R #,(%>%Q"CC%.?
M]UD80? 3V>$ (  &$NP1978Q<< EA4 $   #&!P6&U #SFL(.%P#%S!:2P &
MJG@K7."Y1< 3+V(25B E72(8+R(HA#(B0T ==/ #/_ $IC&93[ "1<"FO[G+
MO%R;O/S+P/R;<A#,Q/S+OES,Q7S,R!S,P[S,O]S,O S-NZS,5"'-OTG-<6#-
MO4P.<8 $DK4CCDD1.I";B80,X>PE54 $8B(#[T0J3_ F?O*7,$!,*6 :Q/"7
M%-%M0E(=1((C,%!:CC('/N #4J#/2*8&:K)N/2 NY@PGH2$%5K("L87-SDS1
MSES-%TW,VNS,&XW^S=B\T2 -S!X-S"']S,%\+959"B9&*D3P!-GQ!"QP%!+2
M7L:<T=-LTR)=S.HT(OZ ;S2  ^""!"[@7(HR!QF1"%@09\E2",)"+,;2'F.
M "7*  Y U0Q@U56-U5E=HE7=U5>]U5[=U5Y-U6%]U60]U5O]U5^-UEA]UF,=
MUEQ=UE9-UFW-U6LMUVPMUFU]UFJ-UWRMUUG=UVS]  2P%G4$#45  A2 FO=
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M0&.8OU"P\.XDFQ_5(0.*4?427P3OM/'?4$LDH!X)&T^%I ;KKQC@+P=7G_R
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M\ ,PA&\GTWJ#X;0G@RC8X Q#X)_Q; "Y\FW-%.3*7Z6.6(JWD8$"0^ 4'7Z
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MT $4O($',7N#&CQ "4I@H;XRB(,29#""A[D3'#!XPP]@T L7S0%LG5D""W0
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MC:5PCO&XC?5HC_>(C_FHC_O(CZ(P!B-@'&. *F9 4TCP)V]S72+@*T2C/"Z
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32[9E:[9GB[9IJ[9KR[8:&@@ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g82292bgi002.gif
<DESCRIPTION>G82292BGI002.GIF
<TEXT>
begin 644 g82292bgi002.gif
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MW^#?X.3CX^CGY^CGZ.SL[/#O[_#O\//S\_CW]_CW^/[^_@
M
M                                                 "'Y!
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M7[3PP*=B#K)FF(3^:N&!!H5$BP #!N1 2 <"/!NQJ!*H( @,!,PZ*", )_
MKK<F((#)AR:2YLTC2UPFSBX(X"\802!0 9X+_XGS(0U#H*P3"22 ;Z^L1I$
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M, HCX( *K 6&)8   1D(@A1()X 1O   -/"6!PA0-3!(804<@"#1A' !!(A
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M9XY  @  P ^\ (' +F #!OC9,QWP*9'"P*8&0$ "%KB$!I"TIQL @,D6=@(
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M++DELQ"@;@U&LHW5MX+P3 ] )U@09 )0 <W5LE6;7X>+<45+M/1X S]5M1'
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M+/P; 0M  1UP!5>0 1LP0UV0]FN? &TOW"K0 +S6 R^  89M+RO 98KNGB,
M 0M0 1RP/"!W #DD"%?0 DLV/Q-P %H_ )[O]H0,]!$@]'($]ST09+=5!)=#
M !( _.YG 4(0 ;PF I030(DO J-DYS\/6#2PA&+R @K04X_O+05O!(=. 5F
M!+L?6K,<\/6.50>*61<06A?06"JE 2&@8<"9!1"PG&#06H# \066 @ "-@@#
M@ '6Z-CU0(%D<!AE$"($ --8 F !(G'@< 7& _#@(*#QM2%0$0(AH-+^V,7
M0&% T$)%8. $1I6 T,'1($L[00!42K#  <( <(+8.*@"X.  ,/OE(< 0HG%@
MT-/8LGB0T(!5#=9SFKH:P;#0$.* X, .IB(0$5)!P(8NC@IBB8"@"1@. WA0
MT\*@@84%]_*1<B)@0H0(T RL<G>*(,@'6\", /!*0KY], 0<*M@H"H$20 #$
M )-IA@T 01#U^Q=P@Y9&/T-0$-BEBX($#A8(D"*% ()?$!M4 (=/7Z,, A:
MP,6 P"^8623X&U&!0 *%"Q0T%3"V( @#"SS ."*2E@1Z#BJ. E/D&P@-3AV"
MB2* P@,$ GHP09"@0X=T11H!,; 8 X<% V;^@2E[-FV")8U "'C1:(D!!!)
M)&"0P$.C%/Z,"AP*9H.!"P8.<&@B+$.(")Y@&C^./+GRY<R;.W\./;KTZ=29
M#P)!0$01($)*..T)QD."!$&B4.E2P< TG L0"&DD! $$& @>1$F]X($4,%TR
M&' XR",/2$#%@#@!,$,1FH#AA0H.D+;$ @G\TH40"RP01!<\N,*.%!00P 1_
M$BCPP!).:!'% @S\XD0%( S2 @$=($- .2H0,! 82-@018"/V,#:$NS$Q\![
M8)Q@@ 4$O8"  310$1<M05PH1!9=3(# !EG@Y, !Y:CF@$)=>   @(X,0H,
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M1@*H3)P.0-3#V.+^%R)H& QTK0"AXF(9YT! "F9P F&@,*\&Z%R<!D !&JC
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M!@"0K?^>/O75H $$/@;079U# NR($  B-P@L[,5QUT/:4$SQEW>D/@0&$
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MT0(Z7'R>@8"H( U@< $ @&RSZ[%YLS<!PB3^"7 "4B $AV8O4L  !T #EO@
M V $.11'PZ.O!/N7E45-]* "+2"PPP,"8X8=G7-K*7 $HJ H/2P"M) >Y.4(
M!=0]NWH"09DG)=  "W "#E'$-Y %?S(AI9 !)M<"YY-&0( %H+, ^Q$G*O);
M'>!U&Q %_G(U(R 0:BP < ,$6K4!3L $%I  YAL%)6 +@6P<NK8)6G!H+= %
M3G !''"WCG %7B<$GELSO\=A%CP V9(#]T<%2V !!K!&ZJ:MYS04-T#,2\ ;
MR<PD"* !5" K &7#_&$! X "Q1P0%]<.5_"70G %IF0S1> !"P !+? >(Y
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M50"NHA2!4$4QP 6A ,"!6*PX%=J S<#0P7S8X>(! $O,H@ !!AA  "*L%)'
M  8($$%RB9P@P -:R)-%!"P20$ $6(QGY)%T=4&! 4" "$8) "#SW@E1.HG5
M+ 2(D @- M#05XPV!@?1:A^1V9 0!(0 !@P"@+ 2&#8 X&9#75B@P",9'  "
M%2LHL, C74Q@@ U9H"" FHE0<8(!#4A@"2LV$%#!$DM40("72&:JZ5C^6DQ
M0!!9P-""$!U2H8$!*5#1A:D$I-I%%TX(LT0+-A393!1-],B*"P TQX$ 3F31
M1&U?1!$K+L8ZX42/TBB+H!9.-.%L*<8R"ZT38 GQ@@ND#C,K#"]TJP@-"$RP
M1!:PRDJKK=(L@446--  WBPOA,L2KE=<@NNK3D01#;1/P(0%#2_ @&-^+G#+
MDA9-%"E$"S"X@X4-*S3'R@L '.1"F[A<88,+!A.S!,@P-!$-%=AF84,+*2:2
MQ:(<^)M%OR*A7%L4!&P QA4.&*!*IP3(U40"#P@C8P0]_N!B!0M$\&@H'(,!
M@@#MF;GIU5A;U(4$"9RP  !"\M?% @HXL,#^ $@\D(#9 DA!19L\" "V T9<
M$H$ 328RP@$I:F&! U_$[8 PY0VP(1A%$.  !0.4D$@/0J+WI  99"" XV!
M'G0B)5!.3!<>& "   3PEX@--8Y.P F)I""  PX \,(5<KHU=Q&) +'?!@
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M\&**KI   =B %@EP5"(\ $,-("$%"-A@*"*P  EH '<T(  %L! " CC^;E<
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M&R4X -+$"D?03/9& !?W@M2X*5V@6:;5!1>P %WE!!G09D7B!!KP $;!< R
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M@UZUQ9F.>7B7 )I-$9F*T)B=.9J:N9FI&1*5"5'-YIFGJ16'EQ2SZ9B>B05
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M)JI<&& !)R ,.D#^OMN+!3U0 1BP 2KZ(& P P!POOR: 0#  -F9$# 5!$*
M.SS  &.$R& P 58%4SK0 PK Q>B0"!1P$ M@ T4 !$@P-C:P!"> (2=@34(
M*E"!!"1P#\.0 A;P, )@,@Z@ O'9@NAT$ IW1+#< =0C!#T0 2?  X+1 W@#
MS%$ ! UP!$, !%K0 ^^8 PD0+0\0 1@'!A>  G?$ ):0 ^2(+CP0 _HG!&45
M!)F<D8[9 B. 'JS0! H05U V 0>! ">P!&\%!I=L!$#0!#Q -]8C%SV0 PL
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MM068  ,3&! 7#A# <$TPWR\V0%0&2* HB3 "32%@F1X,H*@(J&!!$M  !B"
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M( %.D.*I$1D% JR+73!H5[E!.K(!'P $'NB  =1E" (TT(,UHQ@976! $8H
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M%P1P 6B%"4UPA)4P@[^ !*8@74<07LWPA3B69%VH#)!78T#@7A]%A:"3 1I
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M#M  *' *%Q 0.S%D' "*E= "*\ 7B\D )S!(E $MJ6! $0 M* $&(L  $.
M$Z!1BA$%&S!8I$F9!I2',[  0-4 0I59H(D<2& !T(("R. $=JF4]OA11:54
M?],%O5E0"' #,X"93%4!62!4OJ !17 %#5!0"> 46;8,4M !V>(!@%&8S= "
M-A8%@XF)2P&2V6G^6$*P !$  0NP7;P)+2?0!5)  0$D$A. !4+@7KAV!%=0
M4PZ@F[Z !)KYFQ^%GL#PGG\I#TY03T!@F#9UG4!%=DO! ZA9 <CH,S;FF02J
M9>7)$@Y !7SIEX YESWB?,22,LBF++_@3L7B#R]:++S2F;R".C Z&<BB#,'B
MHCBZ*XJPHSBZHS\:+$'*'2^:.C/Z';Z2.KM2HS,JH]ZA+$Z:H\O HX@@=2[*
MI*GC$;Z2++H2ID^*'[TBHUK*1CZJ'TIZIFN:I877IL;2*V+ZI&GT&VJ:HU\P
M+'6:HDPR14'D0\310]WSISK$(87Z0D#$#4V$J((:#8W:IY$JJ9-*J97^:JF7
MBJF9JJF;RJF=ZJF?"JJA*JJC2JJE:JJGBJJIJJJKRJJMZJJO"JNQ*JNS2JNU
M:JNWBJNYJJN[RJN]ZJN_"JS!*JS#.JJ02B']$2+IL3^U@:Q&9*Q,1*PF9*S/
MBD6+^JC16B8U"D*Z,BS&HJ;^@:3"@A7=JJ0].J[<&J3>J@S#,J3>"J:ITZWD
MNJ5H6J[(%J_?.J?NBJ3%H@7 \J+N>J_JJJ;IH 5"D!A;.1]%\ ,21Q'2P*\_
M:JY2UP5&H)-%,*_82B74TP -D%'*X)X3( $3('<B*P$7X'Q/(3<MYQY"H%82
M0 $N&P'Z)1TC\  CNSHN2P$/<'$QP  1 !C^W@%2#.8.N>:R(CL!(NNSBF !
M$1"R(ONR&BEU5_"R#6!CR$%R$E"T3WM1D4";1TL!1RNR#]!50K"Q':L(JG=Q
M8$"S<B<!3!NR.?LRJI=RB/23!D  !.!8ME8)2%!]!&"W#M XRCH##/  W3*X
M#J!EOC ""."-Z4 5%(  =ZL ($>M&.LC/V  !B!!Z_$#"A6Y=WNW F!6OQ "
M![  "6"7R)%0N@6Z!J  0+,,&   =KLU#'  ?@L 8],"KOM*3J  !F!C3H
M[@.Z=VL  G (6O V"E"\!)  !-!\ 1(#!@ W@X@>(^8^ V"\"R  V.8"!-
M=MNZ ,!EF*NY*Z'^.@8 "V @N[2;+9%K  #P-/,SC7*Q  =@ #"[-01 G$?
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M\=N$!7$ "3 59.?&B"'&(0 #+S #&Z  "GRQ_BS+D0#)#F"WXFL UCW$'.,
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ML1SHZ"K=@2^O5F?H\.A%5' #7W?),:]#6QWTE[/2P!SJG&ZEM_T4PQN=!J<
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M0KA:BOWC9/7K]HS/W@Y$>JXN0DYX .'!!G-ZSOWG#7C$M44>;5$AI4@3,'0
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M0.@@NP#>!90(!7'A0R08*%@0! \\Z##$/44@<$(//$CPLCZ):/\W_V P'>@
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M 0(PT $J>$!?#^A&$P[0A2YLH (2L$ "<G.!"&A  @1P1Q0@8-1A".X!&+!
M!.:AGA \( ,2B$!43H"!#5Q IMESP AN- PA/$ #%.  RIA@ %P>@*<#L\$"
M') #+%3  AAHP#-R48)Y>$&6M7," SC @:4:!@4+J$ +FE#8(P#UKD)8PF)1
M<-8-0("U8+B !RJ @04H3+.<14 &#$/4"APUJ0?(@&#OXX H8,$!RWM3%R3
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MP+41P!(-J'K2B*9%!(*P7=!=5 .'&*,4!HT!ECB W%UH@2M ,+ NZ!78S93
M/D<PCR:H5Y=$M="L:_TY2\Z;)1E(<!=&T "K\4"9-'4 %>H7%22(&@Q(?,<#
MP  #[ GNY18 0A1>H(@K+" W$ BW+B*="Q<X&0,9H( Y+W$"#].4 528P2(%
M9ST=W#)[FH[" PK^E\46U%K;$T"9#:PG!73G) $\YTH/+*#'8:Q@X0/;MF&$
ML#D72, P8^>OW17Q;FI,F\/_='@ENC !UJX@P;K GL?!@ 0"! $,1V  UXMU
MYV3NS %7<,$$6G "%R"@=3M[ %E2,#"U7?X**C!@A,'@@!,@L00(P"7*!WX!
M%?" &L>&+G8<<)._HZ2"#RC!ZP_0WURXOBLY. %B-HP"U?^] =.[IP20$$=%
MZ* "6+GXY7O_N5U *#V7\/TE;+F8%(+A!+ ]M@X20/$E4(/TEO;O^0=V@<]E
MKP%1D((#%E-PU@M?!; G>PJR7 1  Q&07,>C<C8@-3" "[P'!A; $@W^,$&$
MI!\&P',.AR)+,'T.L (GT (:@#W'ME['= G)AQBS8'&+<0$LP0 H E'\=7*T
M '6<EPOU=W[_E!.W=(--\X!_IP4P< (/-@HWP'XML 3KLP(9  3P8U!/<GSJ
M,1=7T +I]P!?0 5 97NXMW58<H(&L&%-)W,H@2.) (6$5FPG\ ((D .*$ 0G
M8!8\5P&@9Q@I4(729G]SP57IDPAUF#VB1VC_A $<P'DM, #YMW\YP84E:&=_
MR!"ZU(-4  ,2X($?2")W!@;P9WI-PP!3V'"K]P C0'HHL#P\\(C90P,4\!!+
MH']@8'Y?@#QZZ#U' 0$CT'RCB!+*]'Y.US3^&* !)V #-QB&?G<(#Y@3TS=U
MQ3>"C^APO:="LQ8!!P !D+ ('S@D23$#75!B*_@YZ/<.B-@$)>  !) !,%=Z
MN8B)K/5WKUA<5("(GQB*Z$>*IIAR%E,_[=0D#B<%^M<%&# +/BB!9'$"A3<#
M(# 4Q=@$$[ $#M!\KC=4VD=^]Y$!&?"+%A!P7+AZQ0B1N5"*UE@.1\1:B7"#
M*)"#Q^:*6O"'%B =>_&+@X85(R".&V U??@W4]%,1&2%'NB-U* %J/@03;"/
M2\*/OF@#%7E^L&5QN-@TF)B#B= "$L!YE7A^$G "!"D(14D-U%!H,B=M<9&!
ML45MA-9P)N53K/7^1ZF' C"0C0[ 6]57@O;"*Y-$@3Q CCUX!<#8(=.!'0R
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M $)-8#V:LS/PJ0$>0 5(   M$ 0VT ")Y!?^!@ #^=$.MK,8%,"&(^ V3:
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M,A6@NQ7XG3U#C8(0 DI#N*,@!1@@'H%[?N[@ ?_A!" @ 2Y0N4T3 OG^<0'
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M VH&( (K4&2@PS?\ VP)=C!-TYH8 \J<TR7^D;PW$"0!;%C++=$[6O(X=P-
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M!1N0U/6"SZJ!H1K:.WF8F%_RU9=((W/QSZOA*$U0<EB-<DI]SQF:R24 DKF
MGU42VJG!D?^@6;K(S"S"ATFT#^B#$YN=G071! TKTPQ @9Q"!2-@5/:';"73
M E83!2* !$\5,H,#@K 1QJV+O03<!50 PV# !%@&QU\\ L*KN.N1OJV+=;Z5
MEHJ0QQ20QIAX/Q0P M.1"+&K"#- HC1@ UF "RG@"$L0!!=0!!>P 23^ F9B
M]@4/  0HP#JY -Z_VB05DS\AD"%O3 TQ@$DQH-_A)@7IZW5-,P)!((?&MP 1
MH#!+(,/B30OBJ;E8&0)%\%-L4;D$C@&N8+B;MQ@DRSX\, *;US1$5@%8-)<$
M;N"D@.)85KZ7X,;DR\<6G##L<P(_L%8L$Y@6<!4(+@BK23FWB04>L!@G< 2X
M=N)8)P%*+B8)YULO0 V5FP,3P &N\ 4MO-\T&ID<8 $:$#+'NS,AX 0<&W:<
MQP,3( +3H06ON\>$Q@,@T!,@(%(1(+T<X-U,ON)!$%[.?0DX?NE-,[[QNQAY
M/ $]48X], $C8-%R7@$<@"**!0%7488,\ #^2Q"]0B W-X[>T^&X^9.6*A !
M[+TS05Y>^[)TA*0";GX%"6?FTY@"9+I6)#8"FGH2@=D!B:0%;ON[WH"F'$"]
M(_ #%3#@YV?B[:0I ;L".)0 )Z$#GBH$'#"/3I  J39V(+0"\M $6E"Q'*!,
MQ7,2%% )J6H[-N!G_X0%$*"K-F  (-0D61!11= O[_J@#G 5DOFUI-YI!. "
M/\  G;21F[-<$D -$P $5)  7S $#+"Y0D  A'P!T)H+?J0![A<!C'JIAZ!:
M_UX!BCP3#"#B'J!,3(  -" $$<!:=KI<^T5L!K<""W\4<\$Z>Q($#N "6> $
M/B\$:AM^'A $/\#^6'EU 2_P ZB)$K?  RW0 %I0[RJ@[G51 KR3 0AP SE
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MI@%2U/*0=1B1(C21 N8TL-$#ME(A9+.P=#@BQ+.0 Y9"P>E)2: A-$+@5+0
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M41<F5/.:V?Q$,(=)@UH8JUE=6(!E6C ?,-R@+E!AP">N, &#=*$!/ '!",
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M$CTV\.('^.@6 *8O@4TR@0Q@X %7[8$#LHN G4%@ ^.UA7<C(*D<A 8+$YB
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MB+\%%GCP5&R+(PB-Z (//D%RT,_\)G6WQ>-_P) FK#:$3$=Z4J4P>=83!/'
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M";!(D17IC7?X!30@ DE0DZAXB8SX@SYIC[U1!,+"A%=0DOS8A4<0 OYS"T"
MCZMHD31)CT2HCE86=+D0+3L9DJEU D'WDM9(9K!XB0BHE7;854AY"ZGTBE)9
MAUUI$H"&EEM9C[N@EI8XC2TH! [P/&4I#?BV!-?&B.\1 A@0 RC#0]'^!I<8
M.8LG\A51^(U@, ,1X (JR9-I\Y*Z,#7 F(GD8W#<B"$4I1^IY5V7.94G> 5-
MX 1>T!N_V$'-DGR)E0M:4 $PT'E-0)F,48*\R!I+T"4A$ *'9!)+P':^$ 5,
M((Q:L#E*>)J1A16G\A 3\0U!LD ?5 S$\!"_> M2L#FW  ,7@!T+]&7N8!ET
MTX+)5U=RHT=E&$*^F064(3=+X(K:J9FKV05,< _@>0O8R16G@9_T:9^L89PN
M(YR]D &8L 08^ 5/<"JL^1=.<!KYV00H\P(7 $*Z@)Q.$"1^LH*X$ 41RA@2
MX%AEQY[NJ05,("SRZ0M.T'ZV4* ]488=5(+^#(H./%:<PYD+3F!<SO!2-_B<
M*&.>MT AE' A6?"?K.$X)KJ;KMBA*(.>1;H+69"<A@4S#'$%O.DR42I<7'&@
MN[! ]@8$,=&"GY4+*)J? >H.A]0$5U&:'$<#4Z( OT8N#2 "#O!>ME $$L
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MN9 "OTP!F-  - #^!$!  XBU @Z@ W)G)"UP!:@,RN12-' %7",PN&-$"0R
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M:3NMSEJ$"QIPA)!<#+&-"\.^SVN4.$_1@DA@&5VC $   I(2,-5F&!G1AP[
M%-$N>29Q!1=@8I/B(WD)WJ>(Z+8 !"\ \;9 Z&!1UF7=Y$4"O?9.[@H0[W!=
MVEP1!)N^4$O@:I#^)T804PP! R'7 -^[X?GI&G;UZG^>"\/>[L=.*_P!)-D0
MZA3 P92M-E2P $ 0!2<@ *Y<-+W2LU+  P) +S)H 2W0#!S  51P! @@#FS(
M PD 65+@N04A(.KQQQ$  HT78U\ G;D0 Q2P@(73Y1M[!3/ U_F) "[^8(0
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M3!0(Y!XG2 $5$&"0";CV("EX,!@BW 0)S*(#I:""!;CF+%-VX6/+Y:=F9M
M#X#,G&+30D?O(0_^#K1@ 1G0W@4PX(((-$,%!.A #X20  -78"I:V8 '4M#*
M<S@ !"UP"QB80&%$$(4*$5!K%Q#P-1L8H 0B6, 5P+D"%3#@%0<K'U<PH( 3
MC$  T.J"!GH1 ?H0[04(& &0?UN""+@@ Q>X!WN*P  5>$!ZD[)!+T+P "J
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M.B5$#"L@"_=#6+/0!+O')WVV :ZP%IFW>4F8>(K74>I46(.H4 V@ 16P 0*
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M@ 0>8! @D ) <(]@  %Q!@9E> ]H2##]%T[<H)<K( (7T(Q"  1/&04+X)?
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M%" +$@ M]-L"()  K(:_G;MFH4L!#: 91X  X@L?]:8!ET8 AQ ##-!OWZ4
M/,&Y?.*YZW'#.1S^&@]@ 3>6??0!<2$P738A !JP A^!!3HP "GGDNUA! R
M BD0<DO\-8U$ (-1 8WF# 00CP^P##]0O+T&?+ &!M][DAXFO:(KO%H1 ?OD
M **JQ1%W$8F2 1K@ A/0#*8[$ DP*=_;!)2&"%V2!0@@ B+P  =@#C2LORL
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M$E%0WW>QZWLRZ,MHZ)>>$J)NW.XJF\6XCSGP8KMA,UK0 Z,^-7=>YVBS 8<
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M R+.[IS!E"@+>?"RPJ%(E%7,X.S:-SA=,B +,V@&$B/(  @\P 634($*M-
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M< )3M1@8\ J(N$P+\(CE(7Y48 #@)WXV@  ,0'_247@(H%>3L *!^  ATP/
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M/6.3 A(@!#2  .&V>SP@(%(F.D@8BF+<OJ+3!?J3*!H !"50Q%2W<$[^H #
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M7C$*=Y'Z@02-W$"C7>&5X5='4.57GB"A@ 1.'ESR2K7$-^$48  1P &,700
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MM)ZS +"QNF[NC5/Q#7#Q&:_O_.X(&O#Q&1#RY5D?47  $3  NJ)##Q H%B
MDU14C  , D  < ,$ / /&T  HB[U'HP(#L\**J#Q54$ >+ET#D  !W4#&\\
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MHJTB C24%&*@ DN=4*-*G4JU*E29/34%$9#BBA,J&X#Z)$ E2P(*30Y)8_C
M&A@.!H9=7+@!@98> F@@RB> AZ$L%Q <<,82!@ ;%X=]<S*@!1@4&&@L -.$
M@#8@ %1XI0+78CHJ44*#Z=) !88+HQDX_M8%@ML.!*10(7#*T!("NK#I;40#
M ) KM/]&>-"E]8,FH:-(>7FJ4&418 S'>HIY!:3IT^;9 !WEB33 @FM".YY\
M.18'%C05$C(L2O!$ +"[;QY=0 [N433--=3^I8*@?ALXT 4K/##@EP8-=/$%
M! \LT]-37;2U5C_00" -#P#HA9D*W#DQD3>%G"  $F!<H4 (8"QA #^-"$&
M8ZL80)\B-ER1G'XN]>? (/T@V 4'#621438??O$4-0\T.!0-!.BPC0"V=)!C
M!0)*08 K&RA@2R%+(,'2"@)0H4@EC7A  #[P;"!%<N9@YHPF-/15CS<SO>"3
M2_T4,I0-33YI"YA#R#*" 61:9>BAB";:STR$;7/  @(,(, ""\AU)A@M#$
M!BT4RE $#O!0! JB#-(! AAL $([VA2$G4.1C ;&#0A$D),E&"!@@ TZL<(!
M,BY0(8 3/,4 1@_^CPJ@+*7#=)#  <H*@("""M# TS$+P+A)(>.)BL( F4B1
M0 0:<!#" X1B&I\L,\UPA0$8""&$!P)TU(4$"Q 0*0"H.3'N!AV<FZYTTYQ@
M@ $G0/4" @DH.P  :15R0P(2E'1OOOM6 (83P4T#CSS1 : *<XV\8$ "DCZ<
M%FQ;@F&F8MZ$$&8."8"! 70.2."%<0[6I%8$%D8%#0,::+#! @EO8X "RA(
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M1CA! %K321 DI0+;?*TV;2[$!N!<Z L@N0)' (,!4OM- :R&(7KF<T@@[0\
MU$;0A"; H4DA !T>J0L.0$#1C&:!*T@! +;VR*^:6@$D8\ 6I-ESGC E  JL
MF *\2K0E&.V$+S! UT7;0.8LL>FB$2 !H5:7 SH@ 5?OY=%<9':QC0;M.!/
MTQHP  ) RYH("&!'AMB K-_+@,G,) *TW0 %0LV !&0 <Y5FB ,,;K0) " %
MQY)CP"^0\'Z4(@($D$\$^%4Y^^PE"K5N1%.=7:YV=WH#DT" I]S:&SP7 @D
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MA7!:";>B]^FBAI I:HJDXGD(0A!O2#JGAL -21JFCO:EFG*F8/ #D#H DA)
M;AH[T:H8:5JF%1<%'M P\#)?I,!ADZ*CI,  !B"HAU"C4#$"6[J=B"5H$' ^
M&T!>7Z "27$^[9!P(*!=^59;RP<["6 #\F(/"."P0: ##.  ZX<$\4 ^+-0"
M0_ #0% !!) 6Z% )&*(++0%("Z!CJV9*3X  &2 O3.( YI *?+$!0L #$B
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MM3'(=Y-%S'#(Z:+(VMP38, $!J!#D/#*Z)P!E#'&N&K&AU ]0_ BKY1S4C
M%% !"J'!AU4*'9%2FD!2IJ0@3^(,&. !^E )L)4\0S5#0K F2) SFC X8& P
M^* (-R!+3J !'24""0 ;NU&U5' %?7$:M&9**U0('.,*AG$$,&<GF<D2I9 P
M%6 -&"7% ( $,>W^3AL#$RL0 =P0AL",5;80 0:@ E;F#1D  C"@,4VP $%@
M &$+ @F@!3H 7JL$5P!@+*=R BW0 BOP @J633^G'PB  B_P @/VR0A  6'=
M BAPQB0C@0O@8 ^'E%%P @!P!%=P ,U1"";5Q>R[  ?01J-! 2H&6&Y5$$70
M!8=6>& @,WUS"NX!9:L R-6U3LJ1 @H0:MR@ 2\0UBC@*0!M"!RP9_<" 2SE
MML@V0XI1"G"] G(=I)B!6UC$9!1E2D'-#7CFQFN1)J&!F\R0 UJ  /RE"'YQ
M&Y6V%<+%TC!QQ!L-E/&V$+WPD6U!-RC T259UT=PU]HMEGSMUP@0T(+^[1H]
M8P@Z8*9@D$\BZ3((L!P2,&J"&<HV[19\_ U1P"OY[<^I=-EW=<3[HSHVPP%=
ML*1QID.SD%7I6I^7*P'J$ K+@QF?T#7RAJ0+\ !/%6!F&C4]+"Q%,!-^#4XD
MA$(<$3)(D$<^@XJG%:1-I4!1W$J&@01&D$59@RF5I0'* -Q[L1]& *T/, )T
M5 @9X %.H !:8 ,O. "F)"Y=2@!)@TVN5#G]Q@#,I9U&S4@)T&]W7=X;<[F4
MP@ $\-RD,"Y&TS"\ @0C*BT5"W$3]3.D' 70I;F-L 3Y<FJ-4#5%@!190 ,*
M,)]5,KJ:_1+"K!;QHRRK 00&X  +P  -0 #^IO04<.'#.J128(PGLZ, #=#H
M8NX8IRSE(;/+.=X@+U!9[]#HC#.I8% "4I4ERW$;KI"B?K'-Z/0KS]LP6_X
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MTA]$RBH [/]1[3]W)(]V BM  5?X $B@ +5U3Q?E4[W8ZZ$"226  ,VMREI
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M V #UK+0!7:!H=*@* CF07#U(W$DF!7Q "FHD0%V$C+A1"4 ! :"@"! H&"
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M00-7?&6 "@EHI4)]]^7WC6_=+60 !&[:@J225/0  0*8 $F+J+Z$--*.>;X
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MX'Q@N$(+6O"J>J3 2$)8P0M<L()"/F,)'^:P0'2@@AET8@@IZ.E"7%"+&;3
M!1]&0CBQH )&"2'(X B""VBJ@Q7(^!?W60$,7M@%)'PXBO3DP0I<@(2#Z'C'
M'S9EAE_P81M(H:T9WG D/ QB@:K E:9J,@RH\@4=\]@%/ [QD53@)B&<8*%.
M.$$1M%#CWGSX!2=.01&.L.=IP,!%9]8PH0FM B?T ,]J9I2'3SQG&,Q5SZ[D
MM*)=%.<YMR#+OIC^XH>?' DA[#C$5^!Q=W+ Y1:\8,U@F &M:^&"IMS@RH1&
M,<W D055MT (B 06EV<MO2[ 8,>]-C2BG_D%&,3 5#.@\X?K_,IJ<SEE'9;U
MM5L ZFJ+6GI?$+;T:N%F- GTPR'&0@H6:FHS_T(WC*+&D5.M83MW0<=DH<:'
MLY %68N:%DY0 9A;8(,HT'3?*["Q0&V@ E3_0@>QMH%#A@QF'MN .&>4<HKM
M#(03Z!/1X#R!#2#A!1NDP,X7]JD(!D  $8 #(@*@ 31:!@;X+6 !#"#  K )
MAG0E  $6LBH8I)" !& $# -<P>>81@ O8(@ #&C XS@@(+'U3N=4:5K^)^*2
M]*4[Y :N<,  %A 5+6Q   Y   "POD"E-R !;R\,A@S  )ZS8@:*4P#/#6
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M!-!V"@!T<*-W$U@S/-> %* (V#" H@<53&0 !_B#%;&"AB!Y - L+:=36,
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M'*K@2EJ CJ5F.C62.+IBC1(@=<%H=^9EBL11! ]@ %?PC#YB*B 5)ZCX!4[
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MT 30.(YU) A L%(K( $K,!=?, $("C(<8 #^_GA&#C "R?A[[S<0$?"9\R8
M^<.(F](!AX$8T5 <[M,%>?&&!!$!W/DBQ@D)R4$%5. /]:FB![$)K4@/>!$%
MB*0*UED/@(@,1MF8 HB? A!!7X %42 @H3F:L0D)OI%A(DJ0*E !?"<$#A #
MSCBCQ.B>R7EN"($!5)  S9(<<)$B+Z(8OPD&^<ETO3$V6(">D4")M' -&; *
M&;!)5Y@#DU>8/G4"S@@VT  ?*9  :2( *<.F\F%ZG=,"R@D,11$0XZA/K3DF
M'X((?[BA&?J?S$!^K1D%!T /+D%/8UIK @ E6D"<(*2-W!(E[D"43 $&#^
M5P8#(0  ?)<5B0/^%C@6"LYH $+SF$.  H5J($WA +GW2O%7?=6Q& 3A #EW
M% GP Z9 ?ET!#3.ZI@?@ #R7=R9R6%WJ 028=W-7K0G0 #Q'/AAZ6/>YIK":
MH6_H!04!"5H0 7NA&'Q1"E10&*V)! R !5R(!!#PH 3(<PK GPHP ^G@2@N
MH0B1J9&P%$WA$+L*!L*) F!&*<!@GFL:@;:'*>BHK'I'?@YAG$MP!390>UB
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M"X X9U2Z^^NNMB +T$*9>><7A,D5V H#!%"W+9"^$3!+$=  UYN#<")\ W-
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M!^ILI04WEF'%$<JJ?GDZ:4X]Q(@PS ,D+:! )5U8  $AA(  3! C,2 P AN
M,0,!RUC  #J:3"35#Q[DLLLQ(R#0PC$>>##^U145,.#!6",D</$K'G0 1@X(
MK$#+#0FD( P\\CRP0CTN$#"2! XD0$$3#!CS"@T(@P$# P\4X@ !%P,Q4B$+
M1$##@%$,TLHK(C!PP2PZ",PP$ 2 @O,"#[20 -@3.,! 1C80W9$!%W\2"B$:
M! 1&%BIXA,%2P=1\<P,Z,\& O#\'_<H29E\,AA,),." !(,8\$.;P^C3"=56
MSW(%!1Z_@H0"(!Q8A -.U2*2-XK?D$@,:A-"P>.)P)S  _2<KG8#$> #, 0=
M$2QTZB6Y ]51)R.@PC$Y)#"\,#]PH$ #-;T3CP(0S$QQY7 UP  21RR ^\ <
MO#8ZTW'#M70A"'3^/W31#93?>CRO2S\OZ0LXD )*Y^<RB@MU19!  Q+H0P -
M.A@ /J "'Q@TH&@,:( !\">,RWFL%B$S'!@Z8+(H0$ IB8A" DI!#)\93'#I
M&,3(8!&5=C&I P. %P&Z%P4#0*(%+5C!"S0QB!6T  8B$  (P/ # 6C@!394
M@0W \ ( + ,"!B!'%Q8PPEKD0  ,@"$#!)"#1'3   RH1P8R\",>$  #!K &
MR;!8#PUP\0L9$, RHH  !UPA&%K@   V,(,<1N!?*H"!!!!P@A;0H DKU 01
M ?"X%N@0B"U( 2^ X$,8M. %%%"C,-A(/2H4K1*)R, #'J"!EN0Q P;^ ,$+
M7B"$&VH@E#!001=@H$,7P! %I>"  4[@ A>@P(5EV0 !3D ) 12A3:\00AXE
MD( ^_M$ W;.$"P!0"DNL( $5:$!TKI!'$!A  ZED0F(H>0&O;&0DL^"! 4!I
M#3"H  "MT (%"""W8S 2FRU@  %,YP(!A,"1+4@?,+2P 1_.( 0"N",8ZGG/
M$R!  4;@H0\1*40BVA.?Z9,"&$"AC2]H0))L=*,PGGB!.A(  A+-P@;F^,^
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MMPBNQ@(!-.S.ZL:(W! X-P<,8@DIX%K7,=*! %"@L#<&@[JH\/"8"3FW+HQ
M &^-YAN3K0 M@'7%+68DISW- U +P!U9</D WFKC8*A@V,5.#(L_^Y<HW,4"
M#D!)LI<-!@R 8 4(<<(Y# !3 8Q ")#F@41/#@#\=2$+%8@ 2G2N[9X+C>4"
M=\4%&C#S1"@["U)P+%N^( 0!N S;VM;WCUK^J#%+V)N4V^Y& >\=^ /5XM:Y
MCD ),Q!K^<Z9M.766)X/9P"-T3L1$*>!Q.72!0A (+&#KI$'$H   0@  0DP
MF=:G*  " ,!E6I! +AQ @0<DX)= ,, "7&_[SQ9Q&0F8 931(>KA!O88U)TA
M!CIP!0*XK-9K%;>.K6QW#ER!O+H-MA8J@,5RUD(+1:>%LX$Q1GB-S?4"4( !
MW-$"!+2^]@!XZP\,$(H(R&,#GV%?18 )8% !.4 #"6 )&\  9\$ !>-<@:4L
M[?4*+V!_KC< ^3=!^\,.$6  -I4U\;<!-I!8_.9^PS<  I  !R!6P&4-&L
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M=:5N)],U G,TIO-Y8]%>7K%EP6"0-Q!*\!$7Y20%B[,J &IF PH&1H   I-
MLP1]]SE:#$H!+5#^5RVP %^ !8OHGA= "\8I%=%W&I\G!%A9#_FYGUB09B?*
M&O9I6UH66$*@ 'EXAFF8G?!U7"-$.$-D36_U"EG0G_!A1I=P A;0!+5X!$?P
MHJ\Q@U[QHUC&I'U6"_FYI7.39E\@!02@,?QD )_U=GI9%:3%9WPZE\ZY90["
MG@W@GO"9C_/)19L' PC  PCP.( $J,3E#BDJ,/'3HL*(>L^Y(B"  /!R #O$
MC!_C&IM BHDP4L+%2#,T*@ V!.*(/TA1-#,4#%V: #UP%CP #BBQ 0^8 MI#
MG:\0?!O7 BYP 0GP5KZ:""H -LEU7-K)(!BV =9 !2<  .+YJ?"" )3^NI"L
M]#BNT7>H,)4,,':C)4!@P $+,#SQ] 4@H "$J5.ZH(OKI8O+D*$+Z:J?^@3,
M"@ :=J8;(!E'X  /L"K:FD&BZEX+N80C@$\0@*I&%JT\BJ[J.CP0&GP=X$@O
M@*P)QZT_(J[PQ4KK)7)7TQ,"0*T4<:T7\UZ0TW>M^A8BFP@B9P'0T)]!1R@@
M*Q5=B@ )%044D).MAK)7<*T,]%IVR0 4H 6UZ&[511NB(P"MFFI0:PL"@#^N
M&K-W\0K36JU$:P^1A04/$#2LQ OM,7@>FUY5U07]LWC@JBZOL'\<H+'(JJP/
MV*P/P$($P M7P'L)H+=FT[/D)PEA. (O $/^:'@6:289MM&I*O(*&;")&00
M7.0$K\<O36-J.F@/!Z %6*8 _*(^+1!8!' \?8>M-(B@ I +)I4(%5 !&90
M,@5?(R5&/6&ZX_"Z J">A6BZ4Y$# ] UK0>0\0FYAR.YQQ"Z[G!.3., ;%.[
M%V,)X68,G:A]8/5+6K4$N5L+&D"\H2M6QQM6@K0" - 1"G0Q&$"\Z@0 O]0"
M0=@ *;A2-+*]"6>\K]"]XK@ \%&_X,M#I@LU-(8,Z@L&*$  7] !D*NUO.L$
MQBL56":>^OLXKQ ".7DROYL^;/G J-8#X[NBNA.Z$.P).;D PL<]B? #_2L5
M"#H #M!Z*I,(-_#^NRN,70WA#&!0B[D6!>J+8!UQ-MV3&!K<$2Z%$S_\N=UC
MOXSAN\![P<,0N^M( ;RXP?%# +(Z24S\Q&*U1#6G8QN<0 0P0V,Q4G*JP1=S
MNW0& '6EP%HY YJHE3E  $D\/!R)O]];"B[%P<G%N#*B RK $M1415?P2##4
M5'<! S"@+#V05E&01X&\ J8#HKR(#UY@ RIPDK60!:64;8YG Z:3"#V@ GM*
M"UKP D]S#%G0 D.DR;30R7OZ"DYP I3\%5)@ S<4D<&0 WO<.IY,"W'Q5D(@
M0X&L J70!*[L/"U@KHEP!2GP5E0  Y80!,J7 HB@(4>  DLA!"E NW#^<0)O
M!1<J4+B/-,DG<\NO4 1"-#@P! ,V(15ZS!)8D,O9' 7MS!"O,)AB)<ROW#K)
M7,/,'!(PD 4P8 ->P:6FC,N?G!BM_,J.G$$WE+^Q?$--, O6S(F>Y,TNT% )
M/0PWA 4T8*S&2E2)X 1I514:#4-"8!FQO (P0,LNO,DV( E#ZXW=O,B;7 M-
M$-/G7 \UC4\TU<@HL,VP; ,HK=+M_,E?8 /)7 2^_,WWG KN'!(G4$Y=$ /[
MW,L4#<Z'\0(VH"RE/$0W,-.JG KYG HPL )RN@0_5=)@( 4J(,_#D *E@%6+
M;%-X/-=TC25G4M=X32,]DM=\W==^325I<@S^XU$G>JTARI(F<N(B&O(: K$@
M Q(G7X$A)3+8+4*#EJ$LA-W8+5(GC\W8/_(:AVW9H/T@;(+8GQW8FYT8BSTG
MJ!T;CAW9AJ+7/P+9!P<<F,W:9N(*G;W:D)/9E)W;H6W:B[TFP<W;J&;8#5+:
MO7W;KBW;;)(ADBW;<V+8=_W7UGW=V)W=VKW=W-W=67+:NEW<N@W;ATW;N#W>
MI%W;ZAW8T/TBO#W<N2W=YKW>]$V#L9TDL W>]5W>H<W<#&(E:Y'8A3W:[6TG
MTJW:]HW@H!W<P%3>^2W8Z$W@\5W9C?W>_YW>S6W?R"W?YDW9C]TA_IW@D-W9
MWEWBC6OB4O(B*+[^XBM2W?[AXDL"XRQ>)E30 STP=GSW [_4!#T0!#X>!#U@
M#4?@:3_> Q$Q;4  !#[> ][( T?NY(H !'(*!DSP T$@!(T9#$>@Y$D.Y$AP
M!3S@TT,.'V-^S$E>D[0@!3WNXS_ $CSNXTEN!'UQ!4#P _[6$$N@ V,G!6'>
M!3H ORC* XY'!3Q NU'P S^0SJL!=D= &(>>Z+50YK7 YW*J!=-6!#&B!3R
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MSF^NUWF18O2U(,8N[%)K#Q\*[!3W!_2VUP+^M9B) G  _!ORM5<[PJ %;B\
M<&]W<T0+K1L,XAOR*+@0W2%/!'"!&?BXY:3 P88%EK^?'@SAD8]_.YH81?
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M(C "QNCH%-4A4 26(A 2;9/P0&78 J"C ]!BN&10T=558;!D>&S8"S!%!'#
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MEDI P="$ [QU6SVHAS6P  $&<"K2<EM1?@53.#BQ(@H/0( Y6BV?8IMY&CD
M \W$-BD#,.P8Q8;-'\\!@ U1P0&4!1):2PS^[WC/U*;2 <,%"/"F7#+"!5WS
M6IL14$$@!*$'[R";KA3",S"H((\#^8('3N(P$>CQ%" 0 ;K M>5AK.A!K!B@
M%(24 !T(H023Y>PK0>MC,#"!SJRP@0 DP(.1"V#'#59 !+2@!>*L$WGH"LB<
M%"6!(/S ,V8V1%QF((06)$ "D$1'!LS7U"IY  $WZ+=@Q%:$9TRI-#6&7&8!
ME<1^"_R$(Q!"TK<S'^YJP'Q]+::BP:"#DPHK>%OJ=P4(@*.V]:!\Y8/DI U
MV2 ,( 6/H(++&4N8%W1MX&"8EM 4\P #M* (-F  (F/\>#_AV=2ISB^_!=X#
M'"DFB4(7 @H$ !O^%$N>\G0VQS!04'B7%R-5F&H"G6>K=R'P( ($.'"8/%-V
M'DB@,+&Q38,L,X 2F+T% F"MM)]_"-[,Y7GF$SC0FAH#([2) I.PS,F+P$T9
M=L^.$,8"!09PBA2DNP@TJ#;P0!""B\M[_O3OSVA9\0('<.0"(5N! /;I3;*S
M 0:04-/$.IR@9C3C @IQ %42!0ZP)8:0!33  +V$ !N@4B G?ZZ@?V%D;,?@
M&<#C&:Q0!'TU  0P L4U6K  ,9G$*QQQ)-X =^8D  QP MWG&6,Q#(4 +@[0
M@8/B'BS( Z7Q?QJV"TX0 @E% !F0"U\  Q#02Q   [#$7A0U /]'*!K^=@01
MH% O "QJEA5@V"4&($V5)  'X$IEF #\\BLOP(5U-(6&@ '@%"YB> Q8LT_\
M-!!B@@ %Z$TXTE2Y$ 4SIQX \#>HD0 3T&,(,  G" !44 J\0A_ X@'2Y#SF
M@( \.(F9""AJ!C@ H#;^!X#IMA!M58:-J %@$@65* "7: @C  #A<0Q4L'2J
M]H)@<"0EP(<)-0 5T&WSD04G4($\H5*MT"3R!R#\I%!L" :!V(QH]D EX"U[
M<HK\Q!%9, )*J%W;$H0+4008D%!KF O=&!"]V 58L'"]% 'FH 4*L"GU!X_Q
MN!]9, I@D 5@(@50@@7BD E1, F,T8^:\!/^3K!.5] $FT =NB %37 %NW 8
MZ\0)44!#62&1AJ %#*D+?-%@, $NF3"1%]F0\F&0Q1433/ _B,$4P0!(31 ?
M7P )'XF1%@D)T 5(D'!Q60 )\P60_9A%3=!]6323 TDB@K5.7\"//*D%1TF3
MNZ %Q+40^7AL30!=^]B/)!(%3Q"0',$8_Y,6$=F2J.$$7X %5.&18SE?]=%?
MQ\-?^$&40JD+6, $FW %1PD)(0D0='D7\I$<3/&2NW 67@"7).D$HY"5/P8&
M6&"3"P$)]I&4F: W6[F1>)&4,(&7%4F1><F4/AE.+)&9=NF2FHD:.:D80"6/
MI6F:I[DM(213$XG^FO;!FJXR8J]),:\),;+9FA-CF_5W?/-VFR*6F[T)G,&9
MFJKYE:IY0Q,IF[\YG!5#0[!DG/NAG$R1F[3IFL^9><VYB<L9G;A9G(.BG;"I
M']@IC[69'].)'[:YF^'Y*]"YGNJYG.\)G_'9GO"YG<)IG_>)G_FIG_O)G_WI
MG_\)H $JH -*H 5JH >*H FJH O*H WJH \*H1$JH1-*H15JH1>*H1FJH1O*
MH1WJH1\*HB$JHB-*HB5JHB>*HBFJHBO*HBWJHB\*HS$JHS-*HS5JHS>*HSFJ
MHSO*HSWJHS\*I$$JI$-*I$5JI$>*I$FJI$O*I$WJI$\*I5$JI5-*I57^:J57
MBJ59JJ5;RJ5=ZJ5?"J9A*J9C2J9E:J9GBJ9IJJ9KRJ9MZJ9O"J=Q*J=S2J=U
M:J=WBJ=YJJ=[RJ=]ZJ=_"JB!*JB#2JB%:JB'BJB)JJB+RJB-ZJB/"JF1*JF3
M2JF5:JF7BJF9JJF;RJF=ZJF?"JJA*JJC2JJE:JJGBJJIJJJKRJJMZJJO"JNQ
M*JNS2JNU:JNWBJNYJJN[RJN]ZJN_"JS!*JS#2JS%:JS'BJS)JJS+RJS-ZJS/
M"JW1*JW32JW5:JW7BJW9JJW;RJW=ZJW?"J[A*J[C2J[E:J[GBJ[IJJ[KRJ[M
MZJ[O"J_Q*J_S2J]62I[UZIXY5)_RNJ_XZJ_^-10$.6://, !&3 "HF>=W?D%
M.5!/+S4VW^F=] D&2$ !Q6B8Z?EXLX@!16>/-#!?KZD#%( H\VF<Q]><&-L%
M(1!_&;N>+8 !2SDH5+"Q@](@$PA)\7D,(3NR"?N>QT"QH!9"\6$#"V .Q6FT
M)+LM.IMY$9N:KXD$A=0%\ <STX.>TW,#K!"U*RN>37NQ!.&P#Y:R*_NPAB $
M5>*KS@ ;6=!4E')2F'BOZYE)R]$#]8.;(42.-C2(8J8+'+!0\GD,"UA(&+NT
M%=,%<B5_\^F,MND$A%@?&]"W]W&' /!4_V$-[L&Q]/$$;C&XX(F<NA /DQLQ
MN[FX.19ER@:>U9G^FO& M89[NIM;'][Q1H5KNMA%3:X;J^3V&87X+6E" ?%A
M(SQ@ET5@!%W0 SS "DL0 0L  U>@!<%!$,-;O&!"!5/C!5,2'T*0 [X';#J
M!&)3(D#  SW0?4#@!%D0OI"$+#'7!+FS"T"P !&0 [:Q!#DP0_/!"$* !#J
M(T &!#KP44( O<8[L3H@/0/+ T' $5K  U30O5T@ >?R!=9K#$60O3\A!#I
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M P*@!1@. EIT$=(1C 8!3<#T*+D$080>&0XX&&3  0\+ I" :0'@1 X& E:
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$" 0 .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
